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Intermittent claudication is the first and mildest manifestation of peripheral arterial disease, caused 
by the atherosclerotic process of progressive narrowing of one or more of the arteries of the pe-
ripheral circulation.1 If the arterial system fails, it results in a progressive oxygen debt, experienced 
by the patient as cramping muscle pain during walking or other physical activity, which forces the 
patient to pause. The incidence of intermittent claudication increases with age, especially among 
men, with an annual incidence rate of 0.7%, 3.9%, and 10.6% among 35-44 year, 45-54 year, and 
55-64 year old men respectively.2 In women, the incidence rates are approximately 50% lower than 
in men.2 The development of intermittent claudication is accelerated by the same cardiovascular 
risk factors as known for other expressions of atherosclerotic disease (i.e. coronary heart disease and 
cerebro-vascular disease). These risk factors are smoking, diabetes mellitus, hypertension, and hyper-
lipidaemia.3,4 
To localize the narrowed or occluded artery, non-invasive or invasive imaging tests are needed. Tradi-
tionally, digital subtraction angiography has been considered as the “gold standard” and images are 
easily displayed and interpreted for planning treatment, however it is invasive and associated with a 
risk of morbidity and mortality.5 Therefore, non-invasive imaging modalities are increasingly prefered 
for the evaluation of patients with intermittent claudication. duplex ultrasound was introduced into 
clinical practice in the early 80’s and can be used for preintervention decision making.6 Problems may 
arise, however, when evaluating the aortoiliac arteries that cannot be visualized in their entirety in the 
5%-25% of patients who are extremely obese, have abundant intestinal gas, or who have particularly 
tortuous or calcified iliac arteries.7,8
It would be attractive, if one could rapidly evaluate the aortoiliac arteries for the presence of sig-
nificant obstructive disease without having to visualize these arteries along their entire length. This 
would reduce the number of indeterminate results of duplex ultrasound, reduce the examination 
time for a complete Duplex Ultrasound examination and might also reduce the existing moderate 
observer variability in evaluating the aortoiliac segment.9 Potentially, such rapid evaluation of the aor-
toiliac arteries might be provided by assessing the duplex waveform as measured distally at the level 
of the common femoral arteries.10-13 It is known that the waveform distal to a significant obstruction 
often changes in character, for example from a normal triphasic waveform proximal to a stenosis to a 
monophasic waveform distal to the stenosis. There are, however, only few data in the literature that 
have addressed the question how accurate a marker a duplex ultrasound waveform of the femoral 
artery is in showing or excluding significant aortoiliac obstruction.
Intermittent claudication is neither a life-threatening nor limb-threatening form of peripheral arte-
rial disease. Nonetheless, for those so afflicted, intermittent claudication has a negative impact on 
health-related quality of life and has been associated with increased, risk of mainly cardiovascular 
disease.14  Improvement in health-related quality of life is the ultimate goal of treatment of intermittent 
claudication. The general consensus to reach that goal is that all patients presenting with intermittent 
claudication should initially be treated with exercise training and only if symptoms fail to improve are 
invasive procedures considered.3, 15, 16 Despite this general consensus, however, percutaneous translu-
minal angioplasty is increasingly performed as the first treatment. Exercise training has been recom-
mended since Larsen and Lassen reported their results in 1966.17 Exercise training is a non-invasive 
treatment for patients with intermittent claudication and has shown to improve patients’ walking 
GENERAL INTRODUCTION distance. However, level of evidence A applies only to supervised exercise programs and not to unsu-
pervised programs (level of evidence B).18 Meta-analyses and systematic reviews showed significant 
improvements in physical functioning with an increase of the walking distance of about 180%.19,20 
However, in the literature the type of exercise training varies from home-based to hospital-based 
programs and the definition of supervised exercise training and non-supervised exercise training also 
varies widely, especially in Europe.21-23 The standard exercise training in Western European countries is 
home-based, mostly for logistical reasons, whereas in the United States most guidelines recommend 
supervised treadmill exercise training.24 Not only the type of exercise training varies, but also the fol-
low-up differs across studies.20, 21, 23
The percutaneous revascularization techniques in peripheral arterial disease were initiated by Dotter 
and Judkins in the early 60’s.25 The relatively low mortality and morbidity risk made percutaneous 
transluminal angioplasty an established treatment option for patients with intermittent claudication. 
It has 5 year patency rates of 80% for aortoiliac and 60% for femoropopliteal disease.26-29 However, 
not all arterial lesions are suitable for percutaneous transluminal angioplasty. The current view is that 
percutaneous transluminal angioplasty should be performed in patients with short focal lesions. The 
precise criteria, however, are still a matter of debate.3
There still is no convincing evidence that an angioplasty procedure provides significant functional 
benefit and improvement in health-related quality of life compared to conservative exercise train-
ing after long-term follow-up. It is common knowledge that atherosclerotic disease is a generalized 
process and presents as a multi-level disease. Percutaneous transluminal angioplasty is a local form 
of treatment, and it is therefore not surprising that following percutaneous transluminal angioplasty 
patients may relapse with ipsilateral or contralateral symptoms representing progressive disease at 
other sites. The benefit of percutaneous transluminal angioplasty may have a short-term effect only. 
In addition to health-related quality of life, however, one needs to consider costs and cost-effective-
ness. It is likely that initial hospital costs of endovascular revascularization are higher than those of 
exercise training. Besides these initial hospital costs, costs of follow-up are important to take into ac-
count, such as the costs of diagnostic tests for recurrent symptoms and secondary treatment. Many 
physicians consider exercise training an inexpensive and effective treatment to improve a patient’s 
absolute claudication distance15,19,30, whereas, from the societal perspective it may not be as inexpen-
sive as it seems, due to the required time investment on the part of the patient. This is accompanied 
by an ongoing debate about the optimal treatment for patients with intermittent claudication, in 
which costs play an important role.31,32 
Furthermore, because risk factors for intermittent claudication do not differ from those of athero-
sclerotic disease, many patients have both intermittent claudication and coronary artery disease.33 
Coronary artery disease is the main cause of death in the United States.1 Millions of Americans have 
a history of myocardial infarction or experience angina pectoris.1 Approximately one third of men 
and one fourth of women with known coronary artery disease also have peripheral arterial disease.34 
Many coronary artery disease patients (on average 300,000 per year) enter a rehabilitation program 
in the United States with the objective of reducing cardiac symptoms, improving physical function-
ing, improving cardiovascular risk factors, reducing mortality, reducing myocardial infarctions, and 
improving psychological well-being.35,36 Patients with coronary artery disease who have peripheral 
arterial disease, however, are hampered in their cardiac rehabilitation program because they either 
discontinue the program prematurely or are unable to achieve their target heart rate due to their 
CH
A
PT
ER
 1
12
CH
A
PT
ER
 1
13
limited walking distance. As a result these patients have an increased risk of cardiac events during 
follow-up (20%-60% increased risk for MI).37,38
How clinical effectiveness of a cardiac rehabilitation program is influenced by peripheral arterial dis-
ease, however, is still unknown. Therefore, management that focuses on improving of target heart rate 
as well as improving walking distance may be better in patients with both intermittent claudication 
and coronary artery disease. New rehabilitation strategies which include the diagnosis and treatment 
of intermittent claudication in patients with coronary artery disease undergoing cardiac rehabilitation 
may improve the results of current cardiac rehabilitation. 
AIM AND OUTLINE OF THIS THESIS
The primary purpose of this thesis was to compare the clinical effectiveness and cost-effectiveness 
of endovascular revascularization to supervised hospital-based exercise in patients with intermittent 
claudication.
Though intermittent claudication is not a limb-threatening or a life-threatening disease, the loss of 
walking ability and the experience of pain with ambulation seem to result in a deterioration of physi-
cal and emotional well-being. The impact of intermittent claudication and its treatment on health-
related quality of life are presented in Chapter 2. 
In Chapter 3, a systematic review of the existing literature on exercise training versus percutaneous 
transluminal angioplasty in patients with intermittent claudication is presented. Variables across the 
studies were not uniformly defined or measured under identical conditions. Therefore, we performed 
a meta-analysis using a random effects model. 
A randomized controlled trial was performed to evaluate the clinical effectiveness and cost-effec-
tiveness of endovascular revascularization compared to supervised hospital-based exercise in the 
treatment of patients with intermittent claudication. Chapter 4 presents the clinical effectiveness 
after endovascular revascularization versus supervised hospital-based exercise of this randomized 
controlled trial and Chapter 5 presents the associated cost-effectiveness analysis. 
How the clinical effectiveness of a cardiac rehabilitation program is influenced by peripheral arterial 
disease is described in Chapter 6. This chapter explores whether the clinical effectiveness of cardiac 
rehabilitation was related to the presence of peripheral arterial disease.
New management strategies for coronary artery patients undergoing cardiac rehabilitation are evalu-
ated in Chapter 7. These strategies include the diagnosis and treatment of peripheral arterial disease 
and a comprehensive vascular rehabilitation program. The effectiveness, costs and relative cost-effec-
tiveness of these new rehabilitation strategies are evaluated in an analytic Markov decision model. 
In Chapter 8 a diagnostic test evaluation is described. Duplex ultrasound is often used to plan the 
treatment strategy for patients with peripheral arterial disease. However, duplex ultrasound is op-
erator-dependent and does not provide a “roadmap” of the arterial system. The accuracy, predictive 
value and observer agreement of the Duplex Ultrasound waveform at the common femoral artery as 
a marker of significant aortoiliac disease is assessed. 
Finally, Chapter 9 integrates the main findings of the previous chapters and relates them to current 
clinical practice. This chapter contains a general discussion of treatment for intermittent claudication 
and of management strategies for peripheral arterial disease in patients with coronary artery disease. 
Relevant methodological issues are discussed and suggestions are made for clinical practice and 
future research.
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Improvement in quality of life is the ultimate goal of healthcare for the treatment of intermittent clau-
dication. Until recently, the measures of success after therapy were those derived from the vascular 
laboratory, including ankle-brachial indices and ankle and toe pressures. There are now several vali-
dated and reliable survey instruments that can assess patient-reported quality of life in a generic or 
disease-specific manner. Major survey instruments are reviewed. The information gathered through 
these quality-of-life assessment tools is important to all those involved in the care of patients with pe-
ripheral arterial disease. Although claudication is neither life- nor limb-threatening, it has a significant 
negative impact on quality of life, as measured by these instruments. Patients so afflicted report more 
bodily pain, worse physical functioning, and worse perceived health, in addition to limited walking 
ability. These measures of quality of life do not correlate with standard parameters of ankle-brachial 
index or ankle pressures. Treatment of the claudicant with exercise therapy and percutaneous or 
open revascularization also impacts quality of life. Each of these modalities is capable of improving 
quality of life, but some are associated with decline over time. The major benefits and risks to quality 
of life of these specific forms of treatment for the claudicant are reviewed. This data demonstrates 
that patients suffering from symptoms of intermittent claudication are best served by therapies that 
address their major self-reported impediments to quality of life.
IMPACT OF CLAUDICATION AND ITS TREATMENT ON 
QUALITY OF LIFE
The primary goal of healthcare is improvement in quality of life. This is certainly true of patients with 
peripheral arterial disease. Intermittent claudication (IC) is neither a life-threatening nor limb-threaten-
ing form of lower extremity ischemia. Nonetheless, for those so afflicted, claudication has a negative 
impact on quality of life. Until now, most vascular specialists would agree. The extent to which this 
form of peripheral artererial disease (PAD) disrupts a patient’s life remains somewhat controversial. 
This is due to the fact that physical examination information and clinical data, such as ankle-brachial 
index (ABI), do not adequately describe the impact of claudication on quality of life. This was well-
demonstrated by Pell,1 who interviewed 201 patients with new-onset claudication and asked them 
to rate their quality of life prior to their visit with a vascular specialist. The investigator then obtained 
the vascular specialist’s opinion regarding the impact of claudication upon the patient’s quality of 
life, based upon medical history and physical examination. They found that the correlation between 
physician and patient assessment was poor. Because the impact of the disease upon the patient’s life 
and level of functioning may be quite variable, even for similar clinical levels of ischemia, surgeons 
frequently overestimated the effect of claudication.1 There is little correlation between clinical param-
eters of vascular disease, such as ABI, and the patient’s self-reported level of disability. In a study of 
555 patients, Feinglass and colleagues2 recorded the ABI and the patient’s self-reported level of physi-
cal functioning and walking ability. There was only a modest correlation between these measures. 
Patients with only a slight reduction of ABI to a level of 0.8 to 0.9 indicated that they had significant 
impairment of walking ability, whereas some patients with an ABI reduced to a near limb-threatening 
level of 0.4 to 0.5 reported that they were able to maintain high levels of physical functioning and 
walking ability. Similarly, an assessment of 157 patients with treadmill walking distance, ABI, and a 
quality-of-life survey documented poor correlation between the clinical parameters of walking ability 
and ABI and the measured quality of life.3 These findings indicate that clinical measures, such as ABI, 
vessel and graft patency, and limb salvage, effectively assess the physiologic impact of claudication 
and its treatment, but do not adequately describe the overall patient status or the benefit or adverse 
effect of treatment on quality of life. To accomplish this, specific tools designed to elicit the effects of 
disease and treatment have been used.
QUALITY-OF-LIFE ASSESSMENT
Because IC is not a life-threatening condition, but limits patients’ well-being, quality of life is consid-
ered the most important outcome.4 Quality-of-life measures can be divided into generic (Table 1) 
and disease-specific measures. Subsequently, disease-specific measures can be divided in clinical as-
sessment for identification of a disease (such as the Walking Impairment Questionnaire (WIQ)) versus 
descriptive healthstatus measures (Table 2). Generic measures can be divided in health descriptive 
versus valuation/preference-based measures. 
The most common generic descriptive health measures used in evaluating quality of life in patients 
with PAD is the Medical Outcomes Study Short-Form 36 (SF-36).5,6 The SF-36 was developed to evalu-
ate physical, social, and physical role functioning of patients and to elicit their perceptions of their 
general health and well-being in eight different health dimensions (Table 3).6 Previous studies dem-
onstrated that the dimensions of physical functioning, role-functioning limitations due to physical 
problems, bodily pain, and general health are the most relevant dimensions to describe the health 
status of PAD. The scoring per dimension is valued on a 100-point scale from 0 (worst outcome) to 
100 (best outcome). The reported mean value for patients with IC is 42 (±13) for physical functioning, 
40 (±34) for physical role functioning, 47 (±11) for bodily pain, and 61 (±14) for general health.7
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Another generic descriptive health measure was developed by the The World Health Organization 
(WHOQOL). The WHOQOL produces a profile of scores across six broad domains of quality of life and 
some 24 facets of quality of life. The six domains are: physical domain, psychological domain, level 
of independence, social relationships, environment, and spirituality/ religion/personal beliefs. Within 
each domain, several subdomains (facets) of quality of life summarize that particular dofacets “pain 
and discomfort” and “energy and fatigue.” The scoring on each facet and domain can range from 4 
to 20, in which higher scores indicate better functioning on the respective domain of quality of life, 
except for the facets pain and discomfort, negative feelings and dependence on medication and 
treatments, which have an inverse score. The reported mean value for the overall quality of life in 
patients with IC is 14.5 (±2.8).8
Table 2: Quality-of-Life Instruments and Impact of Intermittent Claudication 
* Scores are the weighted mean from the claudicants with ABI ≤ 0.6 and claudicants with ABI > 0.6. 
† Scores are the weighted mean from the exercise group of the systematic review.
Instrument Questionnaire Scoring Mean (+/-SD) Reference
Disease-specific/ 
identification of 
intermittent 
claudication
Walking Impairment Questionnaire: 
Distance*
Speed*
Stair climbing*
0-100
26 (3)
33 (15)
47 (9)
14
14
14
Disease-specific 
descriptive health 
measure
Vascular Quality of Life Questionnaire 
Claudication Scale Questionnaire
Daily life
Pain 
Social life 
Specific fears
Mood
0-7
0-100
3.7 (1.2)
62 (25)
59 (21)
89 (17)
78 (22)
81 (19)
10
11
11
11
11
11
Generic descriptive
 health measure
Short-Form 36 (SF-36)
Physical functioning†
Physical role functioning†
Bodily pain†
General health†
World Health Organization
Overall quality of life
Physical
Psychological
Level of independence
Social relationships
Environment
0-100
4-20
42 (13)
40 (34)
47 (11)
61 (14)
14.5 (2.8)
13.4 (2.4)
14.2 (2.4)
13.1 (2.6)
15.2 (2.7)
16.1 (2.9)
7
7
7
7
8
8
8
8
8
8
Table 1: Generic Quality-of-Life Instruments*
Nottingham Health Profile
EuroQol Health Assessement
Sickness Impact Profile
Medical Outcomes Study SF-36
Quality of Well-Being Scale
*The most commonly used generic quality-of-life instruments used to assess all comorbid conditions that can accompany vascular disease.
Disease-specific descriptive health measures available for IC are the Vascular Quality of Life Ques-
tionnaire, and the Claudication Scale questionnaire. The Vascular Quality of Life Questionnaire is a 
questionnaire especially developed for patients with PAD and is responsive to measure subtle effects 
after, for example, exercise training or percutaneous transluminal angioplasty (PTA).9 The question-
naire contains five domains (activity, symptom, pain, emotion, and social functioning), in which 0 
means death and 7 indicates maximum health. The average value over these domains that has been 
reported for patients with IC is 3.7 (±1.2) (Table 2).10 A disease-specific descriptive health measure, 
which is specially developed for patients with IC, is the Claudication Scale Questionnaire.11 It originally 
consisted of 80 items in nine dimensions, but the long form made it unsuitable for use in clinical tri-
als, so a short form was developed with the following dimensions: daily life (9 items), pain (10 items), 
social life (4 items), specific fears (13 items), and mood (11 items). Scores varied from 0 (worst outcome) 
to 100 (best outcome) and the mean reported value for patients with IC for these domains are 62 
(±25) for daily life, 59 (±21) for pain, 89 (±17) for social life, 78 (±22) for specific fears, and 81 (±19) for 
mood.11
Disease-specific questionnaires can provide patient-reported information regarding the limitations 
imposed by claudication. The severity of IC as experienced by a patient can be assessed with the 
use of questionnaires like the WIQ.12 This questionnaire has been used to evaluate walking ability in 
patients with IC before and after treatment.13 The WIQ has three domains: walking distance, walking 
speed, and stair climbing, which together characterize the degree of walking impairment in patients 
with PAD.13,14 For each domain symptom, scores range from 0% (worse outcome) to 100% (best out-
come). Distance summary scores range from 0% (patients unable to walk 20 feet without stopping to 
rest) to 100% (patients able to walk five blocks without stopping to rest). The weighted mean value 
that has been reported for patients with IC was 26 (±3). Summary scores for walking speed range from 
0% (patients unable to walk one block slowly without stopping to rest) to 100% (patients able to jog 
one block without stopping to rest). The weighted mean value that has been reported for patients 
with IC was 33% (±15). Stair-climbing scores ranged from 0% (patients unable to climb one flight of 
stairs without stopping to rest) to 100% (patients able to climb three flights of stairs without stopping 
to rest). The weighted mean value that has been reported for patients with IC was 47% (±9).14
Utilizing these patient-assessment tools, the impact of claudication and its treatment on patient qual-
ity of life has been assessed.
Table 3: Medical Outcomes Study 36-Item Health Survey (SF-36) 
Areas of Assessment
Perception of health
Psychological well-being
Role limitations due to physical health problems
Role limitations due to mental health problems
Physical function
Social relations
Pain
Fatigue
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IMPACT OF CLAUDICATION ON QUALITY OF LIFE
Although IC is not limb-threatening, the loss of walking ability and the experience of pain with ambu-
lation seem to result in a deterioration of physical and emotional well-being. In a study of claudicants 
using the Rand-36 generic quality-of-life instrument, Bosch and Hunink15 were able to document 
that patients had significantly lower scores in all eight domains, especially physical function and role 
limitations due to emotional impact, compared to a control population without claudication (Fig 1). 
This finding was confirmed in a broader epidemiologic assessment in Scotland. A community-based 
study utilizing ABI, SF-36, and the Rose Intermittent Claudication Questionnaire, confirmed the nega-
tive impact of claudication on quality of life. Evaluating 53 patients with documented IC and compar-
ing them to 327 patients without symptoms of PAD, Dumville and colleagues16 also noted reductions 
in physical functioning, role limitations due to physical dysfunction, role limitations due to emotional 
dysfunction, bodily pain, energy, and general health perception. Only social functioning and mental 
health were spared the negative impact of claudication.
This generalized adverse effect of claudication appears to be related more to walking distance than 
measured clinical parameters. The imposed limitations of ambulation have both physical and emo-
tional effects. The impact of walking distance and quality of life was documented in a study of 80 
patients with Fontaine Stage II PAD. These patients were evaluated with the WIQ and the SF-36, in ad-
dition to ABI and a 6-minute walking test. The results of the 6-minute walking test correlated well with 
quality-of-life scores. Patients with more limited walking abilities had worse scores on the physical 
function and role limitations due to the physical dysfunction subscales of the SF-36.17  Any additional 
Figure 1: General health status in patients with claudication (dark bars) and without 
claudication (light bars) as measured by the Rand-36. 
 
Reproduced from Bosch JL, Hunink MG. The relationship between descriptive and valuational quality-of-life measures in patients with 
intermittent claudication. Med Decis Making 1996;16:217-225.
limitation in walking ability, whether by worsening atherosclerosis or by comorbid conditions, serves 
to worsen the patient’s perception of quality of life. This was recently demonstrated by Gardner and 
colleagues,18 who examined the walking ability and quality of life of claudicants with and without 
metabolic syndrome. This syndrome is marked by abdominal obesity, hypertriglyceridemia, low high-
density lipoprotein, hypertension with a systolic pressure 130 mm Hg and a diastolic pressure 85 mm 
Hg, and a fasting glucose 110 mg/dL.18 These investigators noted that patients with IC and metabolic 
syndrome have a walking distance 29% shorter than claudicants without manifestations of the syn-
drome. This reduction in walking ability in the setting of additional comorbidities was reflected in 
lower quality-of-life scores documented by the SF-36, with the most prominent impact upon general 
health, vitality, and bodily pain scores. Similar findings were noted by Breek and associates,19 who 
evaluated 200 consecutive claudicants with the WHOQOL and attempted to stratify results according 
to the Society of Vascular Surgery/International Society of Cardiovascular Surgery classification for 
claudication. They noted that reduced walking distance correlated with physical scores on quality-of-
life assessment, such as level of independence, working capacity, and mobility. Increasing comorbidi-
ties correlated with lower overall quality-of-life scores.19 The emotional effects of IC have also been 
directly assessed with stress-specific measurement tools, as was done by Aquarius and colleagues.20 
Using the Perceived Stress Scale and the Rand-36, these investigators evaluated the impact of calf 
pain on 188 patients with new-onset claudication, documented by symptoms; physical examination; 
ABI; and treadmill walking test. Perceived stress was inversely proportional to walking distance, with 
a shorter walking distance correlating with greater perceived stress. Greater perceived stress, and not 
level of reduction in ABI, was associated with a poorer quality of life.
Although the most common disability associated with claudication, there are other studies that sug-
gest that laboratory measurement of walking distance may not specifically correlate with quality of 
life. For example, Barletta and colleagues21 evaluated treadmill performance and perceived quality of 
life with the McMaster Health Index Questionnaire, a validated generic tool, in 251 claudicants and 89 
age-matched controls. They noted poorer scores in physical, emotional, and social function in clau-
dicants compared with controls. The reductions, however, did not correlate with treadmill walking 
distance.21 Thus, laboratory measurement of walking distance may not replicate the limitations expe-
rienced by the patient outside of the vascular laboratory. Nonetheless, these studies and numerous 
others that have evaluated the impact of intermittent claudication on patients, have documented a 
significant adverse impact upon quality of life.
IMPACT OF TREATMENT OF IC ON QUALITY OF LIFE
Treatment options for IC range from walking exercise programs to pharmacological treatment to 
PTA, with or without stent placement, to bypass surgery. The general consensus is that all patients 
presenting with IC should initially be treated with walking exercise and only if symptoms fail to im-
prove, should invasive procedures be considered.4,22,23 Despite this general consensus, however, PTA 
and other invasive forms of treatment are occasionally used as first-line therapy. Regardless of the 
approach to therapy, each of these modalities has associated benefits and adverse effects that may, 
ultimately, affect quality of life. Establishing the impact of treatment on quality of life has been difficult 
because of the limited number of studies with complete information.
Control of risk factors for atherosclerosis and participation in an exercise program has been shown 
to be sufficient to improve quality-of-life scores in claudicants. Imfeld and associates24 compared the 
impact of supervised exercise therapy, supervised exercise therapy with cilostazol, and unsupervised 
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exercise in a group of claudicants. SF-36 quality-of-life surveys were obtained before and 3 months af-
ter treatment. They noted that all patients had improved quality-of-life scores, but the scores did not 
correlate with increases in walking distance.24 This suggests that even nominal increases in walking 
distance can be associated with greater improvements in quality of life. While there are clearly incon-
veniences associated with exercise programs, including delayed onset of increased walking ability, 
the time required, and some cost, there is little risk and few adverse effects from these programs.
In a broader assessment of the impact of exercise therapy on quality of life, Spronk and associates7 
systematically reviewed the published data on the short- and long-term effects on both functional 
capacity and quality of life of exercise training and PTA in patients with claudication.
Figure 2. Weighted means and 95% confidence interval of SF-36 dimensions of physical func-
tioning, physical role functioning, bodily pain, and general health for the exercise training and 
PTA group at baseline and at follow-up.
 
* Significant difference between the two groups.
† If 6 months values were not available, the 12 months values were used. 
§ Significant improvement in group during follow-up.
All articles between 1980 and February 2003 were included if patients with IC were treated with 
exercise training or PTA, and both functional capacity and the SF-36 quality-of-life scores were report-
ed of at least 3 months follow-up. Data were pooled using the random-effects model and weight-
ed means. Pooled results were compared between the treatment groups using Â2-test and t-test 
(®= 0.05, two-sided).
In the analyses, five studies (n = 202 patients) were included in the exercise group and three studies 
(n = 470 patients) in the PTA group. Results demonstrated that at 3 and 6 months follow-up, ABI was 
significantly improved in the PTA group, but not in the exercise group. At 3 months, quality of life 
was significantly improved on the dimensions of physical functioning and bodily pain in the exercise 
group, and on the dimensions of physical role functioning and general health in the PTA group (Fig 
2). Between the two treatment groups, ABIs were significantly different at 3 and 6 months, whereas 
mean change in quality-of-life scores was not significantly different during follow-up.7 This review 
highlights the fact that there is limited information on long-term outcomes for exercise therapy. 
It is well-recognized by vascular specialists that both percutaneous and open vascular therapies fail 
over time. This results in changes in quality of life over time, as well. Angioplasty of iliac or distal vessels 
for the treatment of claudication has a high likelihood of both technical and clinical success. The rela-
tively low mortality and morbidity risk made PTA an established treatment option for patients with IC. 
It has 5-year patency rates of 80% for aortoiliac and 60% for femoropopliteal disease.25–28
There have been multiple studies that have documented the immediate and short-term qual-
ity-of-life benefits of successful percutaneous balloon angioplasty for treatment of claudication. 
Quality-of-life scores, using the SF-36 and Euro quality-of-life Health Assessment questionnaires, were 
recorded before and 1, 3, and 6 months after angioplasty in 108 claudicants treated with balloon 
angioplasty of causative iliac or SFA lesions. Improvements in the subscales and overall quality were 
noted by 1 month after treatment and were sustained at 6 months after intervention.29 Similar find-
ings were reported by Whyman and colleagues30, who performed a randomized, prospective trial of 
angioplasty of short iliac or SFA lesions (n = 30) or medical treatment alone (n = 32) in a cohort of 62 
claudicants. They evaluated these patients with clinical parameters of duplex imaging of occlusive 
disease, ABI, treadmill walking distance, and quality of life with the Nottingham Health Profile. At the 
time of 6-month follow-up evaluation, none of the patients treated with angioplasty reported symp-
toms of claudication. They had lower pain scores and overall improvement in quality of life as record-
ed by the Nottingham Health Profile survey compared to the control group who received medical 
therapy only. Of significance, the investigators reported on the status of these patients 2 years after 
treatment.31 Although the angioplasty sites remained patent, there were no statistically significant dif-
ferences in treadmill walking distance, patient-reported walking distance, ABI, or quality-of-life scores 
between the angioplasty and control groups.
These findings on the diminishing benefit on quality of life of angioplasty over time have been docu-
mented in many other studies. A Cochrane Database systematic review evaluated randomized trials 
of angioplasty for the treatment of mild or moderate claudication. This critical assessment of avail-
able data revealed that patients treated with angioplasty had neither a greater walking distance nor 
quality of life 2 years after intervention compared to patient controls.32 This information suggests that 
angioplasty alone provides an immediate benefit, but the durability of the treatment, as measured by 
quality-of-life assessment, is limited. The amount of specific data on this point, though, is limited.
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Surgical revascularization is infrequently warranted for treatment of the claudicant. The recently pub-
lished American Heart Association guidelines33 for management of claudication are in accord with 
those set forth in the TASC guidelines4 and recommend surgical revascularization only for those in-
dividuals who have significant lifestyle or job-threatening limitations, and who have failed exercise 
and pharmacotherapy. Therefore, the quality of life of claudicants after bypass surgery has not been 
extensively studied.
Klevsgard and colleagues34 reported the quality-of-life changes in 31 patients with IC who underwent 
successful revascularization and 9 patients in whom revascularization was unsuccessful. Using the 
Nottingham Health Profile and the SF-36 to document changes in quality of life, these investiga-
tors noted that those with successful surgery had improved scores in bodily pain, physical function-
ing, and vitality. None of these were improved in those with unsuccessful procedures.34 In a recent 
study of 80 patients undergoing lower-extremity revascularization for treatment of claudication, the 
Nottingham Health Profile was used to assess health-related quality of life at 6 and 12 months after 
surgery and then up to 4 years postoperative. Improvement in scores of energy, pain, emotional reac-
tions, and physical mobility were noted through 12 months. Improvements were maintained up to 4 
years as long as the graft remained patent.35
These and other small studies have clearly established that quality-of-life improvements are associ-
ated with placement and maintenance of a patent bypass graft. The magnitude of the surgical endea-
vour, however, may impact upon this. Schneider and colleagues36 evaluated the functional status and 
sense of well-being in 60 patients more than 6 months after placement of an aortobifemoral bypass 
graft. Although healing and postoperative recovery were complete, patients with functioning grafts 
had physical function, role function, bodily pain, and perceived health scores worse than those with-
out symptomatic arterial disease. Graft failure may also result in significant or prolonged deterioration 
in perceived health and emotional status, as was noted by Ronayne in a small study of 25 patients.37
SUMMARY
Because the ultimate goal of healthcare is improvement in a patient’s quality of life, this measure is 
one of the parameters by which the success of healthcare must be judged. There are many well-
established and validated questionnaires that can ascertain, in a generic or disease-specific manner, 
quality of life and functional status as reported by the patient. When these instruments are applied to 
patients with IC, a significant impairment in functional status and quality of life can be clearly docu-
mented when compared to patients without PAD.
Treatment of those with claudication with any modality that can increase walking distance and re-
duce claudicationassociated pain can improve quality of life. This is true of exercise therapy, percu-
taneous procedures, or open surgery. Exercise therapy, when continued, has a durable benefit on 
patient quality of life and little associated inconvenience. Percutaneous and open revascularization 
procedures, when successful, provide immediate improvement in functional status for the claudicant. 
There is little quality-of-life data to document that improvement in quality of life with invasive pro-
cedures is sustained, but a growing body of information to suggest that quality of life and functional 
status begin to deteriorate over time. Further broad longitudinal studies will be required to better 
document the benefits of intervention in the claudicant.
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ABSTRACT
Purpose: To systematically review published data about the short- and long-term effects of exercise 
training and angioplasty on functional capacity and quality of life of patients with intermittent clau-
dication.
Materials and methods: Articles published between January 1980 and February 2003 were included if 
patients had intermittent claudication treated with exercise training or angioplasty and if both func-
tional capacity and quality-of-life scores from Medical Outcomes Study 36-Item Short Form health 
survey were reported for at least 3 months of follow-up. Data were pooled by using a random effects 
model and weighted means. Pooled results were compared between the treatment groups by using 
the Â2-test and the Student t-test (® = .05, two sided).
Results: In the analyses, five studies (202 patients) were included in the exercise group, and three 
studies (470 patients), in the angioplasty group. At 3 months of follow-up, the ankle-brachial index 
was significantly improved in the angioplasty group (mean change, 0.18; p < .01) but not in the exer-
cise group (mean change, 0.01; p = .29). At 3 months, quality of life was significantly improved with 
regard to ratings of physical functioning and bodily pain in the exercise group (mean change, 18 and 
10, respectively; p < .01) and physical role functioning in the angioplasty group (mean change, 30; 
p = .03). Mean change in ankle-brachial index significantly differed between the two treatment groups 
at 3 and 6 months (p < .01); mean change in quality-of-life scores did not.
Conclusion: Improvement in quality of life was demonstrated after both exercise training and angio-
plasty, whereas functional capacity showed significant improvement after angioplasty. The ankle-
brachial index significantly differed between the two treatment groups at 3 and 6 months, whereas 
the quality-of-life scores did not.
INTERMITTENT CLAUDICATION: FUNCTIONAL CAPACITY 
AND QUALITY OF LIFE AFTER EXERCISE TRAINING OR 
PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY—
SYSTEMATIC REVIEW
INTRODUCTION
Intermittent claudication is the mildest manifestation (ie, Rutherford stage 1, 2, or 3) of peripheral 
arterial disease, and its prevalence is approximately 5% in men older than 50 years.1,2 The overall aging 
of populations in Western societies indicates that the prevalence of this condition will increase over 
the next decades.3 Various treatment strategies, such as exercise training and percutaneous translu-
minal angioplasty (PTA) with or without stent placement, have been proposed in order to ameliorate 
symptoms. The choice between exercise training and PTA in patients with intermittent claudication, 
however, has been the subject of controversy. To our knowledge, there has been no direct com-
parison of exercise training with PTA to determine the relative effects of these two therapies both 
on functional capacity (usually expressed as ankle-brachial index [ABI] or as walking distance) and on 
quality of life.
In 1957, Foley4 described the beneficial effects of daily walks and physical training in patients with 
intermittent claudication. Several subsequent reports5-7 confirmed that exercise training led to an 
improvement in the walking ability of patients with intermittent claudication. It has been shown 
to significantly improve both the onset of leg discomfort (initial walking distance) and the point at 
which the pain becomes unbearable and forces the patient to stop walking (maximum walking dis-
tance).8,9 PTA became available in 1964 and is currently an established treatment option for patients 
with intermittent claudication.10 Low complication rates (4%–5%) and 5-year patency rates of 80% for 
aortoiliac disease and 60% for femoropopliteal disease were reported for PTA.11-14 This technique has 
been popularized as an inexpensive, effective, and simple method.15-17
In recent years, quality of life has been extensively used as a parameter for assessing and expressing 
the success of the outcome in patients with intermittent claudication.18 The TransAtlantic Inter- Soci-
ety Consensus stated that if quality of life could be accurately assessed, it would be the ideal primary 
end point.19 Furthermore, the relationship between functional capacity and quality of life is complex 
and contradictory, and both therefore should be considered in the assessment of outcome.20,21 There 
remains uncertainty surrounding the effectiveness of the treatment strategies in patients with inter-
mittent claudication. Thus, the objective of our study was to systematically review the published data 
about the short- and longterm effects of exercise training and angioplasty on functional capacity and 
quality of life of patients with intermittent claudication.
MATERIALS AND METHODS
Data Sources and Data Extraction Publications were initially selected by the first author (S.S.), and the 
selection was verified by a coauthor (J.L.B.). The final selection was made by both authors together. 
Both authors evaluated all reports independently for inclusion and exclusion criteria.
A literature search was performed by using MEDLINE and the reference lists in articles. Further search-
es were performed by using the same keywords in the Cochrane Central Register of Controlled Tri-
als, Cochrane Anesthesia Group Specialized Register, Cumulative Index to Nursing and Allied Health 
Literature, and PiCarta.
The reviewers used the English-language medical literature published in 1980 or later.22 Published 
studies of PTA dated from 1980, and to find contemporary controls between the exercise group and 
the PTA group, we restricted our review to this period. Randomized controlled trials, prospective 
cohort studies, and retrospective cohort studies were included, while case reports and reviews were 
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excluded. Key words were (“intermittent claudication” OR “claudicants”) AND (“angioplasty” OR “PTA” 
OR “stent placement” OR “balloon dilation” OR “exercise” OR “gymnastics” OR “walking” OR “train-
ing”) AND (“quality of life” OR “QoL” OR “health status”) AND (“functional capacity” OR “ankle brachial 
index” OR “walking distance”) AND (“vascular peripheral” OR “arterial peripheral”). The studies were 
included if they met the following criteria: Patients with intermittent claudication were included and 
were treated with either exercise training (walking or gymnastics) or with PTA with or without stent 
placement in lesions in the aortoiliac or femoropopliteal arterial segments. Both functional capacity 
as demonstrated by walking distance (on a treadmill or as reported by the patient) or ABI, and qual-
ity-of-life scores (generic or disease specific) for at least 3 months of follow-up, were reported. Reports 
about PTA studies that also included patients with critical ischemia were excluded from our analysis 
if the outcome results were not reported separately for patients with critical ischemia and for those 
with intermittent claudication.23,24 When the same group of investigators reported their results in vari-
ous journals, all reports were examined for similarities and completeness, and the results were treated 
as those of a single study in our review.25,26
Data were abstracted independently by the same two authors who selected the publications. The 
following parameters were recorded: study design; patient characteristics; measures of severity of 
claudication, such as Rutherford classification, walking distance, and ABI; type of exercise training or 
intervention; outcomes; and follow-up results reported by using standardized forms. The exercise 
training programs were evaluated by the same two authors, and discrepancies between the evalua-
tions were resolved with consensus.
Functional Capacity and Quality of Life
The ABI at rest and the maximum treadmill walking distance are the most frequently reported out-
comes of functional capacity. The ABI is defined as the ratio of the systolic blood pressure measured 
at one of the ankle arteries to the systolic blood pressure measured at the brachial artery.9 The most 
efficient and reliable test for the determination of the maximum walking distance is considered to be 
a treadmill test.27
The Medical Outcomes Study 36-Item Short Form (SF-36) health survey was most frequently used in 
studies in which investigators evaluated quality of life after exercise training or PTA in patients with 
intermittent claudication. The SF-36 survey was developed to evaluate the physical, social, and physi-
cal role functioning of patients and to elicit their perceptions of their general health and well-being 
in eight dimensions.28 Each dimension is subjectively rated by the respondent and assigned a score 
on a scale of 0–100 in which 100 indicates best functioning or well-being. In previous studies, it was 
demonstrated that the dimensions of physical functioning, bodily pain, and physical role functioning 
showed the most substantial improvement after treatment in patients with intermittent claudica-
tion.29 In this study, therefore, we concentrated on the following three dimensions: physical function-
ing (limitation of usual activities because of a physical problem), physical role functioning (limitation 
of usual role activities because of a physical problem), and bodily pain (pain or discomfort in the 
body). In addition, we added the dimension of general health. If data from the SF-36 survey were not 
reported but data from SF-20 (a shorter version of the same survey) were available, the SF-20 data 
were used. For studies of exercise training, data beyond 6 months of follow-up were not available, 
and for studies of PTA, data at 6 months were poor. The weighted means for functional capacity and 
the quality-of-life scores in the PTA studies did not change significantly between 3 months and 12 
months of follow-up. Therefore, to improve the comparison between the exercise training and PTA 
studies at 6 months of follow-up, we used the data obtained at 12 months of follow- up to calculate 
the weighted means at 6 months.
Statistical Analysis of Data
To pool data for discrete variables such as male sex, cardiac disease, hypertension, diabetes mellitus, 
pulmonary disease, hyperlipidemia, stroke, history of smoking, and current smoking, the random ef-
fects model described by Laird and Mosteller30 was used. The random effects model takes into ac-
count the variance between studies, as well as that within studies. Because of the lack of reported 
data for variance around the means of continuous variables such as age, ABI, walking distance, and 
quality-of-life score, we were unable to use the random effects model to pool the continuous vari-
ables. Therefore, we calculated the weighted mean and 95% confidence interval (CI) for these vari-
ables.
Within the treatment study groups of exercise and PTA, the dichotomous baseline characteristics 
of all patients in the included studies were tested for homogeneity by using the Â2-test (statistical 
significance level, ®   = .05). Differences in pooled patient characteristics between the studies of PTA 
and those of exercise were tested with the Â2-test and with the paired (two-sample) Student t-test 
(statistical significance level, ®   = .05, two sided).
Improvements in functional capacity and quality of life between baseline and 3 months of follow-up 
and between baseline and 6 months of follow-up within the exercise study group and within the PTA 
study group were calculated and tested for statistical significance (paired Student t-test, ®   = .05).
A funnel plot was constructed to detect the presence of publication bias (i.e. bias resulting from the 
greater likelihood of publication for studies reporting a positive result than for studies reporting a 
negative result).31 In the current study, we plotted the number of patients who underwent exercise 
training or PTA as a function of the mean change in physical functioning (i.e. baseline data vs data 
at 3 months of follow-up [or 6 months of follow-up, if 3-month follow- up data were unavailable]). If 
there is no publication bias, the distribution of the data points will be symmetric and shaped like an 
inverted V.
The analyses were performed with software (Excel, release 2003, Microsoft Corporation, Redmond, 
Wash; SPSS, release 11.0.1, SPSS, Chicago, Ill).
RESULTS
Selected Articles and Comparisons
From the literature search, a total of 380 abstracts published between January 1980 and February 
2003 were selected. Many studies (n = 348) were excluded on the basis of the abstract for the follow-
ing reasons: There was no relation with peripheral arterial disease (n  = 191); drug use in patients with 
intermittent claudication was investigated (n = 78); only patients with ischemia were included in the 
study (n = 23); patients with both intermittent claudication and ischemia were included in the study, 
without differentiation according to disease severity in the reported results (n = 2); or the follow-up 
period was shorter than 3 months (n = 54). Of the remaining 32 studies, 22 were excluded because 
patient characteristics were missing (n = 5), no data on both functional capacity and quality of life 
were reported (n = 16), or dichotomous outcomes were used for walking distances (n = 1). Of the 10 
eligible articles, two25,26 reported data from the same study population and were therefore consid-
ered as one study. All publications from studies that met our selection criteria reported either SF-36 or 
SF-20 survey data, with two exceptions: In one article32, data from the Nottingham Health Profile ques-
tionnaire were reported, and in another article33, data from a disease-specific questionnaire, PAVK-86, 
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were reported instead. To improve the comparison of quality-of-life scores between the studies, we 
excluded these two studies from our systematic review. Thus, seven studies12,25, 26,34–38 with a total of 
202 patients who underwent exercise training therapy and 470 patients who underwent PTA (Tables 
1 and 2) were included in our review.
Four of the seven studies were randomized controlled trials (Table 1). However, in none of these 
randomized controlled trials was exercise training compared with PTA directly: In one study, primary 
stent placement was compared with primary PTA, and in three randomized controlled trials, different 
types of exercise training were compared. The remaining three studies were prospective cohort stud-
ies; in one of these, exercise training and PTA were compared. Follow-up periods varied from 3 to 24 
months; in only one study was the mean follow-up period (14.7 months) reported.12
Many baseline demographic and patient characteristics were not reported (Table 3). The percentage 
of male patients was 69% in the exercise training group and 73% in the PTA group (p= .56). The mean 
age of patients in the exercise training group also was not significantly different from that in the PTA 
group (68 vs 63 years, respectively; p= .33).
Across the studies in each treatment group, homogeneity was found in the proportion of the study 
population with male sex, coronary artery disease, hypertension, pulmonary disease, hyperlipidemia, 
stroke, and smoking behavior. Among the studies in the exercise training group, heterogeneity was 
found in regard to the percentage of patients with diabetes mellitus and the percentage of patients 
who were current smokers. Among the studies in the PTA group, no heterogeneity was found for 
these comorbidities.
Between the two treatment groups, patient characteristics were similar, except in regard to the per-
centages of patients with hypertension and stroke, which were significantly higher in the exercise 
training group than in the PTA group (64% vs 31%, p= .01, for hypertension; 23% vs 11%, p= .03, for 
stroke). 
The weighted mean ABI at baseline in the exercise training group was lower than that in the PTA 
group (0.64 vs 0.71), but the difference was not statistically significant (p= .13). Also, no statistically 
significant difference was found in the weighted mean for maximum walking distance at baseline 
between the exercise training group and the PTA group (289 m vs 155 m, respectively; p= .11).
To detect publication bias, we constructed two funnel plots: one for the PTA group, and one for the 
exercise training group. Neither plot appeared symmetric. There were too few studies, however, to 
permit a proper evaluation of publication bias.
Exercise Training Programs
The exercise training programs differed across the studies (Table 4). These differences included varia-
tions in supervision, intensity, frequency, duration, and type of exercise. Of the five studies included in 
the exercise training group, one study involved supervised training, one study involved unsupervised 
training, and three studies each included one group with supervised training and one group with 
unsupervised training. Supervision implied that patients participated in a structured hospital-based 
exercise program. 
In all programs, the frequency of supervised exercise training was at least three times per week, and 
walking was the mode of exercise used. In addition to walking, one study used a combination of 
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Study Inclusion criteria Exclusion criteria
Bosch et al12 Intermittent claudication or critical ischemia 
caused by stenosis or occlusion in the iliac 
arteries
Stenosis of more than 10 cm in length; arterial 
occlusion of more than 5 cm, or of 5 cm or less 
in length and not allowing the passage of a 
guidewire; stenosis involving the distal aorta; 
severe comorbidity (eg, severe cardiac or cere-
brovascular abnormality, malignant disease); 
and nonmedical factors such as inability to un-
derstand Dutch, or expected poor compliance
Chetter et al25 Treatment with PTA for intermittent claudica-
tion
Critical ischemia as defined by the European 
Consensus document
Curie et al34 Intermittent claudication and lower limb ar-
terial disease potentially suitable for vascular 
intervention
Not reported
Gardner et al35 Positive response on Rose et al (45) question-
naire, age  60 years, ABI  0.97
Fontaine stage I or III disease; exercise toler-
ance limited by factors other than claudica-
tion; poorly controlled hypertension; pulmo-
nary disease; hemiparetic gait; severe arthritis; 
poorly controlled diabetes mellitus; active ma-
jor medical problem, including cancer, renal 
or liver disease, anemia, substance abuse, and 
dementia
Patterson et al36 Symptoms  3 months, ABI  0.9 at rest, or systolic 
blood pressure decrease of 15 mm Hg or more 
after exercise test
Ischemic rest pain or tissue loss, inability to 
participate in an exercise program because of 
limitations of comorbid illness, failed cardiac 
screening
Regensteiner et al37 Stable intermittent claudication  3 months; ABI 
0.94 at rest, decreased to  0.73 after exercise 
test
Pain at rest, no ischemic ulceration or gangrene, 
inability to walk on the treadmill at a speed  2 
mph, symptoms of angina, congestive heart 
failure, chronic obstructive pulmonary disease, 
arthritis, diabetes, previous vascular surgery or 
angioplasty within previous year
Savage et al38 Age  50 years; Rutherford stage I, II, or III disease; 
unilateral intermittent claudication
Unstable cardiopulmonary disease; severe 
extremity arthritis; tobacco use; weight  40 kg 
above ideal; renal insufficiency; use of beta-
blocker, pentoxifylline, or cilostazol within 8 
weeks of entry; functioning lower extremity 
bypass; severe cognitive impairment
Note.—PTA = Percutaneous Transluminal Angioplasty, IC = Intermittent Claudication, ABI = Ankle Brachial Index
Table 2: Criteria for Inclusion or Exclusion of Patients in Each Study
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walking, standing on tiptoe, and cycling.33,36 The duration of the supervised exercise training session 
varied from 15 to 60 minutes. The duration of the exercise training programs varied from 12 to 24 
weeks. The mean percentage of compliance among patients in the supervised programs varied from 
73% to 100%. (In one study, compliance was not reported.)
In the four unsupervised programs, the type and intensity of contact with the patient varied from 
weekly or monthly conversations by telephone to weekly lectures and instructions or to no contact 
during the exercise program. In one study, patients were asked to maintain a weekly log. The mean 
compliance of the patients in the unsupervised programs varied from 78% to 100% (in one study, 
compliance was not reported).
Functional Capacity
All studies reported the ABI during rest at baseline (Table 5). The maximum walking distance was 
determined in two of the three studies in the PTA group and in four of the five studies in the exercise 
training group. It should be noted that the test duration and the speed and grade settings used dur-
ing the treadmill test to determine the maximum walking distance varied between studies. Grades 
of 0%–10% were used with speeds of 1–2 mph (1.6–3.2 km/h), either fixed or increased in increments 
of 1 or 2 mph.
In the exercise training group, 1- or 2-year follow-up data were not available (Table 5). Improvement 
was shown in the mean ABI at rest between baseline and 3- or 6-month follow-up, but the difference 
was not statistically significant (p= .29 and p= .73, respectively) (Fig 1). At 3 months, there was no 
statistically significant improvement in the mean maximum walking distance (p= .09), but a statisti-
cally significant improvement in the mean maximum walking distance was demonstrated between 
baseline and 6-month follow-up (p= .02).
In the PTA group, a significant improvement in the mean ABI at rest was demonstrated at 3 and 6 
months of follow- up (p< .01 for both) (Fig 1). In addition, a statistically significant improvement in the 
mean maximum walking distance was demonstrated at 3 months (p= .01) and 6 months (p< .01).
The difference between the two treatment groups in ABI at 3 and 6 months was significant (p< .01 
and p= .02, respectively). Although the weighted means of the maximum walking distance at base-
line were not significantly different between the treatment groups, we did not compare this outcome 
of functional capacity during follow-up, because of the variation in measurements of the maximum 
walking distance among the studies.
Quality of Life
In the exercise training group, the mean scores for the dimensions of physical functioning, physical 
role functioning, bodily pain, and general health demonstrated improvement at 3 and 6 months (Fig 
2, Table 6). However, the improvement was statistically significant only for the dimensions of physical 
functioning and bodily pain at 3 months and for the dimension of bodily pain at 6 months. The effect 
of treatment was highest for the dimension of physical functioning at 3 months (p< .01).
In the PTA group, mean scores for the dimensions of physical functioning, physical role functioning, 
bodily pain, and general health showed improvement at 3 and 6 months. Improvements were statisti-
cally significant for the dimensions of physical role functioning and general health at 3 months (Fig 
2, Table 6). The effect of treatment was greatest for the dimension of physical role functioning after 3 
months (p< .01).
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Follow-up
Baseline 3 months 6 months
Study, Reference, and
Patient Group
ABI rest
Maximum Treadmill
Walking 
Distance (m)
ABI rest
Maximum Treadmill
Walking 
Distance (m)
ABI rest
Maximum Treadmill
Walking 
Distance (m)
Exercise Training Studies
Currie et al34 Group 1 0.65 ND 0.64 ND ND ND
Gardner et al35 0.68 396 ND ND 0.67 702
Patterson et al36
 Group 1 0.57 145 ND ND ND ND
 Group 2 0.59 145 ND ND ND ND
Regensteiner et al37
  Group 1 0.64 245 0.63 ND ND ND
 Group 2 0.56 331 0.53 ND ND ND
Savage et al38
 Group 1 0.75 532 0.76 763.5 0.71 742
 Group 2 0.71 521 0.71 833.3 0.81 715
All of the above
 Weighted mean 0.64 289 0.65 787 0.71 713
 95% CI
  Lower limit 0.54 -0.04 0.55 690 0.62 682 
  Upper limit 0.74 579 0.75 884 0.80 744
PTA Studies
Bosch et al12
  Group 1 0.74 190 0.92 263 0.92* 261*
 Group 2 0.73 204 0.93 255 0.94* 263*
Chetter et al25 0.65 56 0.88 111 0.87* 125*
Currie et al Group 234 0.70 ND 0.81 ND ND ND
All of the above
 Weighted mean 0.71 155 0.89 215 0.91* 222*
 95% CI
  Lower limit 0.64 29 0.89 83 0.87 99
  Upper limit 0.78 282 0.90 348 0.95 344
Note.—ND  no data.
* Twelve-month follow-up values.
Table 5: Functional Capacity in the Exercise Training and PTA Study Groups at Baseline and du-
ring Follow-up
There were no significant differences at baseline between the two treatment groups with regard to 
the dimensions of physical functioning, physical role functioning, bodily pain, and general health. In 
addition, no significant differences in the mean change of quality of life were demonstrated between 
the two treatment groups during follow-up.
Figure 1. Weighted means and 95% CI of Ankle-brachial Indices for the exercise training and PTA 
group at baseline and during follow-up
* Significant difference between the two groups.
† If 6 months values were not available, the 12 months values were used. 
§ Significant improvement in group during follow-up.
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Figure 2. Weighted means and 95% CI of SF-36 dimensions for the exercise training and PTA 
group at baseline and during follow-up.
* Significant difference between the two groups.
† If 6 months values were not available, the 12 months values were used. 
§ Significant improvement in group during follow-up.
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Study, Reference, and
Patient Group
baseline 3 months 6 months
PF PRF BP GH PF PRF BP GH PF PRF BP GH
Exercise Training Studies
Currie et al34 Group 1 36 26 42 ND 39* 31* 49* ND ND ND ND ND
Gardner et al35 41 ND ND ND ND ND ND ND 41 ND ND ND
Patterson et al36
 Group 1 43 45 53 64 52 44 64 65 56 49 62 64
 Group 2 41 30 51 60 53 49 61 62 54 45 64 64
Regensteiner et al37
 Group 1 52 65 ND 45 72 63 ND 56 ND ND ND ND
 Group 2 61 65 ND 50 71 66 ND 40 ND ND ND ND
Savage et al38
 Group 1 54 84 59 71 60 77 70 64 56 84 65 66
 Group 2 45 47 50 67 61 68 72 65 54 47 64 65
All of the above
 Weighted Mean 42 40 47 61 50 45 57 61 56 52 63 64
 95% CI
  Lower limit 29 6 36 46 28 15 40 46 36 27 61 63
  Upper limit 55 74 58 75 71 74 73 75 77 77 66 66
PTA Studies
Bosch et al12†
  Group 1 40 27 50 57 74 67 78 63 7 0 ‡ 6 2 ‡ 7 5 ‡ 6 0 ‡
 Group 2 42 32 49 53 74 64 74 58 7 6 ‡ 6 8 ‡ 7 5 ‡ 5 9 ‡
Chetter et al26§ 35 2 44 ND 50 25 44 ND 50 25 56 ND
Currie et al34 Group 2 38 27 41 ND 50* 46* 58* ND ND ND ND ND
All of the above
 Weighted Mean 39 22 47 55 64 52 65 61 66 53 69 60
 95% CI
  Lower limit 34 -1 40 51 41 19 38 56 45 17 52 59
  Upper limit 44 45 54 59 87 86 92 66 87 89 86 61
Notes.—Unless otherwise specified, data are mean values from ratings on a scale of 0–100, with 0 indicating worst health and 100 indicat-
ing perfect health. BP  bodily pain, GH  general health, ND  no data, PF  physical functioning, PRF  physical role functioning.
 * Values are medians obtained from Chetter et al 26 for the same study population.
 † Values were obtained from Klein et al 47 for patients in the Dutch Iliac Stent Trial.
 ‡ Values were obtained at 12-month follow-up.
 § Values are medians.
Table 6: Quality of Life in Exercise Training and PTA Study Groups at Baseline and during Follow-
up
DISCUSSION
In the current systematic review, functional capacity and quality-of-life outcomes after exercise train-
ing or PTA were reviewed and compared. Results demonstrated that at 3 and 6 months of follow- up 
the ABI was significantly improved in the PTA group but not in the exercise group. Quality of life was 
significantly improved in the dimensions of physical functioning and bodily pain in the exercise group 
and in the dimensions of physical role functioning and general health in the PTA group at 3 months. 
ABI significantly differed between the two treatment groups at 3 and 6 months, whereas the mean 
change in the quality-of- life scores did not significantly differ between the groups during follow-up.
To our knowledge, no review has been published in which exercise training and PTA are compared 
with regard to both functional capacity and quality of life. In addition, results have been published 
from only two randomized controlled trials in which exercise training and PTA were directly com-
pared.32,39 These studies, however, did not meet our inclusion criteria; one study did not report both 
functional capacity and quality of life, and the other study did not use the SF-36 survey for qual-
ity-of-life assessment. The results of one of these studies showed that, at 12 months of follow-up, 
patients with mild or moderate intermittent claudication who underwent supervised exercise train-
ing had greater symptomatic improvement than did patients who underwent PTA.39 Results of the 
other study showed no significant difference in quality of life between control subjects (patients after 
unsupervised exercise training) and the PTA group after 2 years of follow-up.32,40 The PTA group, how-
ever, included substantially fewer patients with arterial occlusion and/or severe stenosis than did the 
exercise group. Data from these two randomized controlled trials were collected for a review, but the 
trials were relatively small, and the results must be interpreted with caution.41
Unfortunately, one of the limitations in our systematic review was that data for both functional ca-
pacity and quality of life were inconsistently reported. In particular, data about long-term functional 
capacity and quality-of-life outcomes for exercise training after 6 months were lacking, and, in con-
sequence, the deleterious effect of postangioplasty restenoses must have been somewhat underes-
timated. Furthermore, many baseline demographic and patient characteristics that may have been 
relevant to a comparison between treatment groups, such as the disease location (aortoiliac vs femo-
ropopliteal arteries), smoking history, and the use of medications (eg, cilostazol, statins), were not 
reported.
Another limitation, which became apparent after review of the exercise training programs, is the 
lack of standardization in the different components of exercise training. This limitation hampered 
the comparison of the reported results of the different studies. Investigators in the different exercise 
training studies evaluated the effectiveness of supervised or unsupervised exercise programs, but 
the relative effectiveness of these programs is still controversial. Some studies, particularly those per-
formed in Europe, have shown good results with a home-based exercise program.42,43 Other studies, 
however, have shown little benefit for this type of program,37 whereas supervised exercise has pro-
vided consistent clinical improvement in almost every study.8,36 –38 There is also a lack of standardiza-
tion of the treadmill test with regard to the use of fixed loading or graded loading, different speeds, 
and different maximum walking times. A longer walking distance was used in the exercise studies 
than in the PTA studies. These different protocols could help to explain the different maximum walk-
ing distances reported at baseline and during follow-up between the two treatments. The existence 
of this bias hampered comparison between the two treatments.
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Another limitation of our study was the potential publication bias. However, studies in the exercise 
training group were relatively small, and there were only four studies in the PTA group, which limits 
power for detection of publication bias. Another limitation of the current systematic review is that 
the included studies were not randomized controlled trials in which exercise training was compared 
with PTA. This implies that the population undergoing exercise training may differ from the popula-
tion undergoing PTA. Nevertheless, in our study, most patient characteristics were not significantly 
different between the treatment groups. Even though randomized controlled clinical trials are sup-
posed to be the superior mode for evaluating and comparing different treatment modalities, they 
too have limitations.44 In general, a randomized trial is performed in an ideal setting, with a selected, 
usually small, patient population, which may hamper generalization of the results. Systematic reviews 
of cohort studies, on the other hand, may reflect general clinical practice and provide additional data 
about a larger number of patients.
There is still no evidence that quality of life for patients with intermittent claudication is significantly 
better after PTA than after exercise training after more than 6 months. Patients with intermittent clau-
dication are often treated conservatively; however, various exercise training programs are used.34–38 
In addition, the definitions of supervised exercise and unsupervised exercise vary widely in European 
countries. Therefore, a standardized exercise training program with measurement of the maximum 
walking distance according to a universally accepted standard would be desirable. Over the past 
decade, PTA has been more widely used in patients with intermittent claudication, mainly because 
of its low associated morbidity and mortality.11–13 PTA, however, is a local form of treatment, and it is 
therefore not surprising that patients may experience relapse after PTA, with ipsilateral or contralateral 
symptoms representing progressive disease at other sites; the benefit with PTA may be a short-term 
effect. A randomized controlled trial of both treatments with long-term follow-up will enable further 
evaluation of effectiveness and determination of functional capacity and quality of life after more 
than 6 months.
In conclusion, our results demonstrate an improvement in quality of life after exercise training, where-
as both functional capacity and quality of life showed significant improvement after PTA. ABIs in the 
PTA group were significantly higher than those in the exercise training group at 3 and 6 months, 
whereas the mean change in quality-of-life scores was not significantly different between the two 
groups during follow-up. Despite the limitations outlined, our analysis has shown the best evidence 
that we have. This is what we know at this point in time, and more needs to be done.
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INTRODUCTION
Intermittent claudication (i.e., Rutherford category 1, 2, or 3) is the most common clinical manifesta-
tion of peripheral arterial disease.1,2 The prevalence varies from 3% to 6% in patients aged 40 to 60 
years.3 As Western society ages, the incidence of intermittent claudication is expected to increase, 
making questions related to its treatment pertinent.4 
Larsen and Lassen5 were the first to recommend exercise training for the treatment of intermittent 
claudication. Exercise training is also recommended as the initial treatment in the Trans-Atlantic Inter-
Society Consensus Document on Management of Peripheral Arterial Disease of 2007 (TASC II).3 En-
dovascular revascularization, however, is becoming more common, presumably because it provides 
immediate benefit and therefore may prevent ‘unnecessary disability’.3 
This randomized controlled trial aimed to compare clinical success, functional capacity, and health-
related quality of life during 12-months follow-up after endovascular revascularization or supervised 
hospital-based exercise training in patients with intermittent claudication.
METHODS
This trial was a single-center randomized controlled trial, in which the clinical effectiveness of primary 
endovascular revascularization was compared to supervised hospital-based exercise training as the 
initial treatment for patients with intermittent claudication (Rutherford category 1, 2, or 3). The study 
was conducted within the context of a large community hospital. We adhered to the guidelines for 
Good Clinical Practice, and the trial was registered under number ISRCTN 64443682.6 Study data were 
analyzed and reported in accordance with the CONSORT guidelines.7 The study was approved by the 
Institutional Review Board, and all patients gave written informed consent.
PATIENTS
From September 2002 to September 2005, all new patients with symptoms of intermittent claudica-
tion referred to the Department of Vascular Surgery were considered for recruitment (Figure 1). Inclu-
sion criteria were: 1) Symptoms of intermittent claudication (Rutherford category 1, 2, or 3) of at least 3 
months duration; 2) a maximum pain-free walking distance of <350m; 3) an ankle-brachial index (ABI) 
of <0.9 at rest or a decrease in ABI after the treadmill test of >0.15; 4) one or more vascular stenoses 
of >50% diameter reduction or occlusions at the iliac or femoro-popliteal level; 5) informed consent. 
Exclusion criteria were: 1) presence of an abdominal aortic aneurysm; 2) life-incapacitating cardiac 
disease (NYHA classification II and higher8); 3) multilevel disease (i.e., stenoses/occlusions at both the 
iliac and femoral levels on the symptomatic side — multiple lesions limited to only the iliac or only the 
femoral level were not exclusion criteria); 4) isolated crural artery disease; 5) lesions deemed unsuit-
able for endovascular revascularization (iliac or femoropopliteal TASC-type D and some TASC type-B/
C lesions9); 6) prior treatment for the same lesion (including exercise training). Multiple stenoses local-
ized in one iliac arterial segment (i.e., common iliac or external iliac artery) were classified as a single 
lesion. Inclusion of the patient was decided at the multidisciplinary vascular conference by consensus 
between the vascular surgeons and interventional radiologists.
ABSTRACT
Purpose: To compare clinical success, functional capacity, and health-related quality of life during 12-
months follow-up after endovascular revascularization or supervised hospital-based exercise training 
in patients with intermittent claudication.
Materials and methods: Between September 2002-September 2005, we randomly assigned 151 con-
secutive patients, with intermittent claudication, to receive either endovascular revascularization -an-
gioplasty-first approach- (n=76) or hospital-based supervised exercise (n=75). The outcome measures 
were clinical success, functional capacity, and health-related quality of life after 6- and 12-months. 
Significance of differences between the groups was assessed using the unpaired t-test, Â2-test, or the 
Mann-Whitney U-test. We performed multivariable regression analysis to adjust outcomes for imbal-
ances of baseline values 
Results: Immediately after the start of treatment, revascularization patients improved more than exer-
cise patients in clinical success (OR 39; 95% CI 15-98, p<0.001), but this advantage was lost after 6- and 
12-months (OR 1.2; 95% CI 0.5, 2.5, p = 0.70 and OR 0.9; 95% CI 0.4, 1.7, p = 0.73 respectively). After 
revascularization, fewer patients exhibited ipsilateral symptoms at 6 months compared to exercise 
(37% vs 69%; OR 0.4; 95% CI 0.2, 0.7, p < 0.001), but no significant differences were demonstrated at 
12 months. After both treatments, functional capacity and quality-of-life scores increased after 6- and 
12-months; however, only the maximum pain-free walking distance after 6 months was significantly 
different between the treatment groups (exercise group higher; a mean difference 16 meters; 95% CI 
2, 29 meters, p  = 0.02). No other outcomes, and no outcomes at 12 months, demonstrated significant 
differences.  
Conclusion: The results demonstrate that after 6- and 12-months patients with intermittent claudica-
tion benefited equally from either endovascular revascularization or supervised hospital-based exer-
cise. Improvement is, however, more immediate following revascularization.
ENDOVASCULAR REVASCULARIZATION VERSUS  
SUPERVISED HOSPITAL-BASED EXERCISE TRAINING FOR 
INTERMITTENT CLAUDICATION: CLINICAL EFFECTIVENESS 
IN A RANDOMIZED CONTROLLED TRIAL
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INTERVENTIONS
Endovascular revascularization was performed as a balloon angioplasty-first approach followed by 
stent placement if the result of balloon angioplasty was deemed unsatisfactory. Revascularization 
was performed using a 10% oversized balloon (Powerflex or Opta-Pro; Cordis Johnson & Johnson; 
Miami, FL). For iliac revascularization, the initial balloon angioplasty was considered technically suc-
cessful if the residual pressure gradient across the treated arterial segment was <10 mm Hg at rest. If 
the post-procedural pressure gradient exceeded 10mm Hg, a 9 mm-diameter, self-expanding nitinol 
stent was placed (Luminexx; Bard; Tempe AZ). In femoral revascularization, the decision to place an 
additional 6 mm-diameter self-expanding nitinol stent was based on evaluation of the post-balloon 
angioplasty angiogram. 
Supervised hospital-based exercise was conducted on a walking treadmill for 30 minutes/session, 
twice weekly, during 24 weeks. A vascular technologist supervised each training session. Treadmill ex-
ercise was initiated at a workload of 3.5 km/h without a graded incline. Patients decreased workload 
to 1 km/h when, in their perception, maximum claudication pain occurred and continued exercising 
at this reduced workload until the pain subsided, usually after a brief period (range 1-3 minutes), 
after which the workload was increased again. If a patient improved his or her walking ability (as evi-
denced by an increase in maximum pain-free walking distance compared to previous sessions), the 
workload was increased by modifying the treadmill grade or speed (or both as tolerated) to ensure 
that there was always a stimulus of claudication pain during the workout. In addition, all patients were 
instructed to walk for at least 3x30 minutes weekly outside the hospital setting. After the 24-week 
supervised exercise program, patients were encouraged to continue their walking exercise in their 
own environment.
In addition to revascularization or exercise training, all patients underwent management of risk fac-
tors, including hypertension, serum glucose, cholesterol, lipid profile, and homocysteinaemia (in pa-
tients <50 years), and all were prescribed aspirin therapy (100 mg/day).
CLINICAL EFFECTIVENESS
Clinical effectiveness included clinical success, functional capacity, and health-related quality of life. 
Clinical success was defined as an improvement of at least one category in the Rutherford scale above 
the pre-treatment level, following the standards of the Society of Vascular Surgery/International So-
ciety of Cardiovascular Surgery (SVS/ISCVS).10 Clinical success was measured one week after revascu-
larization or after the first two exercise sessions (i.e., one week), and at 6 and 12 months of follow-up. 
Furthermore, we determined whether clinical success at follow-up was impaired by recurring symp-
toms of intermittent claudication on the initial symptomatic side (ipsilateral) or alternatively, by new 
symptoms on the contralateral side by using the presence of symptoms as a binary outcome (yes or 
no). We defined “contralateral symptoms” as the first occurrence of any contralateral symptoms in the 
limb including claudication and rest pain that was not the indication for the initial treatment. 
Functional capacity was expressed as ABI, maximum pain-free walking distance, and maximum walk-
ing distance. The ABI was measured at rest and following treadmill walking (speed 3.5 km/h, without 
a graded incline) and the maximum- and pain-free walking distance were reported. Clinical success 
and functional capacity were both evaluated by an independent observer who was blinded to the 
specific treatment that had been assigned, and patients were instructed not to discuss their assigned 
treatment. 
After written informed consent was obtained, the patient was assigned to a specific treatment arm 
using a computer-generated randomization list that had been prepared in advance by an indepen-
dent statistician. Block randomization with a block size of 16 was used. The local trial coordinator (SS) 
was unaware of treatment assignment prior to randomization. 
Figure 1: Flow diagram of study.
Diagram illustrates reasons for exclusion, random assignment to endovascular revascularization and supervised hospital-based exercise 
training and the treatment actually received, including 6- and 12-months follow-up.
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Significance of differences in mean score improvement between the treatment groups was assessed 
with the unpaired t-test or the Â2-test. To adjust outcomes for imbalances of baseline values and 
characteristics between the treatment groups, we performed multivariable regression analysis. The 
variables included were baseline scores, age, gender, diabetes mellitus, smoking, hypertension, hyper-
lipidaemia, and disease severity (mild/moderate claudication vs. severe claudication). These variables 
were selected based on the TASC II report3 and on clinical judgment. In the analyses, imputation of 
mean values for clinical success, functional capacity, and quality of life at 6- and 12-months follow-up 
was performed for patients who died of causes other than peripheral arterial disease and for patients 
who refused a follow-up visit.16 There were no patients who died of peripheral arterial disease.
A significance level of 0.05 was considered statistically significant. Calculations were performed with 
SPSS 14.0 for Windows (SPSS Inc., Chicago, IL).
RESULTS
Patients and treatments
During the inclusion period, 293 new, potentially-eligible patients with intermittent claudication were 
seen at the Department of Vascular Surgery (Figure 1). Fourteen patients refused to participate in 
the study, and 128 were excluded based on the study criteria. Thus, 151 patients entered the study, 
of whom 76 were randomized to revascularization and 75 to exercise training. One patient refused 
further participation after randomization to revascularization but before baseline data was collected. 
This patient was excluded from analysis. Thus, 150 patients were analyzed (Figure 1). 
The two treatment groups had similar demographics and co-morbidities (Table 1). In addition, there 
was no significant difference at baseline in functional capacity or quality-of-life scores, except for the 
maximum pain-free walking distance, which was significantly higher in the exercise group (p = 0.04) 
(Table 1). 
Table 2 shows the lesion characteristics of the two groups. Four patients failed endovascular revas-
cularization technically. Two of these patients were advised a home-based exercise program, and 2 
patients underwent surgery. Stents were used in 46 of 71 iliac lesions in 34 patients and in 20 of 40 
femoral lesions in 16 patients. Asymptomatic iliac and femoral lesions on the contralateral side re-
mained untreated. The two groups had a similar distribution of lesion characteristics (Table 2).
The mean number of sessions in the exercise program was 33 (+/-10; median 32). During follow-up, 
10 patients in the revascularization group and 11 patients in the exercise group underwent additional 
treatment (Table 3). Eight patients in the exercise group underwent endovascular revascularization 
whereas no patient crossed-over in the opposite direction (Figure 1). There were 10 patients lost 
during the follow-up period because of death (n=9), or refusal to continue participation in the study 
at 12-months (n=1) (Figure 1). In the revascularization group, the response rate to the questionnaires 
was 92% (69 of 75) at 6 months and 89% (67 of 75) at 12 months. In the exercise group, the response 
rate was 99% (74 of 75) at 6 months, and 96% (72 of 75) at 12 months. 
Clinical outcomes
Health-related quality of life was assessed using the generic Medical Outcomes Study 36-Item 
Short-Form Health Survey (SF-36) and the disease-specific Vascular Quality-of-life questionnaire (Vas-
cuQol).11,12 The SF-36 was developed to evaluate physical-, social-, and physical-role functioning of 
patients and to elicit their perceptions of their general health and well-being in eight different health 
dimensions.11 Based on a previous study, we determined that four of the eight health dimensions 
were relevant to describe the health status of intermittent claudication (physical-functioning, role-
functioning limitations due to physical problems, bodily pain, and general health perceptions).13 The 
scoring per dimension is valued on a 100-point scale from 0 (worst-outcome) to 100 (best-outcome). 
The VascuQol is a questionnaire especially developed for patients with peripheral arterial disease and 
is responsive to subtle effects after, for example, endovascular revascularization or exercise training.12 
The questionnaire contains five domains (activity, symptom, pain, emotion, and social functioning), 
in which 0 means death and 7 indicates maximum health.
In addition, the EuroQol-5D, rating scale, and costs were assessed, but these results are reported sepa-
rately in a manuscript focusing on the cost-effectiveness outcomes. 
DATA ANALYSIS
The required sample size was estimated based on the primary outcome, which was the mean im-
provement of quality-of-life. With adequate treatment, approximately 40-50% of patients were ex-
pected to have a substantial improvement of their symptoms after 6 months as measured by the 
physical functioning attribute of the SF-36.13,14 A percentage difference of 20-25% between the treat-
ment groups was considered to be clinically relevant.15 To demonstrate a difference of 25% with an 
alpha of 0.05, a power of 0.80, and a 2-sided test of differences in unpaired proportions with an esti-
mated 45% improvement in the control group, required 68 patients in each trial arm. With 2 trial arms, 
this implied recruiting 136 patients for the trial. To allow for some redundancy, we recruited 15 extra 
patients. 
Results were analyzed according to the intention-to-treat principle, which implies that once a patient 
was randomly allocated, the patient remained in the allocated group for the analysis regardless of 
whether cross-over to the other strategy occurred and of whether follow-up was completed. The 
only patients excluded from the analysis were those for whom no data was available as they refused 
further participation immediately following randomization. 
Significance of differences between group means at baseline was assessed with the unpaired t-test 
or the Mann-Whitney U-test, as appropriate, whereas dichotomous outcomes were assessed with the 
Â2-test. 
To assess the difference in the clinical success rate between the treatment groups, we calculated the 
Odds-Ratios (OR) of revascularization versus exercise at 6- and 12-months follow-up. To assess a pos-
sible interaction between the treatment strategy and the level of disease (iliac vs. femoral disease) 
on clinical success, we performed a logistic regression analysis. In the model, clinical success was 
the dependent variable, and an interaction term for treatment strategy and the level of disease was 
included. In addition, we calculated ORs to determine if the clinical success at follow-up became 
impaired by recurring symptoms of intermittent claudication on the initial symptomatic side or alter-
natively, by new symptoms on the contralateral side. 
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exercise program lasted 6 months) (Figure 2). Although clinical success at 1 week was significantly 
higher with revascularization than with exercise (OR 39; 95% CI 15, 98, p<0.001), there was no statisti-
cally-significant difference at 6- or 12-months follow-up (75% vs. 77%; OR 0.9; 95% CI 0.4, 1.8, p=0.70 
and 68% vs. 65%; OR 1.1; 95% CI 0.6, 2.2, p=0.73 respectively). Clinical success of revascularization 
versus exercise was not significantly associated with the interaction term “treatment group and level 
of disease” after 6- or 12-months (OR 2.1; 95% CI 0.9, 5.1, p=0.07 and OR 0.9; 95% CI 0.4, 1.8, p=0.70 
respectively).
At 6 months after revascularization, there were significantly less patients with recurrent or remaining 
symptoms of intermittent claudication on the ipsilateral side on the binary yes/no scale compared 
to the exercise group (37% vs. 69%; OR 0.4; 95% CI 0.2, 0.7, p<0.001) (Figure 3). However, there was 
no significant difference in symptoms on the ipsilateral side between the groups at 12 months (41% 
vs. 58%; OR 0.7; 95% CI 0.4, 1.3, p=0.25) (Figure 3). The percentage of patients with new symptoms of 
intermittent claudication on the contralateral side was higher — but not statistically-significant — in 
the revascularization group than in the exercise group after 6- and 12-months (17% vs. 8%; OR 2.4; 
95% CI 0.9, 6.7, p= 0.09 and 21% vs.17%; OR 1.6; 95% CI 0.6, 4.2, p=0.34 respectively) (Figure 3).
After both revascularization and exercise, there was an improvement at both 6- and 12-months in 
the mean ABI, the maximum pain-free walking distance, and the maximum walking distance (Table 
4). Prior to adjustment for baseline variables, the ABI improved more in the revascularization group, 
whereas the maximum pain-free walking distance and maximum walking distance improved more in 
the exercise group. After adjustment for baseline variables, only the difference in maximum pain-free 
walking distance at 6 months remained significant, being in favor of exercise (mean difference -16 
meters; 95% CI -29, -2 meters, p=0.02). 
After both revascularization and exercise, there was an improvement in both the mean quality-of-life 
Variable
Endovascular
revascularization (n=75)
n (%)
Hospital-based
exercise (n=75)
n (%)
p-value
Iliac disease
 Bilateral iliac disease
 Unilateral both common and
 external iliac artery disease
Total number of iliac lesions
 Stenosis*
 Occlusion
55 (73)
13 (17)
3 (4)
71
62(87)
9 (13) 
51 (65)
12 (16)
5 (7)
68
61 (89)
7(11)
0.47
0.88
0.77
0.90
0.96
Femoral disease
 Bilateral femoral disease
 Unilateral multiple (>1) femoral lesions
Total number of femoral lesions
 Stenosis*
 Occlusion
20 (27)
8 (11)
5 (7)
40
23 (58)
17 (42)
24 (32)
12 (16)
6 (8)
45
29 (64)
16 (36)
0.47
0.32
0.17
0.18
0.67
* Diameter reduction of 51-99%
Table 2: Baseline lesion characteristics
After revascularization the clinical success rate was 88% (66 of 75 patients; 95% CI 80, 96%) at 1-week, 
decreasing to 75% (56 of 75 patients; 95% CI 65, 85%) at 6 months and 68% (51 of 75 patients; 95% CI 
57, 79%) at 12 months (Figure 2). After initiation of exercise, the clinical success rate was 16% (12 of 75 
patients; 95% CI 8, 24%) at 1-week, increasing to a peak of 77% (58 of 75 patients; 95% CI 67, 87%) at 6 
months and then decreasing to 65% (49 of 75 patients; 95% CI 54, 76%) at 12 months (the supervised 
Characteristic
Endovascular 
revascularization(n=75) 
n (%)
Hospital-based 
exercise (n=75) 
n (%)
p-value
Age (y) 65 (+/- 11.4) 66 (+/- 9.1) 0.34
Male gender, % 44 (59) 39 (53) 0.62
Arterial hypertension† , % 32 (43) 28 (38) 0.87
Diabetes Mellitus, % 11 (16) 15 (24) 0.83
Hyperlipidemia‡, % 40 (53) 38 (51)) 0.87
History of ischemic heart disease, % 14 (19) 21 (28) 0.19
Pulmonary disease, % 7 (9) 9 (12) 0.50
Osteo arthritis of the lower limb, % 7 (9) 5 (6) 0.66
Renal insufficiency, % 1(1) 3 (4) 0.35
History of cerebrovascular disease, % 8 (11) 4 (5) 0.32
Smoking, % current
 ever
 never
12 (16) 
40 (53) 
23 (31)
17 (23) 
32 (43) 
25 (34)
0.87
Body Mass Index 26 (+/-4.3) 25 (+/- 4.9) 0.88
Ankle-Brachial Index 
 at rest § 
 after exercise §
0.62 (+/-0.18) 
0.41 (+/-0.22)
0.63 (+/-0.17) 
0.42 (+/-0.21)
0.62 
0.60
Maximum pain-free walking distance (m)* 82 (+/- 48) 104 (+/- 65) 0.04
Maximum walking distance (m) 174 (+/- 76) 186 (+/- 97) 0.62
Rutherford classification¶, % 
 1 & 2 
 3
57 (76)
18 (24)
57 (76) 
18 (24)
0.87
Quality of life 
 SF-36 physical functioning װ 
 SF-36 role physical װ 
 SF-36 pain װ 
 SF-36 general health װ
 VascuQol total** 
42 (+/-26) 
37 (+/-52) 
50 (+/-21) 
53 (+/-23) 
4.2 (+/-1.1)
49 (+/-20) 
49 (+/-45) 
55 (+/-23) 
54 (+/-20) 
4.3 (+/-1.1)
0.11 
0.18 
0.18 
0.91 
0.79
Table 1: Baseline characteristics of patients and disease severity*
* Data are presented as mean (SD) unless otherwise indicated
† diastolic pressure > 95 mm Hg
‡ cholesterol ≥ 5.0 mmol/l
§ minimum of Right – Left 
¶ Most severe classification per person
װ SF-36 Dimension scores = 0-100 (worst-best) scale.
** VascuQol index scores = 1-7 (worst-best) scale
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were not reported. A recently-published systematic review comparing effectiveness of exercise train-
ing and endovascular revascularization showed that quality of life was improved after both exercise 
training and endovascular revascularization at 6 months follow-up, whereas functional capacity im-
proved only after endovascular revascularization.14 This systematic review, however, was limited by 
the quality of the included studies. These were not randomized, had insufficient power, the data for 
quality of life and functional capacity were inconsistently reported, and the exercise training pro-
grams were not standardized. 
Different exercise training studies have evaluated the efficacy of exercise programs, but the relative 
value of supervision is still controversial. Some studies, particularly in Europe, have shown good results 
from a home-based program;18,19 however, other studies have shown little benefit from home-based 
exercise.20 Supervised exercise, however, has provided consistent clinical improvement in almost ev-
ery study.20-23 Despite solid evidence that supervised exercise improves claudication distance and is 
better than a “go home and walk” advice, supervised exercise programs are not readily available, and 
many patients are unable or unwilling to participate. We experienced only minor resistance towards 
supervised exercise. Out of fourteen patients who refused participation in the trial, only four had an 
aversion to hospital-based exercise. As is reflected in the high compliance rate of our exercise group, 
most participants were retired and enjoyed the program.
From the patient’s perspective, the most relevant outcome is probably the symptomatic outcome. 
We measured symptoms subjectively with a binary outcome (symptoms: yes-or-no), which may have 
been affected by the patient’s attitude to his/her health status and care-giver. This could explain why 
more patients in the exercise group had ipsilateral symptoms at 6-months, despite the proportion 
of patients with clinical success being equal between the groups. Clinical success was based on the 
quantitative Rutherford criteria adopted by the SVS/ISCVS, including maximum walking distance and 
post-exercise ankle pressure.24 These parameters are unlikely to be biased by attitude and are consid-
ered more objective.
Endovascular 
revascularization (n=75)
Supervised hospital-based 
exercise (n=75)
Additional treatment 0-6 months (n) 6-12 months (n) 0-6 months (n) 6-12 months (n)
Home-based exercise 3 0 0 0
Endovascular revascularization with or without 
stent placement
 Common Iliac artery 
 Femoral artery
0
0
1
1
2
2
3
1
Surgical intervention 
 Aorto-bifurcation graft
 Femoral-femoral cross-over graft
 Femoro-popliteal bypass
 Patch plasty of common femoral artery
2
1
0
2
0
0
0
0
1
0
2
0
0
0
0
0
Table 3: Additional treatment during follow-up
scores of the SF-36 dimensions and the total score of the VascuQol (Table 5). Regardless of adjustment 
for the baseline variables, there were no significant differences in the quality-of-life scores between 
the two groups at 6- or 12-months follow-up (Table 5). 
DISCUSSION
This prospective randomized controlled trial evaluated the effect of endovascular revascularization 
versus supervised hospital-based exercise training on clinical success, functional capacity, and quality 
of life after 6- and 12-months follow-up in patients with intermittent claudication. While patients re-
ceiving revascularization scored better for clinical success immediately after the start of treatment, the 
benefit over exercise was lost over time. Revascularization reduced ipsilateral symptoms at 6 months, 
but this did not translate into improved clinical success, functional capacity, or quality-of-life. There 
was a small but significant difference in favor of exercise in the maximum pain-free walking distance 
at 6 months. After 12 months, though, there were no significant differences between the treatment 
groups in functional capacity and the quality-of-life scores. 
Before this trial there was no randomized controlled trial performed that evaluated clinical success, 
functional capacity, and quality of life after revascularization or exercise in patients with intermittent 
claudication. In a randomized controlled trial, which evaluated functional capacity, maximum walking 
distance at 6 years was better for patients treated with exercise training than for those treated with 
percutaneous transluminal angioplasty.17 This study, however, was small and quality-of-life outcomes 
Figure 2. Clinical success at 1 week, 6- and 12-months after endovascular revascularization (light 
bars) or supervised hospital-based exercise (dark bars); Error bars indicate 95% confidence in-
tervals.
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Figure 3. Site of symptoms at 6- and 12-months after endovascular revascularization (light bars) 
or supervised hospital-based exercise (dark bars); Error bars indicate 95% confidence intervals.
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A previous meta-analysis concluded that after stent placement for aorto-iliac occlusive disease the 
long term failure was reduced compared to percutaneous transluminal angioplasty.25 One of the 
limitations of our study was that endovascular revascularization was performed as a balloon angio-
plasty-first approach followed by stent placement if the result of balloon angioplasty was deemed 
unsatisfactory. The criterion for stent placement was a pressure gradient over the stenosis. Pressure 
gradient determination can be complex, and difficulties may have influenced the choice for stent 
placement, which in turn may have affected the outcome after endovascular revascularization, but 
this represents “real world clinical practice”. One of the potential limitations of our study was that the 
results of endovascular revascularization, which reflected the clinical practice at the time of the study, 
may have been inferior to results achievable nowadays with better stents and different insights. For 
example, we now know that primary stent placement in the femoral arteries has better patency at 
6- and 12-months than the balloon angioplasty-first approach followed here.26,27 In addition, the spe-
cific stent type that we used in our practice has in a later study proved to be associated with lower 
patency than would be achievable with new generation stents combined with the use of clopidogrel 
(Plavix) after stent placement 27. Another limitation of our study is that bias towards exercise may have 
occurred in patients with bilateral symptoms, as walking inherently treats both limbs. The severity of 
ipsilateral symptoms at baseline may have disguised latent contralateral symptoms in some patients. 
After endovascular revascularization, increased mobility would encourage the discovery of the latent 
contralateral symptoms. However, most patients with bilateral lesions in the endovascular revascu-
larization group were treated on both sides. Furthermore, peripheral arterial disease is a two-limb 
problem, so a patient-based treatment and analysis of the trial results is the appropriate approach. 
In a previous randomized study, the combination of endovascular revascularization and home-based 
exercise gave better results than either intervention alone.28 Unfortunately, this study included a rela-
tively small number of patients. To the best of our knowledge, early intervention in addition to su-
pervised exercise has never been studied in a large randomized controlled trial, but this combination 
could be an interesting treatment strategy. Endovascular revascularization followed by exercise train-
ing would presumably combine effective short-term relief of claudication symptoms with the added 
long-term benefits of exercise training. Patients may, however, be less motivated to exercise after 
the immediate benefit of the revascularization treatment. Furthermore, the cost-effectiveness of the 
combination would need to be evaluated.
In conclusion, our randomized controlled trial demonstrated that patients undergoing endovascu-
lar revascularization or supervised hospital-based exercise yielded similar benefit in clinical success, 
functional capacity, and quality-of-life after 6- and 12-months follow-up, whereas the benefit was 
more immediate with revascularization.
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(10, 32)
6
(-4, 16)
15
(-1, 30)
7
(-2, 16)
0.11
SF-36-Bodily pain 6 m
onths ‡
14
(7, 21)
7
(2, 13)
7
(-1, 17)
4
(-1, 9)
0.11
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5
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0.74
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2
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(1, 9)
-3
(-9, 4)
-1
(-4, 3)
0.73
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 §
0.6
(0.1, 1.1)
0.7
(0.4, 1.0)
-0.1
(-0.7, 0.6)
0.1
(-0.2, 0.4)
0.08
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ol 12 m
onths
0.7
(0.3, 1.1)
0.6
(0.3, 0.9)
-0.1
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0.1
(-0.1, 0.2)
0.61
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INTRODUCTION
Intermittent claudication is the mildest manifestation (i.e., Rutherford category 1, 2 or 3) of periph-
eral arterial disease, with a prevalence around 5% in men older than 50 years.1,2 As the incidence of 
intermittent claudication will increase over the next decades due to the aging population in Western 
societies, the economic impact of intermittent claudication is expected to be substantial.3
The treatment goal for intermittent claudication is to improve health-related quality of life. The gen-
eral consensus is to initially treat with exercise training, but endovascular revascularization is increas-
ingly performed because of its technical innovations, immediate success, and low risks of peri-proce-
dural mortality and morbidity.4 In addition to effectiveness, however, one needs to consider costs and 
cost-effectiveness. Initial hospital costs for endovascular revascularization are likely higher than those 
for exercise training. Besides these initial hospital costs, costs of follow-up are important to take into 
account, such as the costs of diagnostic tests for recurrent symptoms and secondary treatment. 
The present study compared endovascular revascularization versus supervised exercise training as 
first-line treatment of intermittent claudication, with regard to cost-effectiveness during 12-month 
follow-up in a prospective randomized controlled trial. 
METHODS
Study design and patients
The study was a randomized controlled clinical trial comparing endovascular revascularization to su-
pervised hospital-based exercise in patients with symptoms of intermittent claudication (Rutherford 
category 1, 2, or 3). The study was performed following Good Clinical Practice and was registered (IS-
RCTN 64443682).5 Data were analyzed and reported according to CONSORT guidelines.6 Institutional 
Review Board approval was obtained and all patients gave written informed consent.
All patients referred to the Department of Vascular Surgery with intermittent claudication from Sep-
tember 2002–September 2005 were considered for recruitment (Figure 1). Inclusion criteria were: 1) 
Symptoms of intermittent claudication (Rutherford category 1, 2, or 3) of at least 3 months duration; 
2) a maximum pain-free walking distance of <350 m during a treadmill test; 3) an ankle-brachial in-
dex (ABI) of <0.9 at rest or a decrease in ABI after the treadmill test of >0.15; 4) one or more vascular 
stenoses of >50% diameter reduction or occlusions at the iliac or femoro-popliteal level; 5) written 
informed consent. Exclusion criteria were: 1) presence of an abdominal aortic aneurysm; 2) life-inca-
pacitating cardiac disease (NYHA classification II and higher7); 3) multilevel disease (i.e., stenoses/oc-
clusions at both the iliac and femoral levels on the symptomatic side — multiple lesions limited to 
only the iliac or only the femoral level were not exclusion criteria); 4) isolated crural artery disease; 5) 
lesions deemed unsuitable for endovascular revascularization (iliac or femoropopliteal TASC-type D 
and some TASC type-B/C lesions;8 6) prior treatment for the same lesion (including exercise training). 
After all diagnostic tests had been performed, indication for treatment and in- and exclusion criteria 
were assessed at the vascular conference by consensus between the vascular surgeons and interven-
tional radiologists. An independent statistician prepared a computer-generated randomization list 
with a block size of 16. Study personnel dealing with bias-sensitive data were blinded to the assigned 
treatment and block size. 
ABSTRACT
Purpose: To compare the cost-effectiveness of endovascular revascularization versus supervised hos-
pital-based exercise in patients with intermittent claudication during a 12-month follow-up period.
Materials and methods: Between September 2002-September 2005, we randomly assigned 151 
consecutive patients with intermittent claudication, to receive either endovascular revascularization 
-angioplasty-first approach- (n = 76) or hospital-based supervised exercise (n = 75). The primary out-
come was health-related quality of life using the EuroQol, rating scale, SF36 physical functioning, 
quality-adjusted life years (QALYs) accumulated over 12 months. Secondary outcomes were costs and 
incremental costs per QALY from the societal perspective. Significance of differences between the 
groups was assessed using the unpaired t-test, Â2-test, or the Mann-Whitney U-test. We performed 
multivariable regression analysis to adjust outcomes for imbalances of baseline values. 
Results: The endovascular revascularization group had a larger improvement in 6- and 12-months 
EuroQol, rating scale, and SF36 quality-of-life values than the supervised hospital-based exercise, but 
the differences were not statistically significant. The gain in total mean QALYs accumulated during 12 
months, adjusted for baseline values, was significantly larger following endovascular revasculariza-
tion (mean difference 0.03; 95% CI: 0.02, 0.04; p < 0.001). The total mean cumulative costs per patient 
were significantly higher in the endovascular revascularization group (mean difference €2318; 95% CI: 
€2176, €2460; p < 0.001) and the incremental cost per QALY was  €77 267.
Conclusion: Endovascular revascularization results in a small gain in effectiveness compared to su-
pervised hospital-based exercise during 12-months follow-up but costs more, and only if society is 
willing-to-pay more than 77 300 €/QALY gained should one consider endovascular revascularization 
as first-line treatment in patients with intermittent claudication.
COST-EFFECTIVENESS OF ENDOVASCULAR 
REVASCULARIZATION COMPARED TO SUPERVISED 
HOSPITAL-BASED EXERCISE TRAINING IN PATIENTS WITH 
INTERMITTENT CLAUDICATION: A RANDOMIZED 
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(Luminexx; Bard; Tempe, AZ) was placed during the same session. For femoral revascularization, the 
decision to place an additional 6mm diameter self-expanding nitinol stent was based on evaluation 
of the post-balloon angioplasty angiogram.
Treadmill exercise was conducted in the hospital twice weekly over a 24-week period, supervised by 
a vascular technologist. Each session began at 3.5 km/h without incline, and workload was increased 
(speed or incline as tolerated) until a severe level of claudication pain was reached. The workload was 
lowered to 1 km/h until the pain abated and the patient resumed walking at higher workload. This 
process was repeated for 30 minutes. In addition, all patients were instructed to walk at home for at 
least 3x30 minutes weekly. Feedback and evaluation of these home-based exercise hours were also 
reported. After the 24-week period, patients were advised to continue exercise at home.
Before randomization, all patients underwent management of risk-factors, including hypertension, 
serum glucose, cholesterol, lipid profile, and homocysteinaemia (if age <50 years), and all were pre-
scribed aspirin therapy (100 mg/day).
Outcomes
The outcomes of interest were effectiveness expressed as mean improvement of health-related quality 
of life over the 12-month period and cumulative 12-month costs. Quality of life was assessed using 
a self-administered questionnaire. Costs were assessed from the societal perspective, according to 
national guidelines for cost-analyses.9 Functional capacity and clinical success were also assessed but 
are reported separately in a manuscript focusing on the clinical outcomes. 
The questionnaire consisted of the EuroQol-5D (EQ-5D), rating scale, and the dimension “physical 
functioning” of the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). The EQ-5D 
is a multi-attribute utility instrument that assesses quality-of-life values from the societal perspective 
and classifies patients into a health-state.10 For each health-state, a value was calculated using the 
Dutch scoring algorithm, which was derived from the general population:11 0 equates to death and 1 
equates to maximum health.
The rating scale required the respondent to rate their overall health on a scale from 0-100, where 0 
represents death and 100 perfect health.12 The SF-36 was developed to evaluate physical, social, and 
physical-role functioning of patients, and it elicits their perceptions of their general health and well-
being in eight different health dimensions.13 “Physical functioning” is most relevant to peripheral arte-
rial disease, and we restricted this analysis to it.14 The SF-36 was valued on a 100-point scale: 0 means 
death and 100 indicated maximum health.
Quality-adjusted life years (QALYs) accumulated during the 12-month follow-up period were based 
on the EQ-5D values at baseline, 6-months, and 12-months. 
Costs (medical and non-medical) of all relevant items used during the entire trial were collected. 
Direct medical costs included costs of all therapeutic procedures, personnel, materials, equipment, 
additional associated diagnostic or therapeutic procedures, and associated hospital admissions dur-
ing 12-months follow-up. Personnel costs were computed by multiplying time spent with the mean 
wage rate of the appropriate personnel-category and adding 37% social-security.9 Costs of materials 
were summed cost prices. Equipment costs were calculated as: [time spent on a procedure] * [hourly 
cost]. The annuitized hourly costs of equipment were summed with servicing costs and divided by 
Procedures
Endovascular revascularization was performed using a 10% oversized balloon (Powerflex or Opta-
Pro; Cordis Johnson & Johnson; Miami, FL). For iliac revascularization, the initial balloon angioplasty 
was considered technically successful if the pressure gradient across the treated arterial segment was 
<10 mm Hg at rest. If balloon dilatation was inadequate, a 9 mm diameter self-expanding nitinol stent 
Figure 1: Flow diagram of study. 
Diagram illustrates reasons for exclusion, random assignment to endovascular revascularization and supervised hospital-based exercise 
training and the treatment actually received, including 6- and 12-months follow-up.
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hypertension, hyperlipidaemia, and disease severity (mild/moderate claudication vs. severe claudica-
tion). The variables were selected based on the TASC-II report and on clinical judgment.22 
Significance of differences between group means was assessed with the unpaired t-test or the Mann-
Whitney U-test, as appropriate, whereas significance of dichotomous outcomes was assessed with 
the Â2-test. For the analyses, a significance level of 0.05 was used. Calculations were performed with 
SPSS 14.0 for Windows (SPSS Inc., Chicago, IL), and R version 2.5 (R Foundation, Vienna, Austria).
RESULTS
Patients
Figure 1 shows the flow diagram of patients entering the randomized controlled trial, including the 
actual treatments received and patients who were lost to follow-up. One patient, who refused further 
participation before baseline data was collected, was excluded from the analysis. Thus, 150 patients 
were analyzed for quality-of-life and costs (Figure 1). In the revascularization group, four patients tech-
nically failed initial treatment. Two were advised home-based exercise, and two underwent surgical 
intervention (Figure 1).
Demographics, co-morbidities, baseline Rutherford classification, ABI at rest and after exercise, maxi-
mum walking distance, and quality-of-life scores did not differ between the groups (Table 1), except 
for the maximum pain-free walking distance at baseline. This was significantly lower in the revascular-
ization group compared to the exercise group (p=0.04). 
During follow-up, the response rate to the questionnaires in the revascularization group was 92% 
(69 of 75 patients) at 6 months and 89% (67 of 75 patients) at 12 months. In the exercise group, the 
response rate was 99% (74 of 75 patients) at 6 months and 96% (72 of 75 patients) at 12 months. 
Outcomes
After both revascularization and exercise, all quality-of-life questionnaires showed a significant im-
provement at 6- and 12-months compared to pre-treatment values (Table 2). The treatment groups 
differed slightly – albeit not significantly – in the EuroQol, rating scale, and SF36 values in favor of the 
revascularization group at 6- and 12-months, with or without adjustment for baseline variables. The 
exception to this was the rating scale score at 12 months, which was higher (but not significant) in the 
exercise group without adjustment. The QALY improvement accumulated during 12-months follow-
up was significantly more in the revascularisation group than in the exercise group (mean difference 
0.08; CI 0.03, 0.12; p=0.01) (Table 2). After adjustment for baseline variables this difference was smaller 
but still significant (mean difference 0.03;CI 0.02, 0.04; p<0.001) (Table 2).
The total mean cumulative costs per patient during 12 months were €4254 higher in the revascular-
ization group than in the exercise group (95% CI €1648, €7734; p< 0.001) (Table 3). Adjustment for 
baseline variables reduced this difference somewhat (mean difference €2318; 95% CI €2176, €2460; 
p<0.001) (Table 3).
Although personnel costs were similar, all other procedure costs were significantly higher for revas-
cularization than for exercise (Table 3). Patient costs in the revascularization group were lower than 
those in the exercise group (mean difference €539; 95% CI €444, €636; p<0.001). This was due to the 
time investment in the exercise program. Total mean follow-up costs in the revascularization group 
were higher than in the exercise group (mean difference €2422; 95% CI -€219, €6072; p=0.15), but 
the proportion of total available room time (33% of a 40-hour work-week for endovascular revascu-
larization and 80% of a 40-hour work-week for supervised exercise).9
Non-direct medical costs included costs of supporting departments, housing, overhead, transporta-
tion costs, and patient time costs. The costs of supporting departments were obtained from records 
of our financial department; housing and overhead were estimated at 45% of direct assignable costs.9 
Transportation costs included parking costs and mean estimated gasoline costs. Patient-time costs 
were [hourly wage rate] * [number of hours in-hospital]. The hourly wage rate was estimated with 
the published mean hourly wage rate for Dutch men and women given for different age categories 
(25-44, 45-54, 55-64, >65). The time required for treatment was based on the length of hospitalization, 
which was estimated from the records of patients undergoing revascularization (8 hours) and/or the 
exercise program (30min*number of sessions). In addition, time invested in unsupervised exercise at 
home was reported and included in the patient-time cost analysis. 
Costs were discounted at a rate of 3% per annum.15 All costs are reported in 2005 euros using the 
consumer price indices of the Central Bureau of Statistics, the Netherlands.16, 17
Data analysis
With adequate treatment, 40-50% of patients were expected to have a substantial improvement of 
their symptoms after 6 months as measured by the dimension “physical functioning” on the SF-36.14, 
18 A percentage difference of 20-25% between the treatment groups was considered clinically rel-
evant.19 With these assumptions, 68 patients were required in each trial arm for a power of 80% and a 
5% significance level. Anticipating a 5-10% loss to follow-up, we recruited 15 extra patients.
Results were analyzed according to the intention-to-treat principle: we analyzed all patients accord-
ing to their allocated intervention irrespective of cross-over to the other strategy or completion of 
follow-up. The only patients excluded from the analysis were those for whom no data was available 
as they refused further participation immediately following randomization. In addition, results were 
analyzed with imputation of mean values for quality of life at 6- and 12-months follow-up for patients 
who died of causes other than peripheral arterial disease and for patients who refused a follow-up 
visit.20 There were no patients who died of peripheral arterial disease, and there were no missing cost 
values. To calculate 95% confidence intervals of the mean cost values and of the mean cost differ-
ences, we used the bootstrap resample method.21
QALY improvement accumulated during the 12-month follow-up period was calculated per pa-
tient as the integral under the EQ-5D graph as a function of time adjusted for the baseline value. 
In the revascularization group we assumed that the EQ-5D graph increased immediately after the 
last intervention to the 6-month value, whereas in the exercise group we interpolated between the 
baseline value and the 6-month value to account for the gradual improvement during the course 
of the 24-week training program. In addition, we calculated the incremental cost-effectiveness 
ratio (ICER) as the difference in mean cumulative total costs divided by the difference in mean QALY 
improvements accumulated during 12 months for the revascularization group compared to the ex-
ercise group.
To adjust outcomes for potential imbalances of baseline values and characteristics between the treat-
ment groups, we performed multivariable regression analyses. The variables included in the multivari-
able regression analyses were baseline quality-of-life scores, age, gender, diabetes mellitus, smoking, 
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The data above shows that revascularization is significantly more effective than exercise, but it is also 
more expensive. The incremental cost-effectiveness ratios were 53 175 €/QALY without adjustment 
and 77 267 €/QALY with baseline-variable adjustment (Table 4).
DISCUSSION
In this prospective randomized controlled trial, the cost-effectiveness of endovascular revasculariza-
tion was compared to that of supervised hospital-based exercise in patients with intermittent clau-
dication after 12-months follow-up. The results showed that quality of life improved after both treat-
ments. There was a non-significant difference in the 6- and 12-month EuroQol, rating scale, and SF36 
quality-of-life values between the treatment groups in favor of revascularization. The QALYs accumu-
lated during 12 months were significantly higher after endovascular revascularization but revascular-
ization was also significantly more expensive than supervised hospital-based exercise. Furthermore, 
the incremental costs/QALY gained by revascularization compared to exercise were higher than the 
generally-accepted willingness-to-pay threshold of 50 000 €/QALY and revascularization can only be 
considered cost-effective if society is willing-to-pay at least 77 300 € per QALY gained. 
Prior to the current randomized controlled trial, there was no level-I evidence with respect to the 
effectiveness and costs of treatment for intermittent claudication. In the published literature about 
intermittent claudication, one previous study compared quality of life and costs for percutaneous 
transluminal angioplasty, bypass surgery, or exercise using a Markov decision analysis and data from 
cohort studies.23 This study showed that quality-adjusted life expectancy was higher after vascular 
interventions than after exercise, with incremental cost-effectiveness ratios of 38 000 $/QALY gained 
when angioplasty was performed whenever feasible versus exercise alone and $311 000 allowing 
for additional bypass surgery, if necessary. In our study vascular intervention consisted primarily of 
percutaneous intervention — bypass surgery was used in only a few cases. We found an incremental 
cost-effectiveness ratio of nearly 80 000 €/QALY (in dollars approximately 110 000 $/QALY) which is 
consistent with previously published results. 
Table 2: Mean improvement in quality of life compared to baseline and differences between 
the groups (endovascular revascularization compared to supervised hospital-based exercise *)
* Positive difference indicates endovascular revascularization has a better outcome; negative number indicates supervised hospital-based 
exercise has a better outcome. † Adjusted for baseline quality-of-life scores, age, sex, severity of disease (mild/moderate versus severe), 
smoking, hypertension, hyperlipidaemia, and diabetes mellitus. ‡ EuroQol-5D with Dutch algorithm was used; EuroQol-5D value= 0-1 
(death -maximum health) scale. װ Rating scale and SF-36 Dimension scores = 0-100 (worst-best) scale.
 Mean score improvement (95% CI) * Unadjusted mean
difference
(95% CI) *
Adjusted mean
difference
(95% CI) *†
Adjusted
p-value
Endovascular
revascularization
(n=75)
Hospital-based
exercise
(n=75)
EQ-5D 6 months‡
EQ-5D 12 months
0.16
0.1i
(0.10, 0.21)
(0.04, 0.18)
0.09
0.07
(0.03, 0.15)
(0.02, 0.13)
0.07
0.04
(-0.02, 0.15)
(-0.06, 0.15)
0.02
0.02
(-0.05, 0.08)
(-0.06, 0.09)
0.59
0.63
Rating scale 6 months װ
Rating scale 12 months
8
4 
 (5, 12)
(0, 9)
5
6
(1, 9)
(2, 11)
3
-1
(-2, 9)
(-8, 4)
1
1
 (-3, 5)
(-2, 4)
 0.74
0.60
SF-36-Physical functioning 6 months װ
SF-36-Physical functioning 12 months
19
17
(14, 25)
(12, 22)
12
13
(7, 18)
(8, 18)
7
4
(-0.3, 15)
(-3, 12)
2
2
(-2, 6)
(-0.4, 5)
0.22
0.10
Quality-adjusted life years 
accumulated during 12 months
0.14 (0.11, 0.18) 0.06 (0.04, 0.09) 0.08 (0.03, 0.12) 0.03 (0.02, 0.04) <0.001
were only significantly different for the outpatient visits (Table 3). After adjustment, the difference was 
significant. As the revascularisation group needed more surgical interventions during follow-up (5 vs 
3 in the exercise group), additional admission costs were higher (Table 3).
Table 1: Baseline characteristics of the study participants*
* Mean +/- SD in parentheses, unless otherwise indicated. † Minimum of Right – Left. ‡ Most severe classification per person. § EuroQol-5D 
with Dutch algorithm was used; EuroQol-5D value= 0-1 (death -maximum health) scale. װ rating scale= 0-100 (worst-best) scale. ¶ SF-36 
Dimension scores = 0-100 (worst-best) scale.
Endovascular 
revascularization (n=75)
Hospital-based 
exercise (n=75)
p-
value
Age (y) 65 (+/- 11) 66 (+/- 9) 0.34
Male gender, % 44 (59) 39 (53) 0.62
Arterial hypertension, % 32 (43) 28 (38) 0.87
Diabetes Mellitus, % 11 (16) 15 (24) 0.83
Hyperlipidaemia, % 40 (53) 38 (51)) 0.87
History of ischemic heart disease, % 14 (19) 21 (28) 0.19
Pulmonary disease, % 7 (9) 9 (12) 0.50
Osteo arthritis of the lower limb, % 7 (9) 5 (6) 0.66
Renal insufficiency, % 1(1) 3 (4) 0.35
History of cerebrovascular disease, % 8 (11) 4 (5) 0.32
Smoking, % current
 ever
 never
12 (16)
40 (53)
23 (31)
17 (23)
32 (43)
25 (34)
0.87
Body Mass Index 26 (+/- 4) 25 (+/- 5) 0.88
Ankle-Brachial Index†
 at rest
 after exercise 
0.62 (+/-0.18)
0.41 (+/-0.22)
 0.63 (+/-0.17)
0.42 (+/-0.21)
0.62
0.60
Pain-free walking distance (m) 82 (+/- 48) 104 (+/- 65) 0.04
Maximum walking distance (m) 174 (+/- 76) 186 (+/- 97) 0.62
Rutherford classification‡ , %
 1 & 2
 3
57 (76)
18 (24)
57 (76)
18 (24)
0.87
Quality of life
 EuroQol-5D §
 Rating scale װ
 SF-36 Physical functioning¶
0.66 (+/- 0.20)
62 (+/- 17)
42 (+/- 26)
0.69 (+/- 0.21)
65 (+/- 18)
49 (+/- 20)
0.22
0.47
0.11
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follow-up costs as revascularization patients had more surgical interventions than exercise patients, 
who tended to get a (less-expensive25) endovascular revascularization if secondary treatment was 
needed. This difference in secondary treatment arose because three arterial lesions were not suitable 
for endovascular (re-)intervention after prior failure and because of surgeon preference in two pa-
tients. Whatever the treatment considered, if the initial procedure failed, total costs during 12-month 
follow-up are 2- to 4-fold higher than if the initial procedure was successful.22, 26
Our study may have lacked power as it was designed to visualise clinically-relevant differences, rather 
than equivalences, in quality of life. Although the differences in the 6- and 12-month quality-of-life 
results were small and non-significant, we did find a significant difference in the QALY improvement 
accumulated during 12-months follow-up. Furthermore, it should be noted that quality of life is a 
subjective outcome which may be influenced by the perception of individual subjects. Patients in 
the exercise group may have underestimated their quality of life since improvement in symptoms 
occurs slowly during an exercise program and may therefore have been less noticeable. Conversely, 
the revascularization group may have overestimated their quality of life since their improvement after 
treatment was immediate and therefore would have contrasted with the pre-intervention state. This 
may indicate that the difference in quality of life between the treatment groups may in fact have 
been in favor of exercise. Furthermore, we had limited follow-up time-points and for revasculariza-
tion we assumed that the EQ-5D value immediately after the last intervention equaled that of the first 
measured value, which was at 6 months, whereas the values with exercise gradually increased during 
the course of the 24-week training program. Another limitation could be that our study took place 
in a single centre and with adherence to strict in- and exclusion criteria, which may affect whether 
these results may be generalised. The advantage of our single centre study and adhering to strict in- 
and exclusion criteria is the homogeneous group of study participants, as illustrated by the baseline 
characteristics. 
As with every randomized trial, we could only evaluate a limited number of strategies. In addition 
to revascularization and exercise training, other treatment strategies are of interest, for example, op-
timal medical treatment in combination with home-based exercise or optimal medical treatment 
combined with percutaneous transluminal angioplasty, which have been compared in a previous 
randomized study.27 Other interesting treatment arms could be revascularization plus supervised ex-
ercise training or revascularization plus pharmacologic therapy. Indeed, regardless of the initial treat-
Table 4: Unadjusted and adjusted difference in mean cumulative total costs, mean QALY 
improvement, and incremental cost-effectiveness ratios per patient during 12 months of 
follow-up after endovascular revascularization and supervised hospital-based exercise 
Unadjusted * Adjusted *† 
Difference in cumulative mean total costs €4254 (1648, 7734) €2318 (2176, 2460)
Difference in QALY improvement accumulated during 12 
months
0.08 (0.03, 0.12) 0.03 (0.02, 0.04)
Incremental cost-effectiveness ratio* 53 175 €/QALY 77 267 €/QALY
QALY = quality-adjusted life year. 
* Endovascular revascularization compared to hospital-based exercise.
† Adjusted for baseline EuroQol, age, sex, severity of disease (mild/moderate versus severe), smoking, hypertension, hyperlipidaemia, and 
diabetes mellitus.
Even though the incremental effects gained in our results were in favor of revascularization for the 
treatment of intermittent claudication, exercise has some advantages as well. Exercise increases the 
functional capacity and decreases intermittent claudication symptoms by several mechanisms, in-
cluding improvements in endothelial vasodilator function, skeletal-muscle metabolism, blood viscos-
ity, and inflammatory responses,24 but this means that mobility only improves slowly. A disadvantage 
is the required time investment on the part of the patient. After endovascular revascularization, there 
is immediate improvement in mobility, and only one post-interventional outpatient visit is required. 
Note that the time investment on the part of the patient was accounted for in our analysis by consid-
ering patient time costs. 
Individual aspects should also play a role in the choice of primary treatment. For patients who are 
unable to perform their normal work or other activities important to them, endovascular revasculari-
sation may be preferable to an exercise program. Also, the motivation of the patient to participate 
in an exercise program could play a role in the choice and success of treatment. Endovascular revas-
cularization, however, has higher initial costs. Besides the higher initial costs, we also found higher 
Table 3: Total mean cumulative costs per patient during 12 months of follow-up after 
endovascular revascularization and supervised hospital-based exercise
ABI = Ankle Brachial Index, 95% CI = 95% confidence interval determined with the bootstrap resample method.
* Adjusted for age, sex, severity of disease (mild/moderate versus severe), smoking, hypertension, hyperlipidaemia, and diabetes mellitus. 
† In the endovascular revascularization group, the additional admission costs were due to surgical interventions (n=5) and secondary 
endovascular revascularizations (n=2). In the supervised hospital-based exercise group, the additional admission costs were due to surgical 
interventions (n=3) and endovascular revascularizations (n=8).
Endovascular
revascularization 
(n=75)
Hospital-based
Exercise 
(n=75)
Unadjusted 
meandifference 
(95% CI) 
Adjusted mean
difference 
(95% CI) *
Adjusted
p-value
Procedure 
 Material costs
€ 1444 € 1
 Personnel costs € 441 € 433
 Equipment costs € 76 € 51
 Associated admission costs € 217 € 0
Total mean cumulative procedure costs € 2178 (1949, 2419) € 485 (454, 515) € 1692 (1454, 1938) € 1035 (903, 1167) <0.001
Patient
 Transportation costs € 13 € 164
 Productivity losses € 552 € 941
Total mean cumulative patient costs € 565 (519, 612) € 1104 (1021, 1189) € 539 (444, 636) € 504 (463, 546) <0.001
Follow-up
 Associated outpatient visits  
 and ABI measurements
€ 86 € 0
 Additional imaging costs € 65 € 92
 Additional therapeutic costs € 657 € 532
 Additional admission costs† € 2578 € 339
Total mean cumulative follow-up costs € 3401 (865, 7018) € 958 (333, 1769) € 2422 (-219, 6072) €205 (187, 223) <0.001
Total mean cumulative housing/
supporting departments/overhead costs
€ 793 (767, 818) € 207 (203, 211) € 586 (561, 611) € 586 (560, 611) <0.001
Total mean cumulative costs € 7031
(4522, 10556)
€ 2771
(2158, 3591)
€ 4254
(1648, 7734)
€ 2318
(2176, 2460)
<0.001
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17. Central Bureau of Statistics TN. http://www.cbs.nl/.
18. Spronk S, Bosch JL, Veen HF, den Hoed PT, Hunink MG. Intermittent claudication: functional capac-
ity and quality of life after exercise training or percutaneous transluminal angioplasty--systematic 
review. Radiology. 2005;235(3):833-42.
19. Bosch JL, Hunink MG. The relationship between descriptive and valuational quality-of-life mea-
sures in patients with intermittent claudication. Med Decis Making. 1996;16(3):217-25.
20. van der Heijden GJ, Donders AR, Stijnen T, Moons KG. Imputation of missing values is superior to 
complete case analysis and the missing-indicator method in multivariable diagnostic research: a 
clinical example. J Clin Epidemiol. 2006;59(10):1102-9.
21. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-
parametric bootstrap. Stat Med. 2000;19(23):3219-36.
22. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-Society Consensus for 
the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(1 Suppl):S5-S67.
23. de Vries SO, Visser K, de Vries JA, Wong JB, Donaldson MC, Hunink MG. Intermittent claudication: 
cost-effectiveness of revascularization versus exercise therapy. Radiology. 2002;222(1):25-36.
24. Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 
2002;347(24):1941-51.
25. Adam DJ, Beard JD, Cleveland T, et al. Bypass versus angioplasty in severe ischaemia of the leg 
(BASIL): multicentre, randomised controlled trial. Lancet. 2005;366(9501):1925-34.
26. Whatling PJ, Gibson M, Torrie EP, Magee TR, Galland RB. Iliac occlusions: stenting or crossover graft-
ing? An examination of patency and cost. Eur J Vasc Endovasc Surg. 2000;20(1):36-40.
27. Nylaende M, Abdelnoor M, Stranden E, et al. The Oslo balloon angioplasty versus conservative 
treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in 
patients with intermittent claudication. Eur J Vasc Endovasc Surg. 2007;33(1):3-12.
ment, claudicants should be encouraged to engage in regular exercise, and atherosclerotic risk fac-
tors need ongoing attention during the follow-up period. 
In conclusion, endovascular revascularization results in a small gain in effectiveness compared to su-
pervised hospital-based exercise during 12-months follow-up but costs more, and only if society is 
willing-to-pay more than 77 300 €/QALY gained should one consider endovascular revascularization 
as first-line treatment in patients with intermittent claudication.
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BACKGROUND 
Coronary artery disease (CAD) is the main cause of death in the United States.1 Millions of Americans 
have a history of myocardial infarction (MI) or experience angina pectoris.1 Risk factors of CAD do 
not differ from those of atherosclerotic disease in other circulations, such as PAD.2 Approximately 
one third of men and one fourth of women with known CAD also have PAD.3 Many of CAD patients 
(on average 300,000 per year) enter a rehabilitation program with the objective of reducing cardiac 
symptoms, improving physical functioning, improving cardiovascular risk factors, reducing mortality, 
reducing myocardial infarctions, and improving psychological well-being.4,5 Patients with CAD who 
have PAD, however, are hampered in their cardiac rehabilitation program because they either discon-
tinue the program prematurely or are unable to achieve their target heart rate due to their limited 
walking distance. As a result these patients have an increased risk of cardiac events during follow-up 
(20%-60% increased risk for MI).6,7 
How clinical effectiveness of a cardiac rehabilitation program is influenced by PAD, however, is still 
unknown. This study was performed to evaluate whether clinical effectiveness of cardiac rehabilita-
tion was related to the presence of PAD. 
MATERIALS AND METHODS
Study population
Patients who started cardiac rehabilitation at Advocate Lutheran General Hospital in Park Ridge in the 
United States from January 2004 to December 2004 were potentially eligible for the study (n=231). 
Patients were men and women, who had a myocardial infarction or who had stable angina pectoris 
or CAD defined by angiography or were patients who underwent coronary artery bypass graft (CABG) 
or percutaneous transluminal coronary angioplasty (PTCA). All patients received a self-administered 
Walking Impairment Questionnaire (WIQ) by mail after they had prematurely ended or had finished 
the program. Of the 231 eligible patients, 59 responded to the mailed questionnaire. Because in a 
previous study reliability and validity of subscales of the WIQ were not influenced by the method of 
administration, all non-responders of the self-administered questionnaire were approached by tele-
phone (n=172).8 Of these 172 patients, 67 patients were reached and interviewed by telephone. Thus, 
in total 126 patients were included in the study. The Advocate Health Care Institutional Review Board 
approved the protocol and all patients gave their written informed consent. 
Cardiac rehabilitation
Cardiac rehabilitation consisted of a 2 phase program following the guidelines for cardiac rehabili-
tation and secondary prevention programs.9 All patients were prescribed antiplatelet medications, 
ß-blockers, and statins. Phase I involved integrated inpatient services, such as cardiac education that 
serve as the foundation for a continuum of cardiac rehabilitation interventions that began in the hos-
pital and continued post discharge. Phase II involved a multifaceted program that included a 12 week 
monitored exercise training of 36 sessions (3 sessions per week) and the pursuit of modifiable risk fac-
tor reduction through education, counseling, reinforcement of medical therapies, behavior change 
and acceptance of personal responsibility on the part of the patient. Patients were asked to do differ-
ent muscle exercises, which included a 10 minute warming up, 20 minutes of exercise on a treadmill, 
20 minutes of other muscle exercise (e.g. biking, rowing, or weight training), and a 10 minute cooling 
down period. During exercise, patients were encouraged to reach their target heart rate. Target heart 
rate is a desired range of heart rate reached during a stress test. This range varies based on patient’s 
physical condition and age and was calculated by using the Karvonen method with a range of 50%-
ABSTRACT
Purpose: To evaluate whether clinical effectiveness of cardiac rehabilitation is related to the presence 
of peripheral arterial disease (PAD). 
Materials and methods: From a consecutive cohort of patients who started cardiac rehabilitation from 
January 2004 to December 2004, we included those who completed the Walking Impairment Ques-
tionnaire (WIQ) (n=126). Cardiac rehabilitation failure was defined as a premature discontinuation of 
the treadmill exercise program or an inability to reach target heart rate. Presence of PAD was based 
on the walking distance score and the speed score of the WIQ and in a subset of our patient sample 
(n=39) we assessed the ABI. Chi-squared tests were used to compare the proportion of patients with 
PAD between patients who failed cardiac rehabilitation and patients who were successful. In addi-
tion, age and sex adjusted logistic regression models were used to examine the association between 
cardiac rehabilitation failure and the presence of PAD. 
Results: The presence of PAD based on the walking distance score of the WIQ was significantly higher 
in the cardiac rehabilitation failure group than in the success group (34% vs.17%, OR 2.5; 95% CI 1.1 
to 6.0, p=0.03), whereas the presence of PAD based on the walking speed score was not significantly 
different (30% vs. 28%, OR 1.1; 95% CI 0.5 to 2.5, p=0.79). The presence of PAD based on ABI measure-
ments was higher in the failure group than in the success group (39% vs.14%, OR 3.8; 95% CI 0.8 to 
17.9, p=0.08). Logistic regression analysis showed that when cardiac rehabilitation failure was adjusted 
for age and sex, failure was significantly associated with the presence of PAD based on the walking 
distance (OR 2.8; 95% CI 1.1 to 7.1, p=0.03), but not significantly associated when based on the speed 
score (OR 1.2; 95% CI 0.5 to 2.8, p=0.72). 
Conclusion: This study demonstrated that the clinical effectiveness of cardiac rehabilitation was in-
versely related to the presence of PAD, which suggests that patients with PAD benefit less from a 
cardiac rehabilitation program and are at higher risk of future cardiac events. 
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brachial index < 0.90 in general internal medicine patients with no prior history of PAD (n=34); 3) 
Men and women without PAD identified from a general medicine practice (n=113). We assumed that 
group 1 and 2 were most representative for identifying the presence of PAD in our study population. 
The cut-off value for detecting PAD using the weighted mean value of the two reported walking dis-
tance scores from the two groups was 45 (95% CI, 43-46) (n=177), and the cut-off value for detecting 
PAD using the weighted mean value of the two reported walking speed scores from the two groups 
was 40 (95% CI, 39-40) (n=177). The WIQ stair climbing score was not used in the previous study and 
therefore also omitted in our study for the detection of the presence of PAD. 
In a subset of our patient sample, we measured the ABI to diagnose PAD. The ABI is currently consid-
ered the standard tool to screen for PAD.16 All 126 patients included in the study were invited to the 
hospital for additional testing on a specific date. Thirty-nine patients (31%) responded and under-
went ABI measurements. The ABI was measured with a hand-held Doppler probe (8 MHz continuous 
wave Doppler probe) and a random-zero sphygmomanometer. For each leg, ABIs were calculated as 
the highest systolic blood pressure in the ankle from the right or left posterior tibial or dorsalis pedis 
arteries divided by the highest brachial systolic pressure. The leg with the lowest ABI was used in the 
analyses. PAD was defined as an ABI less than 0.90.17
Ten out of the 39 patients with ABI measurements had an incomplete walking distance score and 9 
patients had an incomplete speed score, so that 29 patients had both a complete walking distance 
score and an ABI measurement and 30 patients had both a complete speed score and an ABI mea-
surement. Theoretically, patients who refused or were unable to participate for the ABI measurement 
could have introduced selection bias. A comparison of the patient characteristics age, gender, smok-
ing, diabetes mellitus, and obesity between responders and non-responders of the ABI measure-
ments, however, were not statistically different (p>0.05). 
Data analysis
The statistical significance of differences in dichotomous variables (gender, smoking, diabetes mel-
litus, and obesity) between the cardiac rehabilitation failure group and success group were assessed 
using the chi-squared test. The continuous variable age was assessed with the Students t-test. Two 
tailed p-values < 0.05 were considered statistically significant. Chi-squared tests were also used to 
compare the proportion of patients with PAD based on the walking distance score, the speed score, 
and ABI measurements between the cardiac rehabilitation failure group and the cardiac rehabilitation 
success group (two tailed p-values < 0.05 were considered statistically significant). Odds ratios (OR) 
of the odds favoring the presence of PAD were calculated for the cardiac rehabilitation failure group 
divided by odds favoring the presence of PAD in the cardiac rehabilitation success group. In addition, 
because age and sex are risk factors of PAD,16 these variables may also be associated with cardiac 
rehabilitation failure. Therefore, we applied logistic regression models to adjust for age and gender 
to examine the association between cardiac rehabilitation failure and the presence of PAD, based on 
the walking distance score and the speed score of the WIQ. Logistic regression models based on the 
ABI to examine the association between cardiac rehabilitation failure and the presence of PAD were 
not performed, as the sample with ABI measurements was too small.
Furthermore, we evaluated whether the presence of PAD indicated by the WIQ agreed with the pres-
ence of PAD indicated by the ABI using the kappa statistic (∙). Strenght of this agreement can be inter-
preted as poor (∙ < 0.20), fair (∙ = 0.21-0.40), moderate (∙ = 0.41-0.60), good (∙ = 0.61-0.80), or excellent 
(∙ = 0.81-1.0).18 The analyses were performed in SPSS for windows (release 11.0.1; SPSS, Chicago USA).
85% intensity in the following formula: THR = ((HRmax – HRrest) × %Intensity) + HRrest.10 In addition, 
patients were encouraged to meet their target metabolic equivalents (METs), which was defined as 
65-80% of the maximum METs attained during the stress test (1 MET =3.5 ml O2/kg/min). The rating 
of perceived exertion (RPE), on a scale of 6-20, was also used as an adjunct to heart rate and as an in-
tensity guide for exercise training.11 Perceived exertion is the feeling that a patient has concerning the 
degree of effort being exerted during his or her exercise. For example, 6 is feeling very comfortable 
without noticeable strain and 20 is feeling exerted to the point of being unable to continue. 
Cardiac rehabilitation failure was defined as a discontinuation of the treadmill exercise program of 32 
sessions or an inability to reach target heart rate. 
Evaluation of PAD
The WIQ was used to assess walking ability and to diagnose PAD.12 The WIQ was chosen in this study 
because prior validation and feasibility in the PAD population was demonstrated.13 The WIQ was de-
veloped to characterize the degree of walking impairment in patients with PAD; it has three domains: 
walking distance, walking speed, and stair climbing.8,12 We used a summary score for walking distance, 
walking speed, and stair climbing, as developed by Regensteiner and colleagues.8
Walking distance scores range from 0% (patients unable to walk 20 feet without stopping to rest) 
to 100% (patients able to walk five blocks without stopping to rest). The summary score for walking 
distance was derived by multiplying each individual score times the approximate distance (in feet) 
being assessed in a particular question, and then summing the scores. The summary score obtained 
was then divided by the maximum summary score possible (14080) to calculate the percent of the 
maximum score achieved by each patient. These responses are ranked on a scale of 0 to 4, (0=unable 
to do, 4=no difficulty). For example, if a patient responded with a 0 (unable to do), a 2 (some difficulty) 
for walking 3 blocks, and 4 (no difficulty) for the remaining 5 questions, the summary score for walk-
ing distance was calculated as: 0 (1500 ft) + 2(900 ft) + 4(600 ft) + 4(300 ft) + 4(150 ft) + 4(50 ft) + 4(20 
ft) = 6280 /14080 = 0.45 = 45%.
Walking speed scores range from 0% (patients unable to walk one block slowly without stopping to 
rest) to 100% (patients able to jog one block without stopping to rest). The summary score for walking 
speed was derived in a similar fashion as that for walking distance. We estimated walking speed in 
miles per hour for each of the 4 questions relating to speed using recommended speed with tread-
mill testing for PAD patients, multiplied by the response score for a given question, and then summed 
the scores.14 The total score obtained was then divided by the maximum summary score possible of 
46 and expressed as a percentage.
Stair climbing scores range from 0% (patients unable to climb one flight of stairs without stopping 
to rest) to 100% (patients able to climb three flights of stairs without stopping to rest). The summary 
score for stair climbing was derived in a similar fashion as that for walking distance and speed. The 
maximum score possible was 288. 
The threshold value of the summary scores that defined PAD in our study population was determined 
with a weighted mean value of cut-off values from a previous study.15 McDermott and colleagues in-
vestigated the prevalence of unrecognized PAD with the use of the WIQ walking distance and speed 
scores in three groups of patients: 1) men and women with PAD identified from the non-invasive 
vascular laboratory (n=143); 2) unrecognized PAD, defined as men and women with a screening ankle 
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metabolic level of less than 6 METS or less than 1.4 watt/kg body weight. In our study, 51of 126 pa-
tients (40%) failed the cardiac rehabilitation and 75 of 126 patients (60%) were successful. Patient 
characteristics were not statistically different between the cardiac rehabilitation failure and success 
group (all p-values > 0.05).
Evaluation of PAD
Based on the walking distance score, 17 of 51 patients (34%) in the cardiac rehabilitation failure group 
had PAD and 13 of 75 patients (17%) in the cardiac rehabilitation success group had PAD (OR 2.5; 95% 
CI 1.1 to 6.0, p=0.03) (Figure 1). Based on the walking speed score, 15 of 51 patients (30%) in the cardiac 
rehabilitation failure group and 21 of 75 (28%) in the cardiac rehabilitation success group had PAD 
(OR 1.1; 95% CI 0.5 to 2.5, p=0.79) (Figure 1). Based on the ABI measurements, 7 of 18 patients (39%) in 
the cardiac rehabilitation failure group and 3 of 21 patients (14%) in the cardiac rehabilitation success 
group had PAD (OR 3.8; 95% CI 0.8 to 17.9, p=0.08) (Figure 1). Cardiac rehabilitation failure, adjusted 
for age and sex, was significantly associated with the presence of PAD based on the walking distance 
score (OR 2.8; 95% CI 1.1 to 7.1, p=0.03), but not significantly associated with the presence of PAD 
based on the speed score (OR 1.2; 95% CI 0.5 to 2.8, p=0.72). 
Table 3 shows the mean WIQ scores in the cardiac rehabilitation failure and success group. The mean 
walking distance score was lower in the cardiac rehabilitation failure group than in the cardiac reha-
bilitation success group with a borderline p-value (mean score difference 0.12; 95% CI -0.02 to 0.25, 
p=0.08). The mean walking speed score and the mean climbing stairs score were not significantly 
different between cardiac rehabilitation failure and success group (mean score difference 0.02; 95% CI 
Table 2: Cardiac rehabilitation performance 
n = 126 (%)
Peak heart rate (beats per minute)* 127 +/- 21 (73-172)
Patients meeting target heart rate 64 51
METS* 8 +/- 3 (2-15)
Patients meeting target METS 91 72
Number of sessions*
31 +/- 19 (2-36)
Patients who completed 32 sessions 99 79
Patients at high risk† 26 21
Successful cardiac rehabilitation ‡ 75 60
Note.- METS = metabolic equivalents 
*Mean +/- SD, range in parentheses
†based on prior stress-test with METS<6 METS / <1.4 watt/kg body weight
          ‡successful cardiac rehabilitation was defined as a continuation of the treadmill exercise program of at least 32     
           sessions or the ability to reach target heart rate.
RESULTS
Patients
Table 1 shows the patient characteristics and severity of cardiac disease. Ninety-three of 126 patients 
(74%) were men. The mean age was 65 years +/- 11 (range 31-91) (Table 1). Sixty-three of 126 patients 
(50%) had a myocardial infarction before cardiac rehabilitation, 58 of 126 patients (46%) had angina, 
3 of 126 patients (2%) had an aortic valve replacement, 1 of 126 patients (1%) a mitral valve repair and 
1 of 126 patients (1%) was assigned to cardiac rehabilitation for congestive heart failure. Fifty-three of 
126 patients (42%) had PTCA as previous treatment, 49 of 126 patients (39%) had a CABG, and 7 of 126 
patients (6%) had both treatments before cardiac rehabilitation. 
Table 2 shows the cardiac rehabilitation performance of the patients. The mean measured peak heart 
rate level was 127 beats per minute +/- 21 (range 73-172). Sixty-four of 126 patients (51%) met their 
target heart rate. Estimated fitness levels ranged from 2 to 15 METs (mean 8 +/-3) and 91 of the 126 
patients (72%) reached target METs. The mean number of cardiac rehabilitation sessions was 31 ses-
sions +/- 19 (range 2-36) and 99 of 126 patients (79%) completed 32 sessions. There were 26 of 126 
patients (21%) at high risk of a cardiac event, which was based on a prior stress-test with an achieved 
Table 1: Patient characteristics and severity of cardiac disease 
n = 126 (%)
Male sex 93 74
Age (y)* 65 +/- 11 (31-91)
Smoking (ever) 58 46
Diabetes mellitus 24 19
Obesity† 43 34
Previous diagnosis:
              Myocardial infarction 63 50
              Angina 58 46
              Aortic valve replacement 3 2
              Mitral valve repair 1 1
              Congestive heart failure 1 1
Previous treatment:
              PTCA 53 42
              CABG 49 39
              PTCA & CABG 7 6
              None 17 13
Note.- CABG = Coronary Artery Bypass Graft; PTCA = Percutaneous Transluminal Cardiac Angioplasty
 *Mean +/- SD, range in parentheses
 †defined as Body Mass Index>30
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in cardiac rehabilitation reported in this study, as reported in many other studies, might be explained 
by the presence of PAD. 
The association between CAD and PAD might be evident as both are manifestations of atherosclero-
sis and therefore patients who participate in a cardiac rehabilitation program and have PAD are likely 
to be limited in their walking distance and do not have optimal benefit of the program. The presence 
of PAD in this patient group, however, and the influence of this on the clinical effectiveness of cardiac 
rehabilitation was not investigated previously. Whereas the benefits of a suitable cardiac rehabilita-
tion program in which both CAD and PAD are targeted may be apparent in success and will result in 
a reduction of cardiovascular risk. 
The results of our study may help to develop future programs in which both CAD and PAD is tar-
geted. 
Previously, in the literature, other barriers than the presence of PAD have been reported for a suc-
cessful cardiac rehabilitation, such as work, time conflicts, financial reasons, inadequate or limited 
insurance, lack of motivation or commitment, fear, and coexisting medical illnesses.20 In addition, all 
of these barriers, including PAD, may not only be reasons for failure, but also reasons for non-atten-
dance in a cardiac rehabilitation. Participation rates in cardiac rehabilitation are low and range from 
17% to 21%.21,22 Therefore, the total number of CAD patients with PAD that may benefit from a cardiac 
rehabilitation may even be higher than the actual number of CAD patients with PAD presented in 
our study.
In our study, the WIQ was used to indicate the presence of PAD and the ABI was used for this purpose 
in a subset of our patient sample. We found that cardiac rehabilitation failure was significantly associ-
ated with the presence of PAD based on the walking distance score, but not significantly associated 
with the presence of PAD based on the WIQ speed score or the ABI. Also previous studies demon-
strated poor correlations between walking distance and the ABI.12,19 This finding suggests the need for 
Table 3: The mean Walking Impairment Questionnaire scores (n=126) and mean Ankle Brachial 
Index (n=39) in cardiac rehabilitation failure and success group
Cardiac 
rehabilitation 
failure group†
Cardiac 
rehabilitation 
success group
Mean 
difference
95% CI p-value
WIQ* (n=51) (n=75)
Walking distance 0.67 +/- 0.38 0.79 +/- 0.32 0.12 (-0.02 to 0.25) 0.08
Walking speed 0.57 +/- 0.29 0.57 +/ -0.39 0.02 (-0.09 to 0.14) 0.69
Climbing stairs 0.40 +/- 0.15 0.41 +/- 0.13 0.01 (-0.05 to 0.06) 0.80
ABI* (n=18) 
0.97 +/- 0.22
(n=21) 
0.99 +/- 0.26 0.02 (-0.14 to 0.17) 0.87
Note.
 - CI = Confidence Interval
 * Mean +/- SD
 † Cardiac rehabilitation failure was defined as a discontinuation of the treadmill exercise program of 32 sessions or an inability to reach 
  target heart rate.
-0.09 to 0.14, p=0.69 and mean score difference 0.01; 95% CI -0.05 to 0.06, p=0.80 respectively) (Table 
3). In addition, the mean ABI in the cardiac rehabilitation failure and success group was not signifi-
cantly different between the cardiac rehabilitation failure and success group (mean index difference 
0.02; 95% CI -0.14 to 0.17, p=0.87).
The agreement between the WIQ walking distance score and the WIQ speed score for indicating 
PAD was good (∙ = 0.70). The agreement between the WIQ walking distance score and ABI and WIQ 
speed score and the ABI was poor (∙ = 0.17 and ∙ = 0.07 respectively).
DISCUSSION
In our study, cardiac rehabilitation failed in almost half of the patients. We evaluated whether this 
failure rate was related to the presence of PAD. Our results demonstrated that in patients who failed 
cardiac rehabilitation, PAD was more frequently present than in patients who ended cardiac rehabili-
tation successfully. More specifically, after adjustment for age and gender, patients who failed cardiac 
rehabilitation scored less on the WIQ walking distance score. Therefore, the high number of failures 
Figure 1 The presence of peripheral arterial disease based on the walking distance score and 
speed score of the Walking Impairment Questionnaire (n=126) and peripheral arterial disease 
based on the Ankle Brachial Index (n=39) in patients who participated in the cardiac rehabilita-
tion program 
Note- WIQ = Walking Impairment Questionnaire; ABI = Ankle Brachial Index; PAD = Peripheral Arterial Disease; OR = odds ratio; CI = confi-
dence interval
* Cardiac rehabilitation failure was defined as a discontinuation of the treadmill exercise program of 32 sessions or an inability to reach target 
heart rate.
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a cardiac rehabilitation strategy which includes measurement of the walking distance regarding the 
association between the presence of PAD and the walking distance score.
A limitation of this study was the lack of the gold standard for defining the presence of PAD. Currently, 
contrast angiography is recommended for defining PAD.16 Ideally, all patients should have had a con-
trast angiography to determine PAD. In our study, both the WIQ and ABI were used to indicate PAD 
and showed face-validity as both measures indicated a higher proportion of patients with PAD in the 
cardiac rehabilitation failure group than in the cardiac rehabilitation success group.
Another limitation may be that our 126 study participants were only a subset of a total cohort of 231 
patients, which potentially could have biased the results. The differences between the proportion 
failures and successful patients of the cardiac rehabilitation, however, were not statistically different 
between patients who participated and patients who did not participate in our study. In addition, our 
study sample size was sufficient to detect a difference in the presence of PAD between the cardiac 
rehabilitation failure group and the cardiac rehabilitation success group of the patients who partici-
pated in the cardiac rehabilitation.
Based on the results of our study, diagnosing PAD in patients eligible for cardiac rehabilitation seems 
important as the presence of PAD influenced the effectiveness of cardiac rehabilitation negatively 
and emphasizes the need to explore alternative strategies to diagnose and treat PAD in patients in 
cardiac rehabilitation. A new cardiac rehabilitation program in which the diagnosis and the treatment 
of PAD if needed are included could potentially increase the success of the program and improve 
cardiovascular risk reduction. 
In conclusion, our results suggest that the clinical effectiveness of cardiac rehabilitation was inversely 
related to the presence of PAD, which means that patients with PAD have less benefit of the program 
and are at higher risk of future cardiac events. The treatment management in patients with both PAD 
and CAD should be with a new combined cardiovascular rehabilitation program, which could poten-
tially increase the success of the program and improve cardiovascular risk reduction. 
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BACKGROUND
Coronary artery disease (CAD) is the leading cause of mortality and morbidity in the United States.1 
Millions of Americans have a history of myocardial infarction or experience angina pectoris1. Many of 
these patients (on average 300,000 per year) enter a rehabilitation program and those who have un-
dergone re-vascularization procedures undergo cardiac rehabilitation with the objective of improving 
exercise tolerance, symptoms, serum lipid levels, and psychosocial well-being, while reducing cardiac 
risk factors and mortality.2, 3 Published guidelines for cardiac rehabilitation and secondary prevention 
programs advocate a multifaceted program that includes a monitored 12 weeks exercise training of 
36 sessions (3 sessions per week) and the pursuit of modifiable risk factor reduction through educa-
tion, counseling, reinforcement of medical therapies, behavior change and acceptance of personal 
responsibility on the part of the patient.4 
Patients with CAD, however, frequently have peripheral arterial disease (PAD). PAD hinders the cardiac 
rehabilitation program because patients are unable to achieve their target heart rate due to their lim-
ited walking distance. Almost half of the patients who start cardiac rehabilitation do not complete the 
program successfully,5 in large part due to the presence of PAD, and these patients are at increased 
risk for cardiac events during follow-up (20%-60% increased risk for MI).6, 7 Therefore, a diagnostic 
work-up if cardiac rehabilitation fails followed by revascularization for PAD if needed, or a work-up 
and revascularization prior to cardiac rehabilitation, may improve the results. Alternatively, rehabilita-
tion that focuses on improvement of both target heart rate and walking distance may be more effec-
tive because it benefits patients who have both CAD and PAD. 
The aim of the present study was to evaluate the effectiveness, costs, and relative cost-effectiveness 
from the societal perspective of new rehabilitation strategies which include the diagnosis and treat-
ment of PAD in patients with CAD undergoing cardiac rehabilitation.
METHODS
Model structure
A Markov decision model was developed to compare current cardiac rehabilitation with new rehabili-
tation strategies for patients with CAD.8, 9 Our primary cohort for analyses (the base-case) consisted of 
64-year old male patients who entered a cardiac rehabilitation program. 
The strategies in the model were 1) Cardiac rehabilitation (i.e., current practice); 2) Cardiac rehabilita-
tion; if rehabilitation fails diagnostic work-up for PAD and if needed revascularization, after which car-
diac rehabilitation is continued; 3) Diagnostic work-up for PAD and if needed revascularization, after 
which cardiac rehabilitation is started; 4) A comprehensive combined cardiovascular rehabilitation 
program focused on achieving both target heart rate and improving walking distance. 
Figure 1 shows a schematic representation of the model. In the cardiac rehabilitation strategy, pa-
tients entered the program which they either completed successfully or they failed. If failure due to 
PAD occurred, no intervention took place and patients were followed in the outpatient clinic. Cardiac 
rehabilitation failure was defined as a discontinuation of the treadmill exercise program of 32 sessions 
or disability to reach target heart rate (individually determined during a stress test prior to cardiac re-
habilitation). In follow-up, patients experienced a fatal or non-fatal cardiac event (i.e., defined as acute 
angina or non-fatal myocardial infarction) or they died from non-cardiac causes. 
ABSTRACT
Purpose: Evaluating the relative cost-effectiveness of new rehabilitation strategies which include the 
diagnosis and treatment of peripheral arterial disease (PAD) in patients with coronary artery disease 
(CAD) undergoing cardiac rehabilitation.
Materials and methods: We developed a Markov decision model to compare the following treat-
ment strategies: 1) Cardiac rehabilitation; 2) Diagnostic work-up if cardiac rehabilitation fails followed 
by revascularization for PAD if needed; 3) Diagnostic work-up for PAD in all patients prior to cardiac 
rehabilitation and revascularization for PAD if needed; 4) A combined cardiovascular rehabilitation. 
The best-available evidence was retrieved from the literature and combined with primary data from 
231 patients. Quality-adjusted-life years (QALYs), life-time costs, incremental cost-effectiveness ra-
tios (ICER), and gain in net health benefits (NHB) were calculated. A threshold willingness-to-pay of 
$75 000 was used.
Results: Cardiovascular rehabilitation was the most attractive with an ICER of $16 461 per QALY gained 
and a gain in NHB of 0.06 compared to current practice. In an analysis without this strategy, a diag-
nostic work-up if cardiac rehabilitation fails followed by revascularization for PAD if needed was most 
beneficial with an ICER of $49 468 per QALY gained and a gain in NHB of 0.02 compared to current 
practice. 
Conclusions: A combined cardiovascular rehabilitation, or a diagnostic work-up in patients who fail 
cardiac rehabilitation followed by revascularization for PAD if needed, could potentially decrease sec-
ondary cardiac events and save society millions of dollars.
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such as 5 METs to reach target heart rate. Furthermore, patients performed submaximal individual 
treadmill exercise with a workload which increased patient’s walking ability. 
For each of the four strategies, the model kept track of time and costs spent in one of the following 
health states: (a) pre-rehabilitation; (b) successful rehabilitation; (c) failed rehabilitation; (d) post non-
fatal cardiac event; and (e) cardiac death or non-cardiac death. A Markov cycle tree was updated every 
6 months after which patients’ clinical status and costs were estimated to model life-time health 
benefits and costs. 
Data Sources
Effectiveness and cost data for the model were retrieved from the literature and from primary data 
collection. Table 1 and 2 show estimates from the best-available evidence of the included variables 
with probability distributions representing the uncertainty around the estimates and the data sourc-
es. Original patient data was collected in Lutheran General Hospital, Chicago, U.S., and included data 
from 231 consecutive men and women who started cardiac rehabilitation from January 2004 - De-
cember 2004. Of the 231 patients, 125 patients (54%) completed cardiac rehabilitation successfully, 
97 patients (42%) failed cardiac rehabilitation, and 9 patients (4%) were lost to follow-up. Of the 9 
patients who were lost to follow up, half were assumed to belong to the cardiac rehabilitation failure 
group and the other half to the success group, so that finally 56% (54%+2%) were assumed to com-
plete cardiac rehabilitation successfully.
Effectiveness 
In addition to estimates derived from the literature and the hospital database that were included di-
rectly in the model, some estimates were recalculated and several assumptions were needed. Hazard 
rates for fatal- and non-fatal cardiac events during follow-up for patients with and without cardiac 
rehabilitation, were calculated from probabilities derived from a systematic review of Taylor and col-
leagues (Table 1).10
Long-term life expectancy was calculated on the basis of age-and sex-specific mortality rates from 
standard U.S. life-tables of the general population.11 In addition, life-expectancy was adjusted for qual-
ity of life (i.e., Quality-Adjusted-Life Years (QALYs) using health-related quality-of-life weights (Table 
2)). To estimate the quality-of-life weight prior to rehabilitation and for successful completion of the 
program, we used the weighted average of health-related quality-of-life weights based on the lit-
erature.12, 13 For patients who failed cardiac rehabilitation, quality-of-life weights were not available. 
We assumed that these patients had the same quality of life as prior to rehabilitation as they did not 
experience any benefit from the program (Table 2). 
The proportion of patients who failed cardiac rehabilitation due to PAD was based on the Ankle-
Brachial-Index (ABI) measured in a subset of our patient sample. All 231 patients were invited to the 
hospital for additional testing on a specific date, of which 39 patients responded. The patient charac-
teristics between the subset and the non-responders were not statistically different (p > 0.05). In the 
responders, the ABI was measured and PAD was defined as an ABI less than 0.90.14 The leg with the 
lowest ABI was used in the analyses. 
In strategies that included revascularization for PAD, we assumed that in the majority of patients (95%) 
revascularization was possible and that 90% of these patients would benefit from treatment. In our 
patient sample, 7 out of 39 patients (18%) failed cardiac rehabilitation due to PAD, therefore we mod-
In the second strategy, patients also entered a cardiac rehabilitation program but now if patients 
failed, a diagnostic work-up with diagnostic subtraction angiography or magnetic resonance angiog-
raphy (proportion 1:1) was performed. If PAD was present, the lesion was treated with percutaneous 
intervention or bypass surgery depending on disease severity and level of disease. Suprainguinal 
percutaneous transluminal angioplasty (PTA) with stent placement, aorto-iliac grafting, infrainguinal 
PTA, and femoro-popliteal bypass were modeled as revascularization procedures. After revasculariza-
tion, some patients had complications or procedural failures and were unable to continue cardiac 
rehabilitation, whereas most patients continued with their cardiac rehabilitation program.
In the third strategy, all patients underwent a diagnostic work-up prior to cardiac rehabilitation. If 
patients had PAD, a revascularization with PTA or bypass surgery was performed prior to cardiac re-
habilitation. 
In the fourth strategy, patients entered a comprehensive combined cardiovascular program. In this 
program we assumed that patients performed maximum arm exercise (e.g. rowing, weightlifting) 
with a peak heart rate or an arbitrary metabolic equivalent (MET) level (1 MET = 3.5 ml O2/kg/min), 
Figure 1.
Schematic simplified representation of the Markov model. It shows four different rehabilitation strategies. Every strategy contains health states 
in which a patient can remain for more than one cycle. These are pre-rehabilitation (from which every patient starts), successful rehabilitation, 
failed rehabilitation, post non-fatal cardiac event, and death (i.e. cardiac death and non-cardiac death). All health states are only demonstrated 
in the upper strategy for simplification. 
MI = Myocardial infarction; PAD = peripheral arterial disease; CAD = coronary artery disease
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eled that 15% (i.e., 18% * 95% * 90%) underwent succesful revascularization for PAD and subsequently 
continued their cardiac rehabilitation program. Thus, including the possibility of revascularization for 
PAD in the cardiac rehabilitation strategy, in total 71% (i.e., 56% plus 15%) of all patients completed the 
cardiac rehabilitation program successfully.
In the comprehensive combined cardiovascular rehabilitation strategy, we assumed that the success 
rate of rehabilitation compared to current practice increased by 25%. This assumption was based on 
an 80% success rate as a result of the vascular component of the combined rehabilitation program 
in patients who would otherwise fail due to PAD. Thus, in this strategy an additional 14% (i.e., 80% of 
18%) completed the program successfully. Therefore, in total 70% (i.e., 56% plus 14%) completed the 
new program successfully; hence, the increase in success rate of 25% (i.e., 70% versus 56%). 
COSTS
Costs included in the model incorporated medical and non-medical costs and were assessed from 
the societal perspective (Table 2). Medical costs included costs of all diagnostic and therapeutic 
procedures, cardiac rehabilitation, costs for personnel, materials, equipment, associated hospital ad-
missions during 6 months follow-up, and overhead. These costs were derived from the financial de-
partment of Lutheran General Hospital. 
Non-medical costs included transportation costs and patient time costs. Transportation costs includ-
ed parking costs and mean estimated gasoline costs. Patient time costs were determined by multiply-
ing the hourly wage rate ($18.55/hour) by the number of hours or days spent in the hospital.15 Time 
spent in the hospital was derived from our hospital database (e.g. cardiac rehabilitation 36 hours (60 
min * 36 sessions) and a bypass procedure was on average 6.5 days). 
Costs of current practice (cardiac rehabilitation) included scheduled cardiac rehabilitation visits, a 
stress test, follow-up visits, transportation costs, and patient time costs. Costs of the comprehensive 
combined cardiovascular rehabilitation program were assumed to be higher than for current practice 
(Table 2) as a cardiovascular program is more extensive and needs to be developed. 
To take into account time preference, future costs were discounted at the currently recommended 
nominal discount rate of 3% per year.16 All costs were converted to the year 2005 U.S. dollars by using 
the medical care specific consumer price index obtained from the Bureau of labour Statistics.17
ANALYSIS
Quality-adjusted-life expectancy, life time costs, and incremental cost-effectiveness ratios (i.e., ad-
ditional costs divided by quality-adjusted-life-years gained) were calculated for all four strategies. In a 
second analysis, the hypothetical comprehensive combined cardiovascular rehabilitation was exclud-
ed and we focused on currently existing strategies only. Strategies were ordered according to increas-
ing effectiveness (QALYs). A strategy was considered dominated if another strategy was both more 
effective and less costly. A strategy was considered extended dominated if another strategy achieved 
more effectiveness at a lower incremental cost-effectiveness ratio. After eliminating dominated and 
extended dominated strategies the incremental cost-effectiveness ratios (ICERs) were calculated as 
the difference in mean lifetime costs divided by the difference in mean QALYs for each strategy com-
pared to the next best non-dominated strategy.18 
Table 1: Data included in the Markov model on rehabilitation strategies for patients with 
coronary artery disease.
ALGH: Advocate Lutheran General Hospital; PTFE = Poly Tetra Fluor Ethylene, PTA = Percutaneous Transluminal Angioplasty, PAD = Peripheral 
Arterial Disease
*Systemic complication is defined as all events that occurred within 30 days after the procedure and that required additional medical care.
†Patency estimates for iliac PTA with selective stent placement have been shown to equal those for iliac PTA with primary stent placement.41
‡ In the Markov model, we assumed that 5% of the lesions were not suitable for surgery.
Variable Base Case 
Value
Distribution Range Literature or 
Database Source
PROBABILITIES CARDIAC REHABILITATION
 Success current cardiac rehabilitation
 Success cardiac rehabilitation after treatment PAD
 Failure cardiac rehabilitation due to PAD
 Diagnosis PAD before cardiac rehabilitation starts
 Success comprehensive combined
 cardiovascular rehabilitation 
0.56
0.71
0.18
0.26
0.70 
Beta
Beta
Beta
Beta
Beta
0.1 - 0.9
0.1 - 0.9
0.05 - 0.75
0.05 – 0.75
0.41-0.99
ALGH
see text
ALGH
ALGH
see text
6-MONTH RATES OF EVENTS DURING FOLLOW-UP
 Cardiac event after rehabilitation (fatal and non-fatal)
 Cardiac event without rehabilitation (fatal and non-fatal)
 Fatal cardiac event after rehabilitation
 Fatal cardiac event without rehabilitation
0.025
0.029
0.012
0.013
Beta
Beta
Beta
Beta
0.01 – 0.03
0.01 – 0.04
0.005 – 0.02
0.005 – 0.02
[10], see text
[10], see text
[10], see text
[10], see text
PROBABILITIES PAD STATUS
 Suprainguinal disease conditional on the presence of PAD
 Suprainguinal lesion is suitable for angioplasty
 Infrainguinal lesion is suitable for angioplasty
 Lesion is suitable for surgery‡
 Aorto-iliac lesion is occlusive vs. stenotic
 Femoro-popliteal lesion is occlusive vs. stenotic
 Vein is available for bypass surgery vs. PTFE
0.56
0.51
0.18
0.95
0.20
0.36
0.20
Beta
Beta
Beta
Beta
Beta
Beta
Beta
0.12 - 0.85
0.43 - 0.59
0 - 0.25
0 - 0.99
0 - 0.5
0 - 0.6
0 - 0.5 
[27]
[27, 28]
[27, 28]
see text
[29]
[30]
ALGH
MORTALITY RATE FOR PAD PROCEDURES AND IMAGING
 Iliac PTA with selective stent placement
 Femoral or popliteal PTA
 Aortic bifurcation grafts
 Femoro-popliteal or infrapopliteal bypass
 Diagnostic imaging (angiography and magnetic resonance
 imaging)
0.013
0.025
0.040
0.047
0.00033
Beta
Beta
Beta
Beta
Beta
0 - 0.037
0 - 0.264
0 – 0.10
0.008 - 0.127
0.00029- 0.00162
[31]
[32]
[33]
[32]
[34, 35]
PROBABILITIES SYSTEMIC COMPLICATIONS OF PAD PROCEDURES*
 Iliac PTA with selective stent placement
 Femoral or popliteal PTA
 Aortic bifurcation grafts
 Femoro-popliteal or infrapopliteal bypass
0.013
0.013
0.083
0.085
Beta
Beta
Beta
Beta
0 -0.035
0.002 - 0.11
0 - 0.1 
0.027- 0.13
[31]
[32]
[31]
[32]
6-MONTH PATENCY IN PATIENTS WITH PAD
 Iliac PTA with selective stent placement †
  Stenosis
  Occlusion
 Femoro or popliteal PTA without stent placement
  Stenosis
  Occlusion
 Femoro or popliteal PTA with stent placement
  Stenosis
  Occlusion
 Aortic bifurcation grafts
 Femoro-popliteal or femoroinfrapopliteal bypass
  Autologous vein above-knee anastomosis
  Autologous vein below-knee anastomosis
  PTFE, above-knee anastomosis
  PTFE, below knee anastomosis
0.9
0.80
1.0
0.88
1.0
0.99
0.98
0.95
0.94
0.87
0.70
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
Beta
0.70 - 0.99 
0.70 - 0.99
0.98 - 1.0
0.81 - 0.94
0.99 - 1.0
0.92 - 1.0
0.98 - 0.99
0.90 - 0.99
0.93 - 0.95
0.84 - 0.90
0.65 - 0.75
[31]
[31]
[36]
[36]
[36]
[36]
[37]
[38, 39]
[40]
[40, 41]
[40, 41]
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accepted threshold and varied the WTP between $50 000 and $100 000 in sensitivity analyses.20, 21 For 
each of the three new strategies considered we calculated the gain in NHB compared to the NHB of 
current practice.22
To explore the effect of uncertainty in our parameter estimates, we performed extensive one-way, 
two-way, and multi-way sensitivity analysis. Using probabilistic sensitivity analysis (second order Mon-
te Carlo simulation), the uncertainty around the outcomes of the strategies was assessed9, 23 by pick-
ing at random a value from each of the distributions of the parameter values, running the model with 
these values to get one set of outcome values, and repeating this 100 000 times.8 
In value of information analysis we determined whether more information from future research is 
necessary to decrease the remaining uncertainty.24 More research is not justified if the expected costs 
of further research exceed the expected benefit of that study. To estimate the total expected value of 
perfect information (EVPI) per patient, we calculated for each of the 100,000 Monte Carlo simulations 
from the probabilistic sensitivity analysis 22 the NHB of the optimal strategy per simulation, which is 
the expected NHB with perfect information. The EVPI is the difference between the mean expected 
NHB with perfect information from the probabilistic sensitivity analysis and the mean NHB with cur-
rent information from the primary analysis. Next, we estimated the population EVPI, which is the total 
EVPI per patient multiplied by the expected lifetime of the technology and multiplied by the annual 
number of future patients expected to benefit from more research of the optimal strategy adjusted 
for the discount rate.22 Based on the annual number of patients who undergo cardiac rehabilitation 
in the United States, we assumed that the annual population that could benefit from future clinical 
research on new rehabilitation strategies would be 300,000. Expressing patient and population EVPI 
in dollars the NHB was reframed in terms of Net Monetary Benefit (NMB = NHB*WTP) which enables 
comparison with research costs. The NMB is the maximum amount that we should spend on future 
research to decrease current uncertainty. 
RESULTS
Analysis of all strategies 
Using our best estimates in the base-case analysis, comprehensive combined cardiovascular rehabili-
tation was the most attractive strategy with an ICER of $16,461 per QALY gained (Table 3). The NHB of 
this new strategy was 3.9 at a WTP of $75,000 (Table 3). The gain in NHB compared to current practice 
was 0.06 and the 95% confidence intervals included 0 (Figure 2), which implies uncertainty around 
the outcome.
 Intermediate outcomes presented in Table 4, showed that in a hypothetical cohort of 10,000 patients, 
the number of patients with a cardiac event during follow-up was lowest when a diagnostic work-up 
for PAD was performed in all patients. This benefit was diminished, however, by an increased number 
of patients with peri-procedural morbidity and mortality related to the PAD revascularization proce-
dure. Furthermore, Table 4 showed that the combined cardiovascular rehabilitation program saved 45 
cardiac events per 10 000 patients. Thus, with 300 000 eligible patients for cardiac rehabilitation per 
year, this new rehabilitation program may cost society 582 million dollars (assuming $1940 additional 
expense per patient), whereas it may save society $27 billion due to a decrease in cardiac events (ap-
proximately 1350 prevented cardiac events in 300.000 patients * $20 000).
Furthermore, we transformed costs and QALYs into one comprehensive outcome measure: the net 
health benefit (NHB).9, 19, 20 The NHB was defined as lifetime effectiveness (QALYs) minus lifetime costs 
($), the latter divided by the societal willingness-to-pay (WTP) threshold to save one QALY ($/QALY). 
The NHB is expressed in QALY-equivalents. Published estimates for WTP ranged from $20 000 to 
$100 000 per QALY gained. In our analysis we considered $75 000 per QALY gained as a commonly 
Table 2: Health related quality of life and costs in U.S. Dollars.
ALGH = Advocate Lutheran General Hospital; PTA = Percutaneous Transluminal Angioplasty; PAD = Peripheral Arterial Disease. 
* Values based on responses on the EuroQol-questionaire [49, 50].
† Average Time Trade-off value among survivors of a myocardial infarction, used as a proxy for the effect on quality of life of a systemic 
complication[44].
‡ Assumes that in 43% of the cases a stent is placed [41].
§ Costs were converted to the year 2005
¶ Based on the average number of sessions patients completed in ALGH
║Costs are average costs of MRA and DSA because they were performed in the same proportion in ALHG.
Variable Base Case 
Value
Distribution Range Literature or 
Database Source
HEALTH-RELATED QUALITY OF LIFE WEIGHTS
 Pre-rehabilitation*
 After failed cardiac rehabilitation
 After successful cardiac rehabilitation
 After non-fatal cardiac event 
 Systemic complications†
0.83
0.83
0.98
0.83
0.72
Uniform
Uniform
Uniform
Uniform
Uniform
0.5 - 0.99
0.5 - 0.99
0.8 - 0.99
0.5 - 0.99
0.6 - 0.90
[12, 13]
See text
[12, 13, 42, 43]
[12, 13]
[44]
COSTS (US DOLLARS)§
REHABILITATION (6 months)
 Scheduled visits cardiac rehabilitation
 Stress test 
 Follow-up visit 
 Transportation costs
 Patient time costs
 Total costs Cardiac rehabilitation if 
 successfully completed
 Total costs Cardiac rehabilitation if patient 
 failed the program ¶
 Total costs comprehensive cardiovascular 
 rehabilitation if successfully completed
 Total costs comprehensive cardiovascular 
 rehabilitation if patient failed the program ¶
 Post-Program after rehabilitation (per year)
3,112
95
75
117
481
3,880
3,289
5,820
4,934
1,257
Lognormal
Lognormal
Lognormal
Lognormal
Lognormal
1,940 –5,820
1,645 - 4,936
2,910 - 8,730
2,467 - 7,401
629 -1,886
ALGH
ALGH
ALGH
ALGH 
ALGH [17]
ALGH
ALGH
See Text
See Text
[45]
DIAGNOSIS FOR PAD
 Diagnostic angiography/imaging║ 778 Lognormal 389 - 1,167 ALGH
REVASCULARIZATION FOR PAD
 Aortic bifurcation grafts
 Iliac PTA with selective stent placement ‡
 Femoro-popliteal or infrapopliteal bypass
 Femoral or popliteal PTA
32,942
9,618
13,932
5,305
Lognormal
Lognormal
Lognormal
Lognormal
16,471 - 49,413
6,369 - 12,739
6,966 - 20,898
1,528 - 8,906
ALGH
[41, 46, 47]
ALGH
[47]
SYSTEMIC COMPLICATIONS AFTER 
REVASCULARIZATION FOR PAD
 Short-term costs
 Annual long-term costs
 Mortality from revascularization procedures
12,430
13,715
14,783
Lognormal
Lognormal
Lognormal
8,269 - 16,539
6,361 - 9,083
4,580 - 25,445
[47]
[48]
[47]
RECURRENT EVENTS
 Non-fatal cardiac event first year
 Non-fatal cardiac event annually thereafter
 Fatal cardiac event
18,589
7,500
20,971
Lognormal
Lognormal
Lognormal
9,295 - 27,884
3,750 - 11,250
10,486 - 31,457
[45]
[45]
[45]
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The outcomes were sensitive to variation in the increase in success rate of the comprehensive reha-
bilitation program. If the increase in success rate was below 10%, this strategy was no longer optimal 
and performing a diagnostic work-up if cardiac rehabilitation fails became the most attractive with a 
NHB of 3.7 QALYs. If we changed the threshold WTP to $50 000 or $100 000, the threshold value of the 
increase in success rate of comprehensive rehabilitation remained 10% (rounded) and the differences 
in NHB were small. 
For other parameters, we found that alternative assumptions either did not substantially affect the 
outcomes or affected all strategies similarly implying that comprehensive rehabilitation remained the 
most attractive strategy.
 
Analysis without the hypothetical strategy 
In our second analysis, in which we excluded the hypothetical comprehensive combined cardiovas-
cular rehabilitation, diagnostic workup for PAD if cardiac rehabilitation fails was the most attractive 
with an ICER of $49 468 per QALY gained (Table 3). The NHB of this strategy was 3.9 at a WTP of 
$75,000 (Table 3). The gain in NHB compared to current practice was 0.02 and the 95% confidence 
intervals included 0 (Figure 2), which implies uncertainty around the outcome.
Figure 2. Gain in net health benefit with 95% confidence intervals of new rehabilitation 
strategies compared to current practice at a willingness to pay of $75,000
PAD = peripheral arterial disease; NHB= net health benefit
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DISCUSSION
In this study, we evaluated whether patients with CAD who currently enter a cardiac rehabilitation 
program would benefit more from the program if treatment for PAD is considered. The results sug-
gest that a hypothetical comprehensive combined cardiovascular approach is cost-effective com-
pared to current practice. Although a comprehensive combined cardiovascular rehabilitation is more 
expensive, the success rate of this new rehabilitation strategy is expected to be higher, preventing 
additional events in CAD patients during follow-up, which would lead to a gain in QALYs. When we 
excluded this hypothetical strategy from the analysis, the strategy with diagnostic work-up if cardiac 
rehabilitation fails followed by revascularization for PAD if needed was the most attractive. A strategy 
that included a diagnostic work-up for PAD in all patients prior to the cardiac rehabilitation program 
with revascularization if needed, did not increase QALYs compared to current practice. 
Current rehabilitation programs in the United States and in Western European countries consist of 
either cardiac rehabilitation for patients with CAD or vascular rehabilitation for patients with PAD. 
A combined program does not exist. Vascular programs range from hospital-based walking on a 
treadmill to home-based walking in the community until a mild or moderate level of pain is reached. 
These programs do not induce patients’ target heart rate. We showed that it is attractive to develop 
a new rehabilitation program in which cardiac rehabilitation and vascular programs are combined, or 
revascularisation for PAD is considered, to decrease the failure rate of cardiac rehabilitation. 
Due to continuously escalating medical costs, third-party payers demand evidence of cost-effective-
ness and cost-related benefits of health care services and programs. With the new comprehensive 
combined cardiovascular rehabilitation strategy or the strategy with diagnostic work-up if cardiac 
rehabilitation fails followed by revascularization for PAD if needed, many secondary events can be 
avoided in patients with CAD. This new rehabilitation program needs to be developed, may be more 
extensive, and therefore may initially cost more. With 300,000 eligible patients for cardiac rehabili-
tation per year, this new rehabilitation program may cost society a little over half a billion dollars, 
whereas it may save society $27 billion due to a decrease in cardiac events. Nevertheless, we must 
interpret these results with caution because of the remaining uncertainty in our analysis. 
Future clinical research could reduce the uncertainty and patients could potentially benefit from more 
precise estimates of test characteristics, costs, and treatment effects. To assess whether the remaining 
uncertainty justifies future research, we performed a value of information analysis. The large popula-
tion EVPI of $6 billion suggests that a substantial investment in future research would be justified. 
One of the limitations of this study was that certain assumptions were needed in evaluating the 
rehabilitation strategies in a Markov model, which may have affected our results. In the analysis of 
all strategies, the preferred strategy depends on the assumption of the increase in success rate of 
the comprehensive combined cardio-vascular rehabilitation. If we assumed a lower increase in suc-
cess rate of the comprehensive combined cardio-vascular rehabilitation, diagnostic work-up if cardiac 
rehabilitation fails followed by revascularization for PAD if needed would be beneficial. Thus, a combi-
nation of a vascular and a cardiac program or a diagnostic workup for PAD if cardiac rehabilitation fails 
would be more attractive than cardiac rehabilitation alone. For many other assumptions, we dem-
onstrated that varying the parameter values did not change the results substantially or changed the 
results for all strategies similarly while the conclusions remained the same. Another limitation of our 
study was the small subset of our patient sample who participated in the follow-up ABI measurement 
to determine the percentage failures due to PAD in our study group. However, the patient character-
Table 4: Intermediate Outcomes: number of cardiac events* during follow-up and number 
of peri-procedural complications in the base-case analysis in a hypothetical cohort of 10,000 
patients.
Cardiac event = acute angina or non-fatal myocardial infarction
PAD = Peripheral Arterial Disease
* unrelated to PAD revascularization
Per 10,000 patients Cardiac event 
during follow-up 
No. of patients
Peri-procedural complications and death 
from PAD revascularization procedure 
No. of patients
STRATEGY 1: 
Cardiac rehabilitation 
2700 0
STRATEGY 2: 
Diagnostic work-up if cardiac rehabilitation fails  
followed by revascularization for PAD if needed
2659 106
STRATEGY 3: 
Diagnostic work-up for PAD in all patients prior to cardiac 
rehabilitation and revascularization for PAD if needed
2644 122
STRATEGY 4: 
Hypothetical comprehensive combined 
cardiovascular rehabilitation 
2655 0
In one-way sensitivity analysis, we varied the “probability that PAD is the cause of cardiac rehabilita-
tion failure”. Below a probability of 0.07, current practice was the preferred strategy with a NHB of 
3.9 QALYs. In a two-way sensitivity analysis where we changed both the “probability that PAD is the 
cause of cardiac rehabilitation failure” and the WTP to $50 000, current practice was the preferred 
strategy below a threshold probability of 0.4 with a NHB of 3.7 QALYs. Doing a diagnostic work-up 
for PAD in all patients prior to the cardiac rehabilitation program would not be beneficial, which was 
mainly due to the higher costs of the diagnostic imaging and due to the peri-procedural complica-
tions. Multi-way sensitivity analysis demonstrated that for a WTP of $50 000 with a 50% reduction in 
peri-procedural complications, 50% increase that the patient has PAD, and below a threshold of 0.10 
that PAD is the cause of cardiac rehabilitation failure, current practice was the preferred strategy with 
a NHB 3.6 QALYs. Performing a diagnostic work-up for PAD prior to cardiac rehabilitation in all patients 
was dominated by all other strategies.
For other parameters, we found that alternative assumptions either did not substantially affect the 
outcomes or affected all strategies similarly. If we lowered, for example, the original estimated rate of 
cardiac events after cardiac rehabilitation, the ICERs decreased for all strategies. Furthermore, varying 
the costs of fatal- and non-fatal cardiac events between 50% and 150% of the original estimates af-
fected all strategies similarly and did not change the results of the ICERs. 
Value of information analysis
In the analysis which included all strategies, the total EVPI per patient was $2 327 using a WTP of 
$75 000. This implies that an infinitely large future study is expected to increase the NMB per patient 
with $2 327 for the optimal rehabilitation strategy. With the annual estimated number of patients that 
undergo cardiac rehabilitation of 300,000, an effective lifetime of a new rehabilitation strategy of 10 
years, and a discount rate of 3%, the population EVPI was $6 billion. 
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istics between the responders and non-responders were not significantly different and varying the 
percentage of failures due to PAD in a sensitivity analysis, we demonstrated that the results remained 
the same. 
Cardiac rehabilitation programs remain underused in many countries. For example, in the U.S. only 10 
to 20 percent of 2 million eligible patients per year who experienced a myocardial infarction or under-
went cardiac revascularization procedures participated in a cardiac rehabilitation program.2 Previous 
studies reported that factors such as poor patient motivation or co-existing illnesses were related 
to non-attendance of the cardiac rehabilitation program.25,27 Many patients among non-participants 
could be physically inactive because of PAD, which could reduce patient’s motivation to participate 
in a cardiac rehabilitation program and emphasizes the need to explore alternative strategies to diag-
nose and treat PAD in patients in cardiac rehabilitation programs. 
In conclusion, the results suggest that a more aggressive approach to the diagnosis and treatment of 
PAD in CAD patients undergoing cardiac rehabilitation is warranted. A combined cardiovascular re-
habilitation program, or if this is unavailable a diagnostic work-up for PAD in patients who fail cardiac 
rehabilitation followed by revascularization if needed, could potentially decrease secondary cardiac 
events and save society millions of dollars.
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INTRODUCTION
Various noninvasive imaging modalities are in current use for the diagnostic workup of patients sus-
pected of having peripheral arterial disease. These studies include magnetic resonance angiography 
(MRA), computed tomography angiography (CTA), and duplex ultrasound (DUS) scans. Although 
MRA and CTA are increasingly used for noninvasive vascular imaging, DUS has proved to be cost-ef-
fective and accurate for the detection of significant vascular stenoses and is therefore often used as 
the first diagnostic modality.1-4 Problems may arise, however, when evaluating the aortoiliac arteries 
that cannot be visualized in their entirety in the 5% to 25% of patients who are extremely obese, have 
abundant intestinal gas, or who have particularly tortuous or calcified iliac arteries.5,6
It would be attractive if one could rapidly evaluate the aortoiliac arteries for the presence of sig-
nificant obstructive disease without having to visualize these arteries along their entire length. This 
would reduce the number of indeterminate results of DUS scans, reduce the examination time for 
a complete DUS examination, and might also reduce the existing moderate observer variability 
(∙ = 0.43 to 0.53) when the aortoiliac segment is evaluated.7
Potentially, such a rapid evaluation of the aortoiliac arteries might be provided by assessing the du-
plex waveform as measured distally at the level of the common femoral arteries (CFAs).8-11 It is known 
that the waveform distal to a significant obstruction often changes in character, for example, from a 
normal triphasic waveform proximal to a stenosis to a monophasic waveform distal to the stenosis. 
However, only few data in the literature have addressed the question of how accurate a marker of the 
femoral artery DUS waveform is to show or exclude significant aorto-iliac obstruction .
The aim of the present study was, therefore, to evaluate the accuracy, predictive value, and observer 
agreement of the DUS waveform at the CFA as a marker of significant aortoiliac disease in a large 
group of consecutive patients who had a diagnostic workup for peripheral arterial disease in a vas-
cular unit.
METHODS
Study design and patients
From October 2001 until March 2004, 250 consecutive patients who had an anklebrachial index (ABI) 
0.9 at rest or a decrease in ABI of 30% after exercise were referred to the noninvasive vascular labo-
ratory of a large community hospital by our vascular surgeons for screening of peripheral arterial 
disease. Of these, 234 patients had both a full DUS examination and MRA of the aortoiliac segment 
and peripheral runoff and formed the population of the current study. For the purpose of another, 
unrelated clinical trial in our institution, these patients were to undergo both examinations irrespec-
tive of the DUS or MRA results. The study we refer to is a therapeutic trial comparing exercise training 
with percutaneous transluminal angioplasty. Patients gave written informed consent to be part of this 
study and for their study data to be reported in the literature for the purpose of scientific articles.
MRA has been validated with angiography in our institution in an earlier stage. This resulted in ac-
ceptable disagreement (10%) between the two methods, and therefore, we decided to use the MRA 
as the reference standard. Our results were in agreement with existing data in the literature on MRA 
accuracy. In a meta-analysis of the literature published in 2000, the pooled sensitivity of the MRA was 
97.5%, and the pooled specificity was 96.2% relative to digital subtraction angiography.4 
VALUE OF THE DUPLEX WAVEFORM AT THE COMMON
FEMORAL ARTERY FOR DIAGNOSING OBSTRUCTIVE
AORTOILIAC DISEASE
ABSTRACT
Purpose: To evaluate the accuracy, predictive value, and observer agreement of the duplex ultra-
sound waveform at the common femoral artery as a marker of significant aortoiliac disease in a large 
group of consecutive patients who underwent a diagnostic workup for peripheral arterial disease in 
a vascular unit.
Materials and methods: In 191 consecutive patients (381 aortoiliac segments), we classified the du-
plex ultrasound waveform at the common femoral artery as triphasic, biphasic, sharp monophasic, 
or poor monophasic. The waveforms were then compared with the findings of magnetic resonance 
angiography of the aortoiliac segment and peripheral runoff vessels. We calculated the diagnostic ac-
curacy of the duplex waveform for detecting >50% obstructive disease of the aortoiliac segment and 
determined the observer agreement for classifying the duplex waveforms done by two independent 
observers.
Results: Magnetic resonance angiography showed obstruction in 152 (39.9%) of 381 aortoiliac seg-
ments in 191 patients. The presence of a poor monophasic waveform, encountered in 91 (24.3%) of 
375 segments, was a reliable sign of significant aortoiliac disease, with a positive predictive value of 
92%. Other waveforms were nondiagnostic for aortoiliac obstructive disease. The sharp monophasic 
waveform reliably predicted occlusive disease of the superficial femoral artery that was seen in 17 of 
23 instances. There was good observer agreement for classifying duplex waveforms (∙w=0.85; 95% 
confidence interval, 0.80 to 0.89).
Conclusion: The poor monophasic duplex waveform at the common femoral artery is in itself an 
accurate marker of aortoiliac obstructive disease. Other waveforms are nondiagnostic for aortoiliac 
disease.
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60° Doppler insonation angles. The patients made one visit to the vascular laboratory in which the 
duplex waveform of the CFA was recorded on a video print and archived in the patients’ records.
For the purpose of this study, the video prints of the DUS waveforms were retrieved, anonymized, and 
presented to two independent vascular technologists (K.G., W.D.) who were blinded to the patient’s 
identity, clinical findings, and the results of the MRA. The left and right CFA waveforms in a given 
patient were treated as two separate examinations. The duplex waveform was classified into one of 
four categories:12
1. Triphasic: three waveform “phases” consisting of a sharp systolic forward up rise and fall, an 
element of reverse flow during diastole, and an element of forward flow during diastole (Fig 1). 
2.  Biphasic: two waveform “phases” consisting of a sharp systolic forward up rise and fall and an 
element of reverse flow during diastole (Fig 2). 
3.  Sharp monophasic: one waveform “phase” with a sharp systolic rise, the lack of a reverse 
diastolic element, and a fast diastolic fall, expected in arterial segments proximal to an obstruc-
tion (Fig 3). 
4.  Poor (blunted) monophasic: the loss of “sharpness” in systole, the lack of a reverse diastolic element, 
and a slow diastolic fall expected in arterial segments distal to an obstruction (Fig 4).
Magnetic resonance angiograms
MRAs were obtained on a 1.5T MR system unit and by using dedicated MR hardware for peripheral 
MRA (Gyroscan Intera 1.5 TN; MobiTrak; Philips Medical Systems, Best, The Netherlands). A T1 weight-
ed three-dimensional gadolinium-enhanced gradient echo sequence was employed with transverse 
time-of-flight scout views and by using the system’s array body coil. Parameters were repetition time, 
5.9 ms; echo time, 1.62 ms; flip angle, 35°; and slice thickness, 1.5 mm. Acquisition times were between 
1.31 minutes and 2.37 minutes. MRAs of the aortoiliac segment and the lower limbs were obtained 
in 26 seconds with a 75% rectangular field of view of 450 * 315 mm and a matrix of 512 * 512. This 
resulted in a voxel size of 0.80  3.05  1.5 mm3 before interpolation. The calculated voxel size after inter-
polation was 0.80 * 1.5 * 1.5 mm3.
Forty ml of gadolinium diethylenetriaminepentaacetic (DTPA) acid contrast material were infused at 
a rate of 2 ml/second using a power injector. Maximum intensity projections in multiple projections 
and source images were stored on hard copy. For analysis, the hard-copy films were retrieved and 
independently read by two experienced radiologists who were blinded to the results of the DUS 
examinations and to the clinical information (P.M.T.P., L.C.W.J).
The arterial tree was divided in the following segments for analysis: the aortoiliac segments, con-
sisting of the distal aorta, the common iliac artery, and the external iliac artery; and the more distal 
segments, consisting of the CFA, the superficial femoral artery (SFA), and the popliteal artery. The seg-
ments were scored as either normal or as obstructed whenever a 50% diameter stenosis was present. 
The most severe stenosis in each segment was chosen for classification. Each limb consisted of the 
aortoiliac segments and the more distal segments.
Any resulting disagreements between the two readers were resolved by a third independent reader 
(L.v.D, an experienced radiologist) who was blinded to the results of the DUS scan, clinical informa-
tion, and the specific readings of the two other radiologists. The final MR results were taken as the 
gold standard in the evaluation of this study.
We did not perform MRA in 16 patients because of recognized contraindications such as the presence 
of a pacemaker or claustrophobia. In all patients, DUS examinations and MRA were performed within 
a 4-week period.
Of the 234 eligible patients, 43 were excluded from analysis because the hard-copy prints of the DUS 
scan (n=16) or of MRA (n=13) were not available or because the MRA was classified as nondiagnostic 
due to imaging artifacts of metallic vascular stents (n=14). Therefore, in this retrospective analysis, we 
compared the results of DUS waveforms obtained at the CFAs of 191 patients (381 limbs), with the 
results of full aortoiliac MRA as the gold standard. There were 106 men (55.5%). The mean patient age 
was ± 67 ± 12 years (range, 34 to 96). The severity of ischemic disease according to the Fontaine classi-
fication, the vascular risk factors, and relevant comorbidity of the patients are summarized in Table I.
Duplex ultrasound scans
Color duplex examinations were performed at the CFA with a 5-MHz transducer (Aloka SSD-2000, 
Aloka, Tokyo, Japan) by one of three registered vascular technologists according to a standardized 
routine examination protocol in our institution. 
Duplex waveforms were obtained 10 to 20 mm proximal to the femoral bifurcation at the location 
where color change suggested the highest velocity. Care was taken to obtain DUS measurements at 
Table 1: Patient Characteristics and Severity of Ischemic Disease 
Note.
 - Data are numbers of patients and percentages
 * Mean age +- SD, range in parentheses
Characteristic n = 191 (%)
Age (y)* 67 +/- 12 (34-96)
Male Sex 106 55.5
Hyperlipidemia 38 19.9
Cardiac disease 15 7.9
Smoking 110 57.6
Hypertension 46 24.2
Diabetes mellitus 51 26.7
Ankle Brachial Index in rest* 0.70 +/- 0.22
Ankle Brachial Index post exercise* 0.55 +/- 0.36
Fontaine classification:
I: asymptomatic 0 0
II: claudication 111 58.1
III: Ischemic restpain 77 40.3
IV: Tissue loss 3 1.6
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Figure 3: Sharp monophasic: a sharp systolic rise, the lack of a reverse diastolic element, and a 
fast diastolic fall.
Figure 4: Poor monophasic: the loss of “sharpness” in systole, the lack of a reverse diastolic ele-
ment, and a slow diastolic fall.
Figure 1: Triphasic: three waveform ‘phases’; a sharp systollic forward up rise and fall, an ele-
ment of reverse flow during diastole, and an element of forward flow during diastole.
Figure 2: Biphasic: two waveform ‘phases’; a sharp systolic forward up rise and fall, and an ele-
ment of reverse flow during diastole.
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Analysis. 
The results of the four duplex waveform categories compared with the MRA findings are summarized 
in Table II for DUS reader 1. The values for reader 2 were similar, attesting to the very high interobserver 
agreement, and are not separately shown. It can be immediately seen from Table 2 that the presence 
of a “normal” triphasic duplex waveform at the CFA did not exclude significant obstructive aortoiliac 
disease, which was present in 51 (24.6%) of 207 segments. By contrast, a poor monophasic waveform 
was closely correlated with aortoiliac disease, with high positive predictive value of 92% (84 of 91 
aortoiliac segments).
Thus the most useful analysis was to group triphasic, biphasic, and sharp monophasic waveforms 
together as “normal” and the poor monophasic waveform as “abnormal.” This classification had high 
specificity (97%) and positive predictive value (92%), but low sensitivity (56%) and negative predictive 
value (80%) (Table 3). Thus, only the poor monophasic waveform had diagnostic importance, and 
whenever it was encountered, it reliably identified aortoiliac disease.
More specific diagnosis of stenotic versus occlusive aortoiliac disease proved not feasible by using the 
duplex waveform. The poor monophasic waveform was associated with occlusive disease in 31 and 
with stenotic obstruction in 53. It is of note that triphasic and biphasic waveforms were seen in 3 of 34 
and 0 of 34 aortoiliac occlusions, respectively. As an additional finding, it was of interest that the sharp 
monophasic duplex waveform at the CFA was associated with occlusion of the superficial femoral 
artery (11 total occlusions and 6 segmental occlusions) in 17 (73.9%) of 23 instances.
Once the waveforms were grouped as in the second analysis (only the poor monophasic waveform 
grouped as abnormal), further subanalysis showed differences between 74% and 50% sensitivity and 
between 65% and 88% specificity. Although the differences are fairly large, we could not demon-
strate a significant difference, probably because of the small number of patients in the subgroup. In 
addition, no significant difference could be demonstrated in predicting aortoiliac disease between 
patients with claudication versus those with critical ischemia (sensitivity, 57% vs 56% and specificity, 
87% vs 86%)
Table 2: Duplex waveforms at the common femoral artery versus the presence of significant 
aortoiliac obstruction
CFA, Common femoral artery.
*Defined as 50% diameter stenosis or occlusion as seen on contrastenhanced
magnetic resonance angiography.
CFA duplex 
waveform
No aortoiliac 
obstruction
Aortoiliac obstruction 
present*
Total
Triphasic 156 51 207
Biphasic 42 12 54
Sharp monophasic 19 4 23
Poor monophasic 7 84 91
Nondiagnostic 5 1 6
Total 229 152 381
Statistical analysis. 
Two-way contingency tables were made comparing the duplex waveform at the CFA versus the pres-
ence of significant obstructive disease in the corresponding aortoiliac segment on MRA. The accu-
racy, sensitivity, specificity, and positive predictive value as well as the negative predictive value of 
the duplex waveform for detecting 50% obstructive disease of the aortoiliac segment was calculated 
separately for the two DUS scan readers.
The analysis was done three times. In the first analysis, all triphasic and sharp monophasic waveforms 
(expected in arterial segments proximal to an obstruction) were grouped together as “normal,” and 
all biphasic and poor monophasic waveforms were regarded as “abnormal.” In the second analysis, 
triphasic, biphasic, and sharp monophasic waveforms were regarded as normal. Finally, the duplex 
waveforms were grouped as in the second analysis but this time for comparing the presence of aor-
toiliac stenotic disease versus the presence of total occlusive disease in the corresponding aortoiliac 
segment on MRA. Separate analyses were performed to adjust for the potential confounding effects 
of downstream disease13-15 and also for the effect of disease severity (claudication vs critical isch-
emia).
The weighted kappa statistic (∙w) was used to test for observer agreement for assessing the duplex 
waveform. If duplex waveform prints were classified as nondiagnostic by one of the two DUS read-
ers, the classified duplex waveform was used for the analyses. Calculations were performed with the 
Statistical Package for the Social Sciences (SPSS) software release 11.0.1 (SPSS, Chicago, Ill) for Windows 
(Microsoft, Bellingham, Wash) and the Statistical Analysis System (SAS) 8.2 software (SAS Institute Inc., 
Cary, NC) for Windows (Microsoft).
RESULTS
The MRAs showed that 152 (39.9%) of 381 aortoiliac segments in 191 patients had obstruction, in 
particular, 50% stenosis in 125 and occlusion in 27 segments, three of which were aortic occlusions. 
Downstream disease due to significant SFA obstruction was present in 221 (58%) of 381 SFA segments 
(i.e., 50% stenosis in 141 and occlusion in 80 segments), whereas significant popliteal artery obstruc-
tion was present in 74 (19.4%) of 381 limbs (i.e. 50% stenosis in 50 and occlusion in 24 segments). 
Disagreements between the two MRA readers were found in the aorta (4%), iliac segment (14%), SFA 
segment (9%), and popliteal segment (8%) and were resolved by the third independent reader.
Duplex ultrasound scans. 
A total of 6 (1.6%) of 381 duplex waveforms prints were classified as nondiagnostic by both DUS read-
ers and were excluded from analysis. The interobserver agreement for assessing the duplex waveform 
characteristics at the CFA of the remaining 375 limbs was very high (Kw 0.85; 95% CI, 0.80 to 0.89). A 
total of 28 (7.3%) duplex waveform prints were classified nondiagnostic by one of the two DUS read-
ers due to CFA occlusive disease, aortobifemoral bypass graft, femoral artery patch, or because of 
artifacts on the prints.
The interobserver agreement for assessing the monophasic waveform was also very high (∙w = 0.92; 
95% CI, 0.88 to 0.97), whereas by differentiating between the sharp monophasic waveform and the 
poor monophasic waveform, the interobserver agreement was still high (∙w = 0.80; 95% CI, 0.68 to 
0.92).
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sible. Occurrence of the sharp monophasic waveform has value in a way that it marks occlusion of the 
SFA. Knowledge of these flow characteristics may also be helpful in reducing DUS examination time 
or in arriving at a correct diagnosis whenever the iliac arteries cannot be visualized in their entirety.
Our diagnostic algorithm is first to check the CFA waveforms and then to proceed with trying to see 
the aortoiliac arteries in their entirety. The value of the current results in our practice is that we can 
be confident that a hemodynamically significant stenosis is present when we measure a poor CFA 
waveform, even if we do not succeed in visualizing the ipsilateral iliac artery. One might also argue 
that once a poor CFA waveform is encountered, this patient will need to undergo a more definitive 
imaging study and the duplex examination can be considered completed. This would be time con-
suming. Our study specifically warns that this shortcut cannot be taken too far: one cannot exclude 
the presence of hemodynamically significant disease in the aortoiliac arteries from a triphasic or bi-
phasic CFA waveform.
A previous study compared the duplex waveform interpretation against aortoiliac duplex scanning 
and found sensitivity and specificity of 95% and 80%.10 Unfortunately, it is not clearly stated in this 
study if the second duplex waveform observer also did the assessment of the full DUS. Otherwise, it 
could have created observer bias and could also clarify the lower observer agreement between the 
two duplex waveform observers (∙= 0.74). Another study validated the systolic rise time of the Dop-
pler waveform by correlation with angiograms; however for this study, a group of patients with SFA 
obstruction was selected.16
A more recent study compared the interpretation of the CFA against aortoiliac disease by using arteri-
ography as the gold standard and found sensitivity and specificity of 95% and 89%.8 It must be noted 
that in this study, 31% of the significant aortoiliac diseases contained occlusive disease, which is more 
likely to be detected, whereas this was 18% in our study. We found a substantially lower sensitivity, 
which implies that a normal duplex waveform cannot exclude significant aortoiliac disease. However, 
the lower sensitivity is not surprising, because it has previously been described that a duplex wave-
form recorded at a sufficient distance from a stenosis can normalize.10,17
Some limitations of our study should be discussed. A known limitation of MRA findings is that over-
estimation of stenosis grade is more frequent than underestimation.18 This might explain some of the 
false-negative DUS interpretations, but given the sheer amount of false-negative results found here, 
it would not affect the overall conclusions of the present study. Furthermore, we are aware of the 
18% MRA disagreement in the aortoiliac segments and made our reference standard more reliable 
by requiring a third MRA reader. When we performed a subanalyses for the two different MRA read-
ers versus the duplex results separately, the conclusions were robust, in that these were similar to the 
conclusions of our study reported here.
Another limitation of this study may be that the waveform interpretations were made directly from 
the prints and not from real-time DUS scans. Some prints that both DUS readers classified as nondi-
agnostic because of artifacts might have been assessable in a real-time DUS scan, and this could have 
caused false noninterpretable waveforms in the study.
DISCUSSION
Duplex imaging of the CFA is an easily performed test with high observer agreement for classifica-
tion of the duplex waveform. The current study shows that such classification has diagnostic value in 
those patients in whom a poor monophasic waveform is present. In our study, we saw this waveform 
in approximately one quarter of patients. The presence of the poor monophasic waveform accurately 
identifies obstructive disease in the proximal aortoiliac vessel segments with positive predictive value 
of 92%. The other duplex waveforms have no diagnostic value for predicting the status of the proxi-
mal vessels: even a “normal” triphasic waveform is seen in almost a quarter of patients with aortoiliac 
obstruction or occlusion.
For clinical decision making, the relevant issue is if a hemodynamically significant stenosis is present; 
and usually, 50% diameter stenosis is implied as meaning it is. In addition, it is of interest if this is ste-
notic disease or complete occlusion. We have designed the scoring sheets of the reference standard 
accordingly.
Although one would expect the poor waveform in the CFA with an occlusion, as we report here, we 
encountered some patients who had occlusion but a biphasic or triphasic CFA waveform. Also, our 
findings demonstrated that a more specific diagnosis of stenotic versus occlusive aortoiliac disease 
was not possible by using the duplex waveform. A more accurate grading would be therefore not fea-
Table 3: Duplex waveforms at the common femoral artery versus the presence of significant 
aortoiliac obstruction*
CFA, Common femoral artery.
*Analysis 2 (see text). The poor monophasic duplex waveform classified as
“abnormal”, all other waveforms grouped together as “normal”.
†Defined as 50% diameter stenosis or occlusion as seen on contrastenhanced
magnetic resonance angiography.
CFA duplex waveform No aortoiliac 
obstruction
Aortoiliac 
obstruction present†
Total
Triphasic, biphasic, and 
sharp monophasic 
grouped together.
217 67 284
Poor monophasic 7 84 91
Total 224 151 375
(%) 95% confidence interval
Lower Upper
Sensitivity 56 48 63
Specificity 97 94 98
Positive predictive value 92 85 96
Negative predictive value 76 71 81
Accuracy 80 76 84
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16.  Burnham SJ, Jaques P, Burnham CB. Noninvasive detection of iliac artery stenosis in the presence 
of superficial femoral artery obstruction. J Vasc Surg 1992;16:445-51; discussion, 452.
17.  Evans DH, Macpherson DS, Asher MJ, Bentley S, Bell PR. Changes in Doppler ultrasound sono-
grams at varying distances from stenoses. Cardiovasc Res 1982;16:631-6.
18.  Chiowanich P, Mitchell DG, Ortega HV, Mohamed F. Arterial pseudostenosis on first-pass gado-
linium-enhanced three-dimensional MR angiography: new observation of a potential pitfall. AJR 
Am J Roentgenol 2000;175:523-7.
CONCLUSIONS
The observer agreement in assessing the DUS waveform at the CFA is very high. The poor mono-
phasic duplex waveform at the CFA is in itself an accurate marker of upstream aortoiliac obstructive 
disease. The appearance of triphasic and biphasic monophasic waveforms is nondiagnostic for aorto-
iliac disease, whereas the sharp monophasic duplex waveform is associated with occlusion of the 
superficial femoral artery.
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major benefits and risks to health-related quality of life of these specific forms of treatment for the 
claudicant are reviewed. In Chapter 2 we demonstrated that patients who suffer from symptoms of 
intermittent claudication are best served by management that addresses their major self-reported 
impediments to health-related quality of life.
To evaluate the effects after endovascular revascularization versus exercise training in patients with 
intermittent claudication, a systematic review was performed (Chapter 3). Articles published be-
tween 1980 and February 2003 were included if patients with intermittent claudication were treated 
with (a) exercise training, or (b) angioplasty, and (c) both functional capacity and the SF-36 quality-of-
life scores were reported of at least 3 months follow-up. Data were pooled using the random-effects 
model and weighted means. Pooled results were compared between the treatment groups using the 
Â²-test, and the t-test (α = 0.05, two-sided). In the analyses, 5 studies (n=202 patients) were included 
in the exercise group and 3 studies (n=470 patients) in the angioplasty group. 
Comparison of published results of exercise training with published results of endovascular revas-
cularization demonstrated an improvement in health-related quality of life after exercise training at 
3 and 6 months, whereas after endovascular revascularization both functional capacity and health- 
related quality of life showed significant improvement at 3 and 6 months. Between the two treat-
ment groups the ankle-brachial indices were significantly higher in the endovascular revasculariza-
tion group compared to the exercise training group at 3 and 6 months, whereas the improvement 
in health-related quality-of-life scores was not significantly different between the treatment groups 
during follow-up. 
In the systematic review, the lack of standardization in the different protocols of exercise training 
became apparent. This hampered the comparison of the reported results between the treatment 
options. Therefore, a prospective randomized controlled trial was performed (Chapter 4 and 5) to 
compare the clinical effectiveness and cost-effectiveness of endovascular revascularization to super-
vised exercise training. From September 2002 to September 2005 all consecutive new patients with 
signs and symptoms of intermittent claudication, who were referred to a Vascular Surgery Depart-
ment, were potentially eligible for recruitment. Of 293 potentially eligible patients with symptoms of 
intermittent claudication due to an iliac or femoro-popliteal arterial lesion, 151 fulfilled the inclusion 
criteria and were randomly assigned to endovascular revascularization (76 patients) or supervised 
hospital-based exercise training (75 patients). 
In Chapter 4 we described the clinical effectiveness of this randomized controlled trial. The outcome 
measures included clinical success, functional capacity, and health-related quality of life after 6 and 
12 months. Significance of differences between the groups was assessed with the unpaired t-tests, 
Â²-test or the Mann-Whitney U-test. To adjust outcomes for imbalances of baseline values we per-
formed multivariable regression analysis. 
Endovascular revascularization yielded a larger improvement compared to supervised hospital-based 
exercise in clinical success immediately after the start of treatment, but this advantage was lost after 
6 and 12 months (OR 1.2; 95% CI 0.5, 2.5, p=0.70 and OR 0.9; 95% CI 0.4, 1.7, p=0.73 respectively). Af-
ter endovascular revascularization there were significantly fewer patients with ipsilateral symptoms 
compared to supervised exercise at 6 months (37% vs. 69%; OR 0.4; 95% CI 0.2, 0.7, p<0.001) but no 
significant differences were demonstrated at 12 months. After both treatments, there was an increase 
in functional capacity and quality-of-life scores after 6 and 12 months, with a statistical significant dif-
The studies presented in this thesis all focus on management of patients with intermittent claudica-
tion. They cover a broad spectrum and include the impact of intermittent claudication on health-
related quality of life, the evaluation of the outcomes of endovascular revascularization compared to 
supervised hospital-based exercise training, the evaluation of new rehabilitation strategies for coro-
nary artery disease, and the evaluation of a diagnostic test for aorto-iliac arterial disease.
The shortcomings and merits of the individual studies presented have been discussed in the previous 
chapters. In this chapter, a summary of the main findings is presented. Subsequently, some method-
ological issues are discussed and implications for future research are considered.
Intermittent claudication is the first and mildest manifestation of peripheral arterial disease, caused by 
the atherosclerotic process of progressive narrowing of arteries. Intermittent claudication is the clini-
cal condition of lower extremity muscle pain, discomfort, or weakness in the lower extremity induced 
by exercise and relieved by short periods of rest. The symptoms are explained by impaired blood 
flow to the lower extremity and are caused by partial or complete narrowing of one or more of the 
arteries of the peripheral circulation. If the arterial system fails, it results in a progressive oxygen debt, 
experienced by the patient as cramping muscle pain. 
The general consensus is that all patients presenting with intermittent claudication should initially be 
treated with exercise training and only if symptoms fail to improve, should invasive procedures be 
considered. Endovascular revascularization, however, may provide immediate benefit and therefore 
may prevent a patient’s ‘unnecessary disability’. This has led to new controversy as to the role of en-
dovascular revascularization compared to exercise training in patients with intermittent claudication. 
This is accompanied by an ongoing debate about the costs of the optimal treatment for patients with 
intermittent claudication. We compared the clinical effectiveness and cost-effectiveness of endovas-
cular revascularization to hospital-based exercise training in patients with intermittent claudication at 
6- and 12 –month’s follow-up. In Chapter 1 a broader rationale for this research project is presented.
Improvement in health-related quality of life is the ultimate goal of healthcare for the treatment of 
intermittent claudication. Until recently, the measures of success after treatment were those derived 
from the vascular laboratory, including ankle-brachial indices and ankle and toe pressures. There are 
now several validated and reliable survey instruments that can assess patient-reported health-related 
quality of life in a generic or disease-specific manner. Major survey instruments are reviewed. Al-
though intermittent claudication is neither life- nor limb threatening, it has a significant negative 
impact on health-related quality of life, as measured by these instruments. Patients so afflicted re-
port more bodily pain, worse physical functioning, and worse perceived health, in addition to lim-
ited walking ability. In general, these measures of health-related quality of life do not correlate with 
standard parameters of ankle-brachial index or ankle pressures. Therefore, the information gathered 
through these health-related quality-of-life assessment tools is important to all those involved in the 
management of patients with intermittent claudication.
Treatment of the claudicant with exercise training and percutaneous or open revascularization im-
pacts health-related quality of life as well. Each of these treatment modalities is capable of improv-
ing health-related quality of life, but some are associated with recurrent symptoms over time. The 
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The presence of peripheral arterial disease based on the walking distance score of the Walking Im-
pairment Questionnaire was significantly higher in the cardiac rehabilitation failure group than in 
the success group (34% vs. 17%, OR 2.5; 95% CI 1.1 to 6.0, p=0.03). The presence of peripheral arterial 
disease based on the walking speed score of the Walking Impairment Questionnaire, however, was 
not significantly different (30% vs. 28%, OR 1.1; 95% CI 0.5 to 2.5, p=0.79). The presence of peripheral 
arterial disease based on ABI measurements was higher in the failure group than in the success group 
(39% vs.14%, OR 3.8; 95% CI 0.8 to 17.9, p=0.08). Logistic regression analysis showed that when cardiac 
rehabilitation failure was adjusted for age and sex, failure was significantly associated with the pres-
ence of peripheral arterial disease based on the walking distance (OR 2.8; 95% CI 1.1 to 7.1, p=0.03), but 
not significantly associated when based on the speed score (OR 1.2; 95% CI 0.5 to 2.8, p=0.72). 
This study demonstrated that the clinical effectiveness of cardiac rehabilitation was inversely related 
to the presence of peripheral arterial disease, which suggests that patients with peripheral arterial dis-
ease benefit less from a cardiac rehabilitation program and are at higher risk of future cardiac events. 
In order to improve the results of current cardiac rehabilitation, we evaluated the cost-effectiveness 
of new rehabilitation strategies in which diagnosis and treatment of peripheral arterial disease in 
coronary artery disease patients were considered (Chapter 7). An analytic Markov decision model 
was developed to determine the optimal rehabilitation strategy for patients with peripheral arterial 
disease in coronary artery disease patients undergoing cardiac rehabilitation. 
The Markov decision model compared the following treatment strategies: 1. Cardiac rehabilitation 
(current practice); 2. Diagnostic work-up if cardiac rehabilitation fails followed by revascularization 
for peripheral arterial disease if needed; 3. Diagnostic work-up for peripheral arterial disease in all 
patients prior to cardiac rehabilitation and revascularization for peripheral arterial disease if needed; 
4. A hypothetical comprehensive combined cardiovascular rehabilitation program. The best-available 
evidence was retrieved from the literature and combined with primary data from 231 patients. Qual-
ity-adjusted-life years (QALYs), lifetime costs, incremental cost-effectiveness ratios (ICER), and the gain 
in net health benefits (NHB) were calculated. 
The hypothetical comprehensive cardiovascular rehabilitation program was the most attractive with 
an ICER of $16,461 per QALY gained and a gain in NHB of 0.06 compared to current practice. In an 
analysis without this strategy, a diagnostic work-up if cardiac rehabilitation fails followed by revas-
cularization for peripheral arterial disease if needed was most beneficial with an ICER of $49,468 per 
QALY gained and a gain in NHB of 0.02 compared to current practice. 
A combined cardiovascular rehabilitation program, or a diagnostic work-up and revascularization for 
peripheral arterial disease in patients who fail cardiac rehabilitation, would decrease secondary car-
diac events and save society millions of dollars.
In Chapter 8 a diagnostic test evaluation is described. Duplex ultrasound is often used to plan the 
treatment strategy for patients with peripheral arterial disease. However, Duplex Ultrasound is op-
erator-dependent and does not provide a “roadmap” of the arterial system. The accuracy, predictive 
value and observer agreement of the duplex ultrasound waveform at the common femoral artery as 
a marker of significant aorto-iliac disease was assessed. In 191 consecutive patients (381 aorto-iliac 
segments) who visited the vascular laboratory between October 2001 and March 2004, we classified 
the duplex ultrasound waveform at the common femoral artery as triphasic, biphasic, sharp mono-
ference between the treatment groups only in the maximum pain-free walking distance in favour of 
the supervised hospital-based exercise group after 6 months (mean difference 16 meters; 95% CI 2, 
29 meters, p=0.02). All other outcomes and all outcomes at 12 months demonstrated no significant 
differences. 
The results demonstrated that patients with intermittent claudication benefited from both endovas-
cular revascularization and supervised hospital-based exercise. Initially minor differences in outcomes 
between the two treatments may occur but at 12 months no significant differences can be demon-
strated. 
In Chapter 5 we described the cost-effectiveness of this randomized controlled trial. The primary 
outcome was health-related quality of life (EuroQol, rating scale, SF36, quality-adjusted life years ac-
cumulated during 12 months) and the secondary outcome was costs from the societal perspective. 
Significance of differences between the groups was assessed with the unpaired t-test, Â²-squared-
test, and the Mann-Whitney U-test. Incremental costs per quality-adjusted life year gained were cal-
culated as the difference in total mean cumulative costs during 12 months between the treatment 
groups divided by the difference in mean accumulated quality-adjusted life years during 12 months. 
Outcomes were adjusted for baseline quality-of-life values and covariates using multivariable regres-
sion analysis. 
The endovascular revascularization group had a larger improvement in 6- and 12-months EuroQol, 
rating scale, and SF-36 quality-of-life values than the supervised hospital-based exercise, but the 
differences were not statistically significant. The gain in total mean QALYs accumulated during 12 
months, adjusted for baseline values, was significantly larger following endovascular revasculariza-
tion (mean difference 0.03; 95% CI: 0.02, 0.04; p<0.001). The total mean cumulative costs per patient 
were significantly higher in the endovascular revascularization group (mean difference €2318; 95% CI: 
€2176, €2460; p<0.001) and the incremental cost per QALY was €77 267.
Endovascular revascularization results in a small gain in effectiveness compared to supervised hospi-
tal-based exercise during 12-months’ follow-up but costs more, and only if society is willing-to-pay 
more than 77 300 €/QALY gained should one consider endovascular revascularization as first-line 
treatment in patients with intermittent claudication.
Chapter 6 and 7 deal with the management of patients with both peripheral arterial disease and 
coronary artery disease. These patients frequently fail the cardiac rehabilitation program due to their 
limited walking distance. The purpose of the study described in Chapter 6 was to evaluate whether 
clinical effectiveness of cardiac rehabilitation is related to the presence of peripheral arterial disease. 
From a consecutive cohort of patients who started cardiac rehabilitation from January 2004 to De-
cember 2004, we included those who completed the Walking Impairment Questionnaire (n=126). 
Cardiac rehabilitation failure was defined as a premature discontinuation of the treadmill exercise 
program or an inability to reach target heart rate. Presence of peripheral arterial disease was based 
on the walking distance score and the speed score of the Walking Impairment Questionnaire and in 
a subset of our patient sample (n=39) we assessed the ankle-brachial index (ABI). Chi-squared tests 
were used to compare the proportion of patients with peripheral arterial disease between patients 
who failed cardiac rehabilitation and patients who were successful. In addition, age and sex adjusted 
logistic regression models were used to examine the association between cardiac rehabilitation fail-
ure and the presence of peripheral arterial disease. 
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this respect. Finally, value of information analysis can be performed to estimate the value of obtaining 
further information through future research. 
Another cohort study design was used for the diagnostic test evaluation of duplex ultrasound, which 
focused on determining sensitivity and specificity of the duplex ultrasound in comparison to a refer-
ence test. Reference tests are, however, commonly not as perfect as we would like them to be. In our 
cohort study this problem applied to magnetic resonance angiography. As known from previous 
studies, overestimation of stenosis grade with magnetic resonance angiography is more frequent 
than underestimation. This may have caused some false negative duplex ultrasound interpretations. 
FUTURE DIRECTIONS
Many clinical and methodological issues need further research, of which most were presented in the 
previous chapters. The studies presented in this thesis all focused on management of patients with 
intermittent claudication. Regardless of the initial treatment, claudicants should be encouraged to 
engage in regular exercise and atherosclerotic risk factors need ongoing attention during the follow-
up period. Endovascular revascularization plus supervised exercise training or endovascular revas-
cularization plus pharmacologic therapy are comprehensive management strategies that should be 
considered in future research.
The studies presented in this thesis were based on the techniques available at the time the studies 
were conducted. New developments in endovascular revascularization technology for peripheral ar-
terial disease are bare-metal, drug-eluting, and covered stents. These techniques are under develop-
ment and broaden the type of lesions and disease locations that can be treated. However, long-term 
patency data on these new technological advancements are currently not available. 
The association between the presence of peripheral arterial disease and cardiac rehabilitation failure 
emphasizes the need to explore alternative strategies to diagnose and treat peripheral arterial disease 
in patients undergoing cardiac rehabilitation. Based on our value of information analysis more re-
search on the costs and effectiveness of new rehabilitation strategies in patients with coronary artery 
disease is justified. The results from our study can help design a future study and restrict the data col-
lection to the most relevant variables. This could potentially increase the success of the program and 
improve cardiovascular risk reduction. 
A new development in duplex ultrasound for examination of the aortoiliac arteries is the use of con-
trast agents. These increase the Doppler signal intensity and should therefore reduce the rate of un-
interpretable test results. Other future directions include ultrasound-guided therapy of arterial occlu-
sions using encapsulated drugs targeted to the thrombus.
 
Clinical implications for the management of patients with intermittent claudication:
1. The results of our randomized controlled trial demonstrated a small gain in effectiveness after 
endovascular endovascularization compared to supervised hospital-based exercise during 12-
months’ follow-up, but endovascular endovascularization was also more expensive, and only if 
society is willing-to-pay more than 77 300 €/QALY gained should one consider endovascular 
revascularization as first-line treatment in patients with intermittent claudication. 
phasic, or stump monophasic. The waveforms were then compared with the findings of magnetic 
resonance angiography of the aorto-iliac segment and peripheral run-off vessels. We calculated the 
diagnostic accuracy of the duplex waveform for detecting >50% obstructive disease of the aorto-iliac 
segment and determined the observer agreement for classifying the duplex waveforms done by two 
independent observers. 
The presence of a stump monophasic waveform, encountered in 91/375 segments (24.3%), was a reli-
able sign of significant aorto-iliac disease with a positive predictive value of 92%. Other waveforms 
were non-diagnostic for aorto-iliac obstructive disease. The sharp monophasic waveform reliably 
predicted occlusive disease of the superficial femoral artery, seen in 17/23 instances. There was good 
observer agreement for classifying duplex waveforms (∙w = 0.85; 95% CI, 0.80 to 0.89). Our results 
suggested that the stump monophasic duplex waveform at the common femoral artery is in itself an 
accurate marker of aorto-iliac obstructive disease. Other waveforms are nondiagnostic for aorto-iliac 
disease.
METHODOLOGICAL CONSIDERATIONS
Several study designs were used to address the clinical problem, each with its own merits and limita-
tions. A systematic review was used to summarize the available evidence of the results of endovascu-
lar revascularization and exercise training after 6 months’ follow-up. The aims of a systematic review 
are to collect all available evidence, to integrate the results of independent studies that on their own 
may have contradictory or non-significant results, and to increase power so that an overall conclusion 
can be made. By doing the systematic review, however, we found that the exercise training protocols 
were not uniformly performed across the studies, which hampered comparison. 
Another study design that we used was the randomized controlled trial (RCT). RCT’s minimize bias 
introduced by extraneous factors and ensure an unbiased comparison between treatment groups. 
Patients were randomized after obtaining informed consent and prior to the initial treatment, which 
is the most straightforward practical approach. In general, RCT’s may not always be the most efficient 
approach because they are time-consuming and can be expensive, but we found our randomized 
controlled trial to be both feasible and inexpensive. 
A third study design we used was a cohort study for a clinical study in which we evaluated whether 
clinical effectiveness of cardiac rehabilitation was related to the presence of peripheral arterial dis-
ease. We found an association between cardiac rehabilitation failure and the presence of peripheral 
arterial disease but, as with all cohort studies, an association does not automatically imply a cause-ef-
fect relationship. 
A fourth study design was a decision-analytic model in which we compared different rehabilitation 
strategies for patients with coronary artery disease. The goal of performing a decision analysis is to 
integrate the best-available evidence in a model that reflects reality but since reality is complex, as-
sumptions have to be made to keep the model manageable. In addition, the input variables of deci-
sion models come from various sources, each with potential confounding factors. However, advan-
tages of decision models are that many alternative strategies can be compared and that lifetime 
outcomes can be estimated which cannot be done in a clinical study for ethical and practical reasons. 
Another advantage of decision models is that “what if” (sensitivity) analyses can be performed to 
explore the uncertainty of the input variables. Probabilistic sensitivity analysis is particularly useful in 
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2. Peripheral arterial disease can limit the benefit of cardiac rehabilitation in patients with coronary 
artery disease. A combined cardiovascular rehabilitation program, or if this is unavailable, a diag-
nostic work-up for PAD in patients who fail cardiac rehabilitation followed by revascularization 
if needed, could potentially decrease secondary cardiac events and save society millions of dol-
lars.
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endovasculaire groep en 5 studies (n=202 patiënten) in de looptrainingsgroep. Vergelijking van de 
gepubliceerde resultaten van de endovasculaire revascularisatie met die van de looptraining demon-
streerde een verbetering in kwaliteit van leven na looptraining, terwijl na endovasculaire behandeling 
zowel de enkel-arm index (een maat voor functionaliteit) als ook de kwaliteit van leven significant 
verbeterden. Tussen de behandelgroepen was de enkel-arm index significant hoger na endovascu-
laire revascularisatie na 3 en 6 maanden, terwijl de gemiddelde verandering in kwaliteit van leven niet 
significant verschilde na follow-up. 
Omdat uit het systematisch literatuur onderzoek bleek dat er weinig consistentie bestaat in de proto-
collen voor de looptraining die gehanteerd worden in de diverse studies, is er een gerandomiseerde 
gecontroleerde studie opgezet (Hoofdstuk 4 en 5). Deze gerandomiseerde gecontroleerde studie 
vergeleek de effecten, het klinische succes en de kosten tussen endovasculaire revascularisatie en 
gesuperviseerde looptraining. Van september 2002 tot september 2005 werden 151 opeenvolgende, 
nieuwe patiënten met claudicatio intermittens (Rutherford stage 1-3) op de vasculaire polikliniek ge-
randomiseerd tussen endovasculaire revascularisatie en gesuperviseerde looptraining. De resultaten 
van deze gerandomiseerde studie lieten zien dat er een klein voordeel was in verbetering van kwalit-
eit van leven na endovasculaire behandeling na 6 en 12 maanden, maar de verschillen tussen de 
beide behandelmethoden waren niet statistisch significant. Direct na behandeling was er wel een 
significant verschil in het klinisch succes in het voordeel van de endovasculaire behandeling, maar 
na 6- en 12 maanden was dit voordeel verdwenen. De geaccumuleerde winst in kwaliteitsjaren was 
significant hoger na endovasculaire behandeling dan na gesuperviseerde looptraining na 12 maan-
den follow-up, maar de kosten na endovasculaire behandeling waren ook significant hoger. Alleen 
als de maatschappij bereid is om meer dan €77 300 te betalen voor de winst van een kwaliteitsjaar, 
dan heeft endovasculaire revascularisatie de voorkeur boven gesuperviseerde looptraining als initiële 
behandelmethode. 
Een ander vraagstuk was de invloed van perifeer arterieel vaatlijden op de klinische effectiviteit van 
een hart revalidatie programma (hoofdstuk 6). Bijna de helft van de patiënten die een hart revali-
datie start, kan het programma niet succesvol afronden. Patiënten met zowel coronair vaatlijden als 
perifeer arterieel vaatlijden hebben vaak geen optimaal profijt van de hart revalidatie omdat zij door 
hun beperkingen hun “target heart rate” niet halen. Het doel van deze studie was evalueren of het 
klinische effect van een hart revalidatie programma is gerelateerd aan de aanwezigheid van perifeer 
arterieel vaatlijden. De resultaten van deze studie suggereerden dat het succes van een hart revalida-
tie programma negatief wordt beïnvloed door de aanwezigheid van perifeer arterieel vaatlijden. Dit 
betekent dat de patiënten minder voordeel hebben van het programma en een hoger risico lopen 
op een recidief myocard infarct.
Om de resultaten van hartrevalidatie programma’s te verbeteren, hebben we de kosteneffectiviteit 
van verschillende revalidatie strategieën voor patiënten met zowel coronair vaatlijden als ook perifeer 
arterieel vaatlijden geëvalueerd. Om de kosteneffectiviteit van verschillende revalidatie strategieën 
te vergelijken, hebben wij een besliskundig Markov-model ontwikkeld waarmee uitkomsten, zowel 
kosten als effecten, werden gesimuleerd onder verschillende revalidatie strategieën voor patiënten 
met perifeer arterieel vaatlijden die een hart revalidatie programma volgden. Het Markov model 
vergeleek de volgende strategieën: 1. Hart revalidatie (huidige praktijk); 2. Diagnostiek voor per-
ifeer arterieel vaatlijden gevolgd door revascularisatie indien nodig als de patiënt de hart revalidatie 
vroegtijdig stopt; 3. Diagnostiek voor perifeer arterieel vaatlijden bij alle patiënten voor de aanvang 
van hart revalidatie en revascularisatie voor perifeer arterieel vaatlijden indien nodig; 4. Een uitgebre-
Het onderwerp van dit proefschrift gaat over management van claudicatio intermittens tengevolge 
van atherosclerose in de perifere arteriën. Patiënten met claudicatio intermittens krijgen kramp in de 
benen bij inspanning en deze klachten verdwijnen na rust. Van deze patiënten met claudicatio inter-
mittens wordt daarom gezegd dat ze last hebben van “etalagebenen”: de patiënt loopt een stukje, 
rust even uit voor een etalage en kan dan weer verder lopen. De symptomen worden veroorzaakt 
door perifeer arterieel vaatlijden, waardoor een verminderde doorbloeding ontstaat tengevolge van 
vernauwingen of verstoppingen in de bloedvaten die de benen van zuurstofrijk bloed voorzien. Als 
behandeling komen looptraining en endovasculaire revascularisatie, beter bekend als “Dotteren” in 
aanmerking. Van oudsher wordt voor claudicatio intermittens een looptrainingsprogramma aanbev-
olen, waarbij de relatief invasieve endovasculaire revascularisatie pas wordt ingezet wanneer de loop-
training heeft gefaald. Echter, door het vroege klinische succes van endovasculaire revascularisatie, de 
technische innovaties en de lage morbiditeit en mortaliteit, wordt de endovasculaire revascularisatie 
steeds vaker toegepast. Sommige behandelaars vragen zich daarom af of de looptraining nog wel 
gerechtvaardigd is om dat met endovasculaire revascularisatie een periode van onnodig invalider-
end lijden kan worden voorkomen. Aan de andere kant spelen de kosten ook een belangrijke rol en 
vanuit het oogpunt van kosteneffectiviteit zou de endovasculaire revascularisatie misschien bewaard 
moeten worden voor meer ernstige symptomen dan claudicatio intermittens. In Hoofdstuk 1 wordt 
een algemene beschouwing gegeven over dit wetenschapsproject.
Hoewel claudicatio intermittens niet meteen bedreigend is voor het been, veroorzaakt de beperkte 
loopafstand en de pijn tijdens het lopen voor een vermindering in de fysieke en geestelijke gesteld-
heid. Verbetering van kwaliteit van leven is het uiteindelijke doel bij de behandeling van claudicatio 
intermittens. Tot voor kort werd de mate van succes van de behandeling bepaald aan de hand van 
enkel-arm indexen. Tegenwoordig zijn er ook gevalideerde en betrouwbare vragenlijsten waarmee 
de kwaliteit van leven van de patiënt kan worden beoordeeld voor en na de behandeling. In het 
algemeen blijken deze maten voor kwaliteit van leven niet goed te correleren met de enkel-arm 
index. In Hoofdstuk 2 gaven we een overzicht van de impact van claudicatio intermittens en de be-
handeling op de kwaliteit van leven. Patiënten met claudicatio intermittens rapporteerden naast de 
beperkte loopafstand ook een verslechterde lichamelijke functie, toegenomen lichamelijke pijn en 
verminderde algehele gezondheid. Ook de behandeling van claudicatio intermittens heeft invloed 
op de kwaliteit van leven. Hoewel looptraining en endovasculaire revascularisatie de kwaliteit van 
leven verbeteren, blijkt er na van loop van tijd weer een afname in kwaliteit van leven te ontstaan 
door terugkerende symptomen. In dit hoofdstuk demonstreerden we dat patiënten met claudicatio 
intermittens het beste zijn geholpen met een behandeling die is gericht op het verbeteren van de 
kwaliteit van leven van de patiënt.
Om een beter zicht te krijgen op de effecten van endovasculaire revascularisatie in vergelijking met 
looptraining hebben we een systematisch literatuur onderzoek uitgevoerd waarbij de verandering in 
kwaliteit van leven en functionaliteit na endovasculaire revascularisatie en looptraining zijn vergelek-
en (Hoofdstuk 3). Gepubliceerde artikelen tussen 1980 en februari 2003 werden geïncludeerd wan-
neer de claudicanten waren behandeld met (a) looptraining, of (b) endovasculaire behandeling en (c) 
zowel functionaliteit als ook de SF-36 kwaliteit van leven score waren gerapporteerd voor tenminste 
3 maanden follow-up. De data is samengevoegd met behulp van een “random-effects” model en 
met gewogen gemiddelden. In de analyses werden 3 studies (n=470 patiënten) geïncludeerd in de 
SAMENVATTING
CH
A
PT
ER
 9
136
  CO-AUTHORS
ide gecombineerde cardiovasculaire revalidatie. De data waren deels afkomstig uit de literatuur en 
deels uit een database bestaande uit 231 patiënten uit “Advocate Lutheran General Hosptial” (Park 
Ridge, Verenigde Staten) die een hart revalidatie volgden in 2004. De voor kwaliteit van leven gecor-
rigeerde levensjaren (QALYs), de “life-time costs” en de incrementele kosten-effectiviteits ratio (ICER) 
werden vervolgens berekend met behulp van het model. De resultaten van dit model worden gep-
resenteerd in hoofdstuk 7. De resultaten suggereerden dat de behandelstrategieën die de diagnose 
en zonodig behandeling van perifeer arterieel vaatlijden bevatten, een hogere “net health benefit” 
opleveren. Dit kan door een gecombineerd cardiovasculaire revalidatie programma, of als dit niet be-
schikbaar is, door de diagnose en zonodig behandeling van perifeer arterieel vaatlijden als de patiënt 
het hart revalidatie programma niet succesvol afrondt. Dit zou de kans op een recidief myocard in-
farct verkleinen en de maatschappij veel kosten kunnen besparen. 
 
In Hoofdstuk 8 is een diagnostische test evaluatie beschreven. Duplex echografie wordt vaak ge-
bruikt voor de planning van een behandelstrategie voor patiënten met perifeer arterieel vaatlijden. 
Echter, duplex echografie is onderzoeker afhankelijk en laat geen overzicht zien van het arteriële 
systeem. We beoordeelden de nauwkeurigheid, voorspellende waarde en variatie tussen de onder-
zoekers in de beoordeling van de duplex golfvorm als een aanwijzing voor een significante stenose 
in de aorto-iliacale arteriën. Bij 191 opeenvolgende patiënten (381 aorto-iliacale segmenten) werd de 
duplex golfvorm van de arteria femoralis communis geclassificeerd als tri-fasisch, bi-fasisch, scherp 
monofasisch of stomp monofasisch. De golfvormen werden vervolgens vergeleken met de bevin-
dingen van de magnetische resonantie angiografie van het aorto-iliacale segment en de perifere 
arteriële vaten. We berekenden de diagnostische accuratesse van de golfvorm voor het detecteren 
van een >50% obstructie van het aorto-iliacale segment en bepaalden de waarnemer variatie tussen 
de twee waarnemers die de golfvorm hadden beoordeeld en geclassificeerd. De stompe mono-
fasische golfvorm was in 24% aanwezig en bleek een betrouwbare indicatie voor een significante 
aorto-iliacale obstructie. De scherpe monofasische golfvorm voorspelde betrouwbaar een occlusie 
van de arteria femoralis superficialis. Echter was dit een kleine subgroep. Er was een goede inter-waar-
nemer overeenkomst voor het classificeren van de duplex golfvorm. Onze resultaten suggereerden 
dat de stompe monofasische duplex golfvorm ter plaatste van de arteria femoralis communis een 
nauwkeurige aanwijzing is voor een aorto-iliacale obstructie, echter de overige golfvormen bleken 
non-diagnostisch voor het aantonen dan wel uitsluiten van een aorto-iliacale obstructie.
In Hoofdstuk 9 werden de algemene discussie en de belangrijkste bevindingen van dit proefschrift 
beschreven. Verder werden relevante methodologische aspecten bediscussieerd tezamen met impli-
caties voor toekomstig onderzoek en voor de klinische praktijk. 
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